annual report new challenges new thinking feel better live longermission global quest improve quality human life enabling people feel better live longer spirit undertake quest enthusiasm entrepreneurs excited constant search innovation value performance achieved integrity attain success world class global leader every one people contributing passion unmatched sense urgency strategic intent want become indisputable leader industry glaxosmithkline plc english public limited company business segments itshares listed london stock exchange glaxosmithkline operates principally two industry new york stock exchange segments pharmaceuticals prescription pharmaceuticals history development company vaccines glaxosmithkline plc subsidiary associated consumer healthcare overthecounter medicines undertakings constitute major global healthcare group oral care nutritional healthcare engaged creation discovery development manufacture marketing pharmaceutical annual report review consumer healthrelated products report annual report glaxosmithkline plc glaxosmithkline corporate head office london forthe year ended st december preparedin also operational headquarters philadelphia accordancewith united kingdom requirements research triangle park usa operations summary report year annual review countries products sold countries intended investor needing full detail principal research development rd facilities annual report produced separate document uk usa japan italy spain belgium theannual review includes joint statement products currently manufactured countries chairmanand chief executive officer summary major markets groups products usa review operations summary financial statements france japan uk italy germany spain summary remuneration report glaxosmithkline plc public limited company annual review issued shareholders incorporated th december english law annual report issued shareholders elected th december company acquired glaxo receive itboth documents available wellcome plc smithkline beecham plc english glaxosmithklines corporatewebsiteat wwwgskcom public limited companies way scheme arrangement merger two companies website glaxo wellcome smithkline beecham glaxosmithklines website wwwgskcom gives additional major global healthcare businesses information group information made available website constitute part annual reportglaxosmithkline glaxosmithkline plc annual report year ended st december contents report directors financial summary joint statement chairman chief executive officer description business corporate governance remunerationreport operating financial review prospects financial statements directors statements responsibility independent auditors report consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements consolidated equity shareholders funds company balance sheet notes financial statements investor information financial record financial information international financial reporting standards ifrs shareholder return shareholder information share capital taxation information shareholders cross reference form f glossary terms annual report approved board directors onndmarch published onthmarch contact details glaxosmithkline financial summary restated growth statutory results cer turnover trading profit profit taxation earningsnet income basic earnings per share p p dividends per share p p merger restructuring disposal subsidiaries trading profit profit taxation earningsnet income earnings per share p business performance turnover trading profit profit taxation adjusted earningsnet income adjusted earnings per share p p groupas multinational business operates many countries earns revenues incurs costs many currencies results group reported sterling therefore affected movements exchange rates sterling overseas currencies average exchange rates prevailing period used translate results cash flows overseas subsidiary associated undertakings joint ventures sterling period end rates used translate net assets undertakings currencies influence translations usdollar euro japanese yen order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates years business performance primary performance measure used management presented excluding merger items integration restructuring costs disposals businesses management believesthat exclusion items providesa bettercomparison way business managed givesan indication performance group terms elements revenue expenditure local management able influence completion programmes group reporting results statutory basis growth rates presented comparing results business performance results statutory results management considers comparison statutory results business performance results gives appropriate indication groups performance period review therefore commentaries presented basis unless otherwise stated cautionary statement regarding forwardlooking statements group 's reports filed furnished us securities exchange commission sec including document written information released oral statements made public future behalf group may contain forwardlooking statements forwardlooking statements give group 's current expectations forecasts future events investor identify statements fact relate strictly historical current facts use words anticipate estimate expect intend project plan believe words terms similar meaning connection discussion future operating financial performance particular include statements relating future actions prospective products product approvals future performance results current anticipated products sales efforts expenses outcome contingencies legal proceedings financial results group undertakes obligation update forwardlooking statements whether result new information future events otherwise forwardlooking statements involve inherent risks uncertainties group cautions investors number important factors including document could cause actual results differ materially contained forwardlooking statement factors include limited discussed risk factors pagestoof annual reportglaxosmithkline joint statement chairman chief executive officer knew would challenging pipeline focused developing new medicines vaccines treat diseases unmet medical need cancer year glaxosmithkline alzheimers disease many potential pleased report achieved important new products financial business objectives example believe cervarix promising vaccine candidate cervical cancer potential make major contribution healthcare globally become last annual report predicted would bestselling vaccine expect file cervarix european challenging year felt full impact generic competition union international markets paxiland introduction generic wellbutrin glaxosmithkline managed year well thanks underlying great opportunities lie ahead us year work strength business fact glaxosmithkline much ensure greater understanding key stakeholders value stronger company today year ago innovative medicines continue contribution finding solution healthcare funding crisis broadbased portfolio fastgrowing products continued seek new ways improving access medicines focus controlling costs enabled us absorb loss people need least able pay billion business generics still achieve corporate responsibility principles continue guide way one per cent increase global pharmaceutical sales turnover business separate corporate responsibility report billion grew one per cent constant exchange rates cer available glaxosmithklinewebsite explains progress achieved guidance earnings per share eps least principles year line business performance eps cer eps grew two per cent pence acknowledgements acknowledge gratitude contribution expect see faster growth eps percentage sir christopher hogg sir peter job retired cer growth low doubledigit range international board end sir christopher chaired glaxosmithkline financial reporting standards ifrs basis driven period saw company derive full benefits strong growth key products continuing efficiencies merger meet challenges caused loss operations exciting phase growth come patent protection major products new compounds vaccines currently development start contributing performance next years john coombe chief financial officer retire board glaxosmithkline st march john served glaxosmithkline one largest promising glaxosmithkline predecessor companies exemplary pipelines industry projects clinical development manner years playing major role guiding end february including new chemical company postmerger period establishing entities nces product line extensions vaccines glaxosmithklineas leader within global pharmaceutical compounds nces moved phase ii trials industry including compounds treat hiv diabetes blood disorders multiple sclerosis data least expected thank three departing directors substantial also anticipate launch six new contributions glaxosmithkline wish well products including rotarixfor rotavirus vesicarefor overactive future bladder bonivafor osteoporosis avandarylfor diabetes requip restless legs syndrome enteregfor postoperative bowel disorders sir christopher gent jeanpierre garnier nonexecutive chairman chief executive officer glaxosmithklineglaxosmithkline description business description business discusses strategy activities resourcesandthe operating environment business identifies developments achievements following headings strategy strategy buildthe best product pipeline industry achievecommercial operational excellence improve access medicines bethe best place best people best work investincommunities consumer healthcare global manufacturing supply products competition pharmaceutical consumerhealthcare regulatory environment regulation intellectual property responsibility environmenthealth safety discussion groups management structures corporate governance procedures set corporate governance pagesto remuneration report gives details groups policies directors remuneration amounts earned directors senior management pagesto discussion groups operating financial performance financial resources given operating financial review andprospects pagesto report glaxosmithkline group means glaxosmithkline plc subsidiary undertakings thecompany means glaxosmithkline plc glaxosmithkline share means ordinary share ofglaxosmithkline plc p american depositary share ads represents two glaxosmithkline shares throughout report figures quoted market size market share market growth rates relate months ended th september orlater available glaxosmithkline estimates based onthe recent data independent external sources valued sterling relevant exchange rates figures quoted product market share reflect sales glaxosmithkline licensees brand names appearing italics throughout report trademarks either owned andor licensed glaxosmithkline associated companies theexception baycoland levitra trademarks bayerhepsera trademark gilead services countries including usa integrilina trademark cor therapeutics micropump trademark flamel technologies nicoderm trade mark sanofiaventis elan novartisor glaxosmithkline certain countries natrecor trademark sciosand janssen navelbine trademark pierre fabre mdicament vesicare trademark yamanouchi pharmaceuticals bonivabonvivaatrademarkof roche enterega trademark adolor corporation pritor trademark boehringer ingelheim used certain countries license group glaxosmithkline description business strategy glaxosmithklines business goal become indisputable bethe best place best people best work leader pharmaceutical andconsumerhealthcare industry single greatest source competitive advantage achieving goal require meeting three key challenges organisationis people groups ambition make face industry society whole place great people apply energy passion make difference world skills intellect key improving productivity research development components successful implementation groups ensuring patients access new medicines strategy work environment supports informed empowered reaching consumers beyond traditional healthcare resilient workforce group values draws professional diverse knowledge perspectives experience styles glaxosmithkline developed strategies focus global community details given page number key business drivers order meet challenges investincommunities buildthe best product pipeline industry glaxosmithkline continues build history community group aiming create thebestproductpipeline investment programmes theseprovide supportfor better industry benefit patients consumers society healthcare delivery education underserved communities includes developing focused portfolio strategy support around world group active engagement pipeline manage full life cycle compounds numerous external stakeholders including world health launch prescription medicine becoming overthe organisation members notforprofit community counter productswhere appropriate strategy includes funds communityled initiatives across world donates selective inlicensing efficient execution development medicines support humanitarian efforts communitybased commercialisation supply chain processes healthcare many programmes longterm commitments help bring sustainable change communities glaxosmithklines rd organisation measures productivityby details given pagesto number innovation products createsand also commercial value products ability address committocorporate responsibility unmet needs consumers includespatients healthcare glaxosmithkline committed connecting business decisions professionals budget holders regulators ethical social environmental concerns thus corporate perspective constitutes valuable new product responsibility integral embedded part way details given pagesto business achievecommercial operational excellence glaxosmithkline published set ofcorporate glaxosmithkline links research commercial operations closely responsibilityprinciples provide guidance standards order maximise value portfolio compounds thegroupis committed sets approach aredeveloped testedmarketing campaigns andsales efforts ten areas standards ethical conductresearch areplanned appropriate within markets group aims innovation products customers access medicines build strong relationships patients consumers employment practices human rights community investment ultimateusersof medicines caring environmentleadership advocacy engagement stakeholders groupreportsannually common approaches management processes business progress upholding principles corporate functions used internationally diverse talented responsibility reportwhich available website management team order create sustain competitive wwwgskcom advantage markets details given page improve access medicines glaxosmithkline created extensive programmes designed improve healthcare people limited access medicines developed developing world set theimprove access medicinessection thisreport pagedescription business glaxosmithkline build best product pipeline industry research development pharmaceuticals finding candidate compounds research development rdoperates global basis early research role genetics employing staff sites mainly uk usa early stages finding new medicines requires essentially two also belgium canada france india italy japan spain components targets shown affect mechanisms addition rd partnerships companies worldwide important pathological processes human diseaseand order benefit particular skills expertise compoundsable modulate behaviour specific targets available particular locations part target validation process glaxosmithkline aims identify genes relevant common diseases focus patient large unmet medical needs major patient burdens glaxosmithklines strategic intent become indisputable many diseases arise complex interactions leader industryitssuccessisdependent vibrant number gene variants environmental factors productiverdfunction supporting existing products challenge significant identifying genes predispose developing new ways help patientsrdis increasingly patients particular disease understanding rolesin seeking views patients understandthe important progression lead new ways intervene diseases aspects disease impact lives genes interest identified asthma noninsulin addition todiscussionswith key opinion leaders glaxosmithkline dependent diabetesfurther genetic association studies well devoting resource dialogue patients phenotyped patientsare way schizophrenia unipolar families information may used shape drug depression obesity alzheimers disease rheumatoid arthritis development programmes new medicine ready osteoarthritis metabolic syndromechronic obstructive pulmonary launch glaxosmithkline knows bring clear benefit disease copd coronary artery disease acute coronary patientslives syndrome productivity glaxosmithkline justly proud reputation applied continued high priority challenge scientific excellence forefront many advances increasing productivity improving science harnessed find new medicines quickly possible managing entire rd organisation resources one example thegroup helping move optimallyfocusedon discovery development new understandingof disease processes forward development medicines scientific initiatives enhanced imaging techniques may validated act surrogate productivity discussed programmes identify markers disease allows increasingly accurate prediction association diseases genes facilitated linkage clinical effect lead molecules drug candidates cellular targets disease identifying glaxosmithkline embarkingon later stages development thus areas research likely produce new ways efficient useof resources helping patients increased automation screening compounds provided lead compounds quickly discovery research higher quality improvements discovery research dr produces lead compounds form made imaging techniques allow early decisions basis drug discovery efforts centresof excellence compounds progress addition greater use automation drug discovery cedds dr provided cedds laboratory environment expansion electronic overhighquality new lead compounds activity collection clinical trial information allow scientists become defined targets investment dr focused increasing productive throughout discovery development quality quantity lead compounds available process year rd completed current phase investment glaxosmithklines product development pipeline set pages automation opening new combined facility shows considerable breadth depth end highthroughput screening highthroughput chemistry february glaxosmithkline hadpharmaceutical upper providenceusa enabled screening vaccine projects development clinic one million compounds success ratio consistently increased investment period addition molecular imaging centre excellence mice upper merion usawas opened providing platform develop noninvasive multimodal imaging technologies preclinical applications glaxosmithkline description business build best product pipeline industry continued compounds progressed phase clinical development number discovery projects listed table progressed nonclinical safety testing early phase clinical development undertaken cedds compounds continuing rigorous nonclinical clinical commercial assessments leading proof concept decisions next months compoundproduct mechanism indication longacting beta agonist inhaled asthmacopd sodium dependent glucose transport sglt inhibitor type diabetes histamine h antagonist dementia calcium antagonist osteoporosis beta adrenergic agonist overactive bladder oral pleuromutilin treatment respiratory tract infections longacting beta agonist inhaled asthmacopd interleukin receptor antagonist copd lipoproteinassociated phospholipase inhibitor atherosclerosis nk antagonist urinary incontinence vanilloid receptor antagonist acute migraine kinesin spindle protein ksp inhibitor cancer parathyroid hormone agonist osteoporosis factor xa inhibitor prevention stroke atrial fibrillation dna antiviral vaccine hiv noncannabinoid agonist inflammatory pain melaninconcentrating hormone antagonist obesity p kinase inhibitor rheumatoid arthritis copd corticotrophin releasing factor crf antagonist depression anxiety irritable bowel syndrome ibs requip xr nonergot dopamine agonist restless legssyndrome rls product submissions anumber significant dossiers submitted regulatory authorities major regions summarised table product countryregion description bonvivaboniva eu usa monthly oral dosing regimen ibandronate bisphosphonate treatment osteoporosis entereg usa alvimopan peripheral muopioid receptor antagonist postoperative ileus hepsera japan adefovir rnadirected dna polymerase inhibitor treatment hepatitis b lexiva japan fosamprenavir hiv aspartyle protease inhibitor treatment hiv product approvals approvals received number new products summarised table countryregion product approval date description bonviva eu february daily oral dosing regimen ibandronate bisphosphonate treatment osteoporosis flolan pah japan june epoprostenol prostacyclin agonist treatment pulmonary arterial hypertension hepsera japan october adefovir rnadirected dna polymerase inhibitor treatment hepatitis b lexiva japan december fosamprenavir hiv aspartyl protease inhibitor treatment hiv telzir eu july fosamprenavir treatment hiv vesicare usa november solifenacin muscarinic acetylcholine receptor antagonist treatment overactive bladder inlicensed yamanouchidescription business glaxosmithkline selecting bestcandidatemolecules early development process metabolicrate safety compounds evaluated laboratory animals prior testing centres excellence drug discovery humans testing required animals humans two fundamental steps turning lead compound mandated highly regulated governmental agencies drug candidate optimising potency efficacy safety see animals research page intrinsic characteristics molecule ii demonstrating validity therapeutic hypothesis pcd researchers investigate appropriate dosage forms eg tablet early clinical trials resulting candidate steps inhaled develop formulations enhance drugs facilitated rapid informed decisionmaking creative effectiveness facilitate ease use patient solutions issues inevitably arise phase processes supporting analytical methods drug synthesis development cedds focused specific disease areas product formulation delivery scaled meet designed nimble entrepreneurial increasing supply requirementsultimately leading technical range skills resources required drive midstage transfer processes methods manufacturing development projects lead optimisation key new product supply process partnership rd decision point demonstration proof concept major global manufacturing supply ensures robust product investments made fund largescale clinical trials developed largescale commercial manufacturing launch seven cedds based europe usa also improving rds productivity new drugdelivery systems predictive technologies particle engineering process biopharmaceuticals centred stevenage uk innovation use particle engineering process innovation cardiovascular urogenital diseases centred upper merion enhances ability manufacture consistently highquality usa products efficiently metabolic viral diseases centred research triangle park usa worldwide development microbial musculoskeletal proliferative diseases including provide focus development process major cancer centred upper providence usa functional components clinical medical biomedical data neurology gastrointestinal diseases centred harlow uk regulatory safety integrated single management psychiatry centred verona italy organisation worldwide developmentwwd respiratory inflammation centred stevenage uk creation medicine development centres cedd responsible identifying optimal drug mdcswhich provide focus latestage developmentwas candidate desired biological effect assessing completed embedded organisation mdcs safety development characteristics preclinical screens responsible creating value delivery full product may involve using animals achieved development plansmanaging daytoday operational activities cedds responsible proving compound safe latestage development portfolio maximising global efficacious patients smallscale clinical trials proof commercial potential products optimising delivery concept decision point portfolioand ensuring strong partnerships cedds decision made whether information available global commercial strategy gcs order deliver differentiated date justifies compounds progression latestage drug products value development necessary largescale clinical trials throughout development process regulatory function conducted register commercialise product maintains dialogue regulatory agencies major major investment announced september markets ensure development programme best establish preclinical research facility neurodegenerative focused generate data required grant diseases singapore facility team licences dialogue also facilitates glaxosmithklines ability scientists focus new therapies treatment respond efficiently emerging requirements safety neurodegenerative illnesses alzheimers disease efficacy data parkinsons disease well schizophrenia rdmodel cedds continued progress significant numbers new compounds first dosing humans initial genetics research preclinical global commercial evaluation efficacy patients discovery research development strategy converting candidates medicines preclinical development centres preclinical development pcd participates wide range medicine activities within drug development process optimising excellence development selection compounds potential development tics rch centres launch marketplace enhancement existing products drug devising convenient formulations discovery rch glaxosmithkline description business build best product pipeline industry continued mdcs based major us uk sites pharmacogeneticbased information provide prescribing therapeutically aligned follows physicians key information help select medicine dosemost likely therapeutic benefit patients cardiovascularmetabolic infectious diseases including diseases thedeveloping clinical trialgovernance worldddw conducting clinical trials required show medicines musculoskeletalinflammationgastrointestinalurology safe effective glaxosmithklines first priority protect neuroscience psychiatryneurology participants future patients clinical trials sponsored oncology group irrespective take place conducted respiratory according international standards good clinical practice matrix teams responsible maximising worldwide applicable laws regulations protocols reviewed development opportunities product within remit external regulatory agencies relevant countries information needed support registration safety required protocols considered ethics review programmes pricing formulary negotiations available committee whose remit covers site study take required commercial input global commercial strategy place safety data routinely collected throughout development ensures early stage regional marketing needs fully programs reported national regional regulatory integrated development plans careful prioritisation across agencies line applicable regulations additionally phases development ensures high potential reviewed internally safety signals glaxosmithkline integrated portfolio achieved context patient needs global safety board responsible internally approving pivotal studies investigating issues related patient safety mdcs collaborate early stage cedds define arise development programme addition target product profiles new molecules integrated clinical compliancedepartment monitors compliance good technical development manufacturing functions ensure clinical practice standards conduct analysis rapid effective launch delivery productto patients reporting clinical trials remit covers glaxosmithkline sites innovative clinical programmes lead molecules running trials well clinical research organisations cros cedds developed using crossfunctional project teams investigators performing clinical research groups behalf programmes one key measure productivity number results audits regularly reviewed rd active subjects clinical trials eachyear wwd increased global risk management compliance board audit number active subjects clinical trials significantly committee thelast three years order keep increasing need demonstrate safety efficacy products glaxosmithkline took another step make information clinical trials widely easily available gold passdesignation assets high value strategic itestablished clinical trial register public websiteon importance glaxosmithklinerequiring specific organisational clinical trials dataispublished regulatory authorities around visibility urgency meet patients needs continued world continue fully informed data way organisations resources generated reassured safety focused developmentsonly small number assets efficacy glaxosmithklines products clinical trial register receive gold passstatus one time enabling organisation enhance ability clinicians make informed clinical fully aligned two products radafaxine judgements benefit patients depression lapatinib cancercontinued progress andthree projects received thegold passstatus global commercial strategy year global commercial strategy gcs organisation provides one combines new longacting betaagonist integrated global commercialisation strategic direction within new inhaled corticosteroidfor treatment rdas well supporting development regional marketing asthma andcopdthe second chemokine receptor campaigns products emerging rd maximise portfolio antagonist hiv infection third project value full product life cycle additiondata cyclooxygenase inhibitor generated supporting added value products assessments improvements quality patients lives development role genetics reductions overall costs healthcare use glaxosmithkline believes pharmacogenetic research glaxosmithklines products correlation genetic data response medicine provide valuable information help improve decision making extending use existing products drug development thus positive impact key product launched important establish causes pipeline attrition ielack efficacy adverse drug additional ways patients helped reactions clinical trial design result rd collecting investigating whether otherillnessesmay treated samples clinical development studies identify development additional dosage forms pharmacogenetic information help predict patients convenient patients developments reflect response prospectively collected efficacy andsafety studies feedback patients medical professions others clinical trials becomestandard elements development result continuing research disease causes information intended define patient groups likely respond best treatment individuals likelyto suffer adverse event compound progresses development clinicdescription business glaxosmithkline line extensionsubmissions anumber ofproductline extensions submitted regulatory authorities major regions summarised table product countryregion description arixtra eu usa fondaparinux synthetic factor xa inhibitor thepreventionof deep vein thrombosis abdominal surgery arixtra eu usa fondaparinux prevention deep vein thrombosis medical conditions augmentin es japan syrup formulation amoxicillin betalactam antibiotic clavulanate beta lactamase inhibitor treatment otitismedia children boniva usa labelling intermittentintravenous dosing regimen ibandronate bisphosphonatefor treatment osteoporosis epzicom japan fixed dose combination reverse transcriptase inhibitors treatment hiv infections imigran stat dose japan thehydroxytryptamine agonist sumatriptan selfinjection device treatment ofmigraine requip japan additional strength ropinirole nonergot dopamine agonist parkinsons disease seretide eu labelling use initial maintenance therapy asthma combination salmeterol longacting betablocker fluticasone corticosteroid seretide diskus japan use treatment asthma copd combination salmeterol fluticasone dry powder inhaler serevent eu chlorofluorocarbonfree formulation pressurised aerosol containing salmeterol treatment asthma andcopd ventolin usa chlorofluorocarbonfree formulation salbutamol shortacting beta agonist pressurised aerosol dose counter wellbutrin xl usa indication treatment seasonal affective disorder dopaminenoradrenaline reuptake inhibitor bupropion zefix japan labelling use lamivudine reverse transcriptase inhibitor treatment liver cirrhosis ziagen qd japan reverse transcriptase inhibitor abacavir treatment hiv zovirax japan cream formulation dna polymerase inhibitor aciclovir use treatment herpes simplex infections line extension approvals approvals received number significant new indications formulations existing products summarised table product countryregion description approval date advair diskus usa april labelling paediatric twicedaily dosing asthma combination salmeterol longacting betablocker fluticasone corticosteroid dry powder device arixtra usa june fondaparinux synthetic factor xa inhibitor thetreatmentof deep vein eunovember thrombosis flovent usa may chlorofluorocarbonfree formulation pressurised aerosol dose counter containing fluticasone corticosteroidfor treating asthma kivexaepzicom usaaugust afixed dose combination oftworeverse transcriptase inhibitors treatment eu december hivinfections japan december paxil cr usa january controlled release formulation paroxetine selective serotonin reuptake inhibitor intermittent treatment premenstrual dysphoric disorder requip eu june ropinirole nonergot dopamine agonist restless legs syndrome seretide eu january labelling paediatric twicedaily dosing combination salmeterol long acting betablocker fluticasone corticosteroid pressurised aerosolfor treatment asthma seretide eu march dose counter formulation salmeterol treatment asthma copd serevent diskus japan february dry powder formulation salmeterol treatment asthma copd zefix japan october labelling use lamivudine reverse transcriptase inhibitor combination hepserafor treatment hepatitis b ziagen qd japan december reverse transcriptase inhibitor abacavir treatment hiv glaxosmithkline description business build best product pipeline industry continued examples lifecycle management include new indicationfor collaborative adi partnerships earlier cytokinetics inc seretideadvairmaking important asthma medicine available oncology mitotic kinesin inhibitors shionogi co hiv use children years kivexaepzicom neurology programmes potential broadbased discovery single tablet combining active molecules used two collaboration antimicrobials oncology metabolic neurology successful treatments hiv order simplify dosing tanabe seiyaku co ltd broadbased neurology gi urology patients line extensions form significant part overall diabetes respiratory exelixis inc oncology inflammation portfolio recent examples augmentin esxr seroxatpaxil theravance inc asthma ranbaxy laboratories ltd broad based crand wellbutrin xl achieved million sales neurosearch central nervous system adi partnerships also established three academic institutions number ofproduct lineextensions submitted supplement internal target validation activities provide better regulatory authorities major regions access tissue samples patient populations clinical studies submissions summarised page glaxosmithkline one academic adi partner uk two approvals received number significant usa long term collaborative relationships new indications formulations existing products group committed funding two years approvals summarised page option renew additional three years managing portfolio inlicensing research collaborations resources available exploit opportunities arising within glaxosmithkline continued identify compounds would group always limited improving productivity progresses enhance portfolio create innovative collaborations compounds later phases development consequently ensure group regarded partner choice putting demands rdresources therefore much large small companies important look objectively portfolio ensure subjects inlicensing comarketing copromotion progress assets prosecuted efficiently possible key agreements projects reaching significant milestones reviewed month product management board pmbwhich responsible albugontm glp albumin fusion protein preclinical determining whether individual asset achieved preset development type diabetes fromhuman genome sciences criteria pass next phase development body exclusive marketing integrilinin europe glycoprotein gp led jointly chairman rd thepresident llbllla inhibitor currently used treat patients unstable pharmaceutical operations includes thepresidents angina nonstsegment elevation myocardial infarction regions global manufacturing supply addition millennium pharmaceuticals inc heads major functions within rd broad alliance develop commercialise novel medicines across variety therapeutic areasincluding bacterial pmb also actively manages overall portfolio infection respiratory urinary incontinenceand gastrointestinal annual portfolio review exercise thorough careful theravance inc assessment assets drug discovery worldwide development leads prioritisation projects basis addition glaxosmithkline already entered number commercial value also unmet medical need agreements third parties codevelop comarket also allows identification alternative approaches balance certain compounds arrangements range milestone groups assets efficiently including use external payments third parties acquire rights intellectual partners development outlicensing products longer property joint ventures develop commercialise specified fit within strategic portfolio compounds many agreements group obligations make payments future specified milestones following annual portfolio prioritisation reviews cedds achieved financial commitments summarised able select programmes pursue internallyotherassets noteto financial statements commitments may developed novel partnership scheme known alternativediscovery initiative adi glaxosmithkline discontinuations partners share risk reward various business rd carries risk failure commensurate extension arrangements scientific knowledge compound effects lead adi partnerships biotechnology companies compounds identified possess positive activity pharmaceutical companies explore different approaches drug validated target prove safe enough introduce discovery formed recent years continue provide humans feasible manufacture commercial scale increased opportunities exploit productivity new glaxosmithkline rd endeavours ensure far possible technologies additional focus placed adis risks ameliorated extensive predictive testing early adding tanabe collaboration forming new partnerships possible development process despite efforts nikem research central nervous system diversa corp ultimate test product remains point antiinfectives toyama chemical co ltd antibacterialsand administered large numbers patients disease meiji seika kaisha ltd latestage projects terminated phase ii include neuropathic painvestipitant dyspepsia depression anxiety piboserod atrial fibrillation talnetant overactive bladderdescription business glaxosmithkline research development vaccines group currently rd projects programmes relevance developing world seven aimed vaccines rd conducted glaxosmithklines biologicals producing vaccines medicines diseases centre rixensart belgium including related activities disproportionately affect developing countries clinical development regulatory strategy commercial strategy scaling packaging support functions primary group also works close collaboration external partners production vaccineswith exception ofinfluenza vaccine worldwide search new treatments diseases isproduced atthe groupsstateoftheart facility developing world partnerships key order maximise germany scientists employed devoted combined expertise talent pharmaceutical industry discovering new vaccines developing costeffective academia discovering developing new medicines convenient combination vaccines prevent infections cause developing world serious medical problems worldwide discovery work involves many publicprivate partnerships remain essential fund research collaborators academia thebiotech industry worldwide commercially viable market potential product allows identification new vaccine candidates group continues work closely many governments expressed yeast bacteria mammalian cells purified united nations agencies global funding bodies high level area example glaxosmithklines pyridone project followed formulation vaccine involves awarded medicines malaria venture project mixing antigens selected novel proprietaryadjuvantswhich year rapid successful progress finding drug designed stimulate good appropriate immune candidate newly selected candidate since moved response humans next step evaluate safety preclinical development efficacy candidate vaccinewhich may involve using animals animals research preclinical proof concept established candidate vaccine tested clinical trials healthy ethical regulatory scientific reasons research using animals individuals evaluate safety effective vaccine remains small vital part research development new inducing immune response protect body disease medicines vaccines glaxosmithkline uses animals encountered later natural setting largescale field trials alternative numbers required healthy individuals follow establish safety efficacy test group strives exceed regulatory standards care cross section population results obtained use animals uses undergoes internal external clinical trials development quality production process review assure standards facilities combined regulatory file vast majority oftheexperimental methods use animals submitted authorities various countries glaxosmithkline actively engaged research develop vaccine made available validate tests either avoid use animals research biologicals long track record developing reduce numbers needed animals used research making vaccines available developing world unnecessary pain suffering scrupulously avoided preferential prices pioneered new south first vaccine strategy glaxosmithkline understands use animals research new rotavirus vaccine involved developing totally purposes commands high level public interest unique novel clinical regulatory strategy ensure glaxosmithkline public policy position care ethical use vaccine first registered made available areas animals research information reports world medicalneed greatest available website wwwgskcom secretariat recently cervarix vaccine prevention cervical cancer received gold passstatus see details gold passprogramme diseases developing world continued investment research diseases affect developing world essential longterm improvement healthcare people live regions include resolution challenges drug resistance poor patient compliance part glaxosmithklines response challenge microbial musculoskeletal proliferative diseases cedd responsibility drug discovery unit dedicated finding new medicines diseases based tres cantos spain work undertaken tres cantos focuses malaria tuberculosis together work elsewhere group hivaids vaccines means glaxosmithkline addressing prevention treatment three world health organizations top priority diseases glaxosmithkline description business build best product pipeline industry continued glaxosmithklinespipeline chartbelowshows glaxosmithklines new chemical entities nce product line extensions pleand vaccine pipeline evolution projects clinic since shows increased levels productivity particularly inphase ii thisis expected tolead increasein phase iii registrations coming years phase nces multiple indications counted oncences later phases counted indication pipeline pipeline late stage growth nce phase iiiregistration nce phase ii nce phase ples vaccines product development pipeline product development pipeline set outon following three pagesshows considerable breadth depthat end february glaxosmithkline hadpharmaceutical vaccine projects development whichare cliniccomprising new chemical entities product line extensions vaccines content drug development portfolio change time new compounds progress discovery development development market owing nature drug development processmany thesecompounds especially early stages investigationmaybe terminated progress development competitive reasons new projects preclinical development disclosed project types may identified key v vaccine phase evaluation clinical pharmacology usually conducted p pharmaccine volunteers compounds shionogiglaxosmithkline pharmaceuticals phase ii determination dose initial evaluation llc joint venture efficacy conducted small number patients inlicense alliance relationship third party phase iii large comparative study compound versus placebo date first submission andor established treatment patients date firstregulatory approval maa first establish clinical benefit safety eu approval letter al approvable letter maa marketing authorisation application europe nda new drug application usadescription business glaxosmithkline estimated filing dates compoundproduct type indication phase maa nda cardiovascular metabolic urogenital lppla inhibitor atherosclerosis lppla inhibitor atherosclerosis p kinase inhibitor atherosclerosis also rheumatoid arthritis copd factor xa inhibitor prevention stroke atrial fibrillation lppla inhibitor atherosclerosis ii adenosine aa agonist dyslipidaemia ii ppar delta agonist dyslipidaemia ii odiparcil indirect thrombin inhibitor prevention thrombotic complications ii cardiovascular disease deep vein thrombosis dvt prophylaxis arixtra synthetic factor xa inhibitor treatment acute coronary syndrome iii coreg cr beta blocker hypertension congestive heart failure daily iii na noratak recombinantbtype natriuretic peptide acute heart failure lll na arixtra synthetic factor xa inhibitor prevention ofdvt abdominal surgery submitted sjul sjul arixtra synthetic factor xa inhibitor prevention ofdvt medical conditions approved ajan sfeb arixtra synthetic factor xa inhibitor treatment ofdvt approved anov ajun metabolicprojects sodium dependent glucose transport type diabetes sgltinhibitor melanin concentrating hormone antagonist obesity ppar pan agonist type diabetes ii dpp iv inhibitor type diabetes ii sgltinhibitor type diabetes ii solabegron beta adrenergic agonist type diabetes also overactive bladder ii avandamet xr ppar gamma agonist plus metformin type diabetes extended release iii avandaryl ppar gamma agonist plus sulphonylurea type diabetes fixed dose combination approvable alaug infectious diseases oral pleuromutilin treatment respiratory tract infections phospholipid antiendotoxin emulsion sepsis ii chlorproguanildapsone antifolate artemisinin treatment uncomplicated malaria ii na artesunate cda topical pleuromutilin bacterial skin infections iii sitamaquine aminoquinoline treatment visceral leishmaniasis iii na etaquine aminoquinoline malaria prophylaxis adults iii tbd antivirals dna antiviral vaccine hiv infections aspartyl protease inhibitor hiv infections ii nonnucleoside reverse transcriptase inhibitor hiv infections ii ccr antagonist hiv infections ii epzicomkivexa reverse transcriptase inhibitor hiv infections combination tablet approved adec aaug musculoskeletal inflammation gastrointestinal urology calcium antagonist osteoporosis calcium antagonist osteoporosis cathepsin k inhibitor osteoporosis osteoarthritis nki antagonist urinary incontinence uialso depression anxiety chemotherapy induced postoperative nausea vomiting p kinase inhibitor rheumatoid arthritis also atherosclerosis copd parathyroid hormone agonist osteoporosis p kinase inhibitor oral rheumatoid arthritis also copd corticotrophin releasing factor crfi antagonist irritablebowelsyndrome ibs also depression anxiety entereg peripheral muopioid antagonist ibs solabegron beta adrenergic agonist overactive bladder also type diabetes endothelial cell adhesion molecule inhibitor inflammatory bowel disease ii selective inos inhibitor rheumatoid arthritisalso migraine asthma ii dual alpha integrin antagonist vla inflammatory bowel disease also multiple sclerosis ii talnetant nk antagonist ibs also schizophrenia ii avandia ppar gamma agonist rheumatoid arthritis ii entereg peripheral muopioid antagonist chronic opiate induced bowel dysfunction constipation ii mepolizumab antiil monoclonal antibody hypereosinophillic syndrome also asthma eosinophilic esophagitis iii avandia ppar gamma agonist psoriasis iii avodart alpha blocker alpha reductase inhibitor plus alpha blocker benign prostatic hyperplasia fixed dose combination iii avodart alpha reductase inhibitor reduction risk prostate cancer iii bonivabonviva bisphosphonate treatment postmenopausal osteoporosis submitted sdec intermittent iv dosing bonivabonviva bisphosphonate treatment prevention postmenopausal osteoporosis submitted ssep smay monthly oral dosing entereg peripheral muopioid antagonist post operative ileus submitted sjun vesicare muscarinic antagonist overactive bladder approved na anov glaxosmithkline description business build best product pipeline industry continued estimated filing dates compoundproduct type indication phase maa nda neurosciences histamine h antagonist dementia endothelin antagonist stroke selective inos inhibitor migraine alsorheumatoid arthritis asthma gap junction blocker migraine epilepsy neuropathic pain dual acting cox inhibitor acute chronic pain conditions including neuropathic pain also schizophrenia vanilloid antagonist acute migraine endothelin antagonist stroke ht antagonist schizophrenia dementia mixed htdopaminergic antagonist schizophrenia nk antagonist depression anxiety noncannabinoid cb agonist inflammatory pain corticotrophin releasing factor crf antagonistdepression anxietyalso ibs radafaxine noradrenalinedopamine reuptake inhibitor fibromyalgia neuropathic pain requip xr nonergot dopamine agonist restless legssyndrome rls radafaxine noradrenalinedopamine reuptake inhibitor depression ii radafaxine noradrenalinedopamine reuptake inhibitor rls ii ns triple htnoradrenalinedopamine reuptake depression ii inhibitor dual acting cox inhibitor acute chronic pain migraine ii tbd tbd glycine antagonist smoking cessation ii reuptake inhibitor nk antagonist depression anxiety also chemotherapy induced ii postoperative nausea vomitingand ui dual alpha integrin antagonist vla multiple sclerosis also inflammatory bowel disease ii vestipitant paroxetine nk antagonist selective serotonin depression anxiety ii talnetant nk antagonist schizophrenia also ibs ii avandia ppar gamma agonist alzheimer 's disease ii lamictal sodium channel inhibitor bipolar disorder acute treatment iii na lamictalxr sodium channel inhibitor neuropathic pain epilepsy nda daily iii lamictal xr sodium channel inhibitor schizophrenia iii requip cr nonergot dopamine agonist parkinsons disease daily controlled release iii formulation trexima ht agonist naproxen migraine fixed dose combination iii na wellbutrin xl noradrenalinedopamine reuptake inhibitor seasonal affective disorder submitted sdec requip nonergot dopamine agonist rls approved ajun adec wellbutrin xl noradrenalinedopamine reuptake inhibitor depression approved aaug oncology kinesin spindle protein ksp inhibitor cancer elacridar oral bioenhancer cancer thrombopoietin agonist thrombocytopaenia ii recombinant human il immunomodulator immunologicallysensitive cancers melanoma renal cellii nk antagonist chemotherapy induced postoperative nausea ii vomiting also depression anxietyandui kinesin spindle protein ksp inhibitor non small cell lung cancer tumours ii vascular endothelial growth factor solid tumours ii tyrosine kinase inhibitor vestipitant nk antagonist postoperative nausea vomiting also chemotherapy ii induced nausea vomiting ethynylcytidine selective rna polymerase inhibitor solid tumours ii lapatinib erbb egfr dual kinase inhibitor breast cancer also renal lung bladder gastric iii head neck cancers hycamtin topoisomerase inhibitor ovarian cancer first line therapy iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy iii oral formulation nelarabine guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas iii hycamtin topoisomerase inhibitor small cell lung cancer second line therapy approved anovdescription business glaxosmithkline estimated filing dates compoundproduct type indication phase maa nda respiratory long acting beta agonist asthma chronic obstructive pulmonary disease copd long acting beta agonist asthma copd il antagonist copd p kinase inhibitor oral copd also rheumatoid arthritis atherosclerosis p kinase inhibitor oral copd also rheumatoid arthritis long acting beta agonist copd also copd asthma combination ii glucocorticoid agonist muscarinic antagonist copd ii selective inos inhibitor oral asthmaalso migraine rheumatoid arthritis ii long acting beta agonist copd also copd asthma combination ii glucocorticoid agonist long acting beta agonist copd also copd asthma combination ii glucocorticoid agonist glucocorticoid agonist asthma copd combination long acting ii beta agonist also allergic rhinitis chemokine ccr antagonist oral asthma allergic rhinitis glucocorticoid agonist asthma copd combination long acting ii beta agonist pde iv inhibitor inhaled copd ii mepolizumab antiil monoclonal antibody asthma also hypereosinophillic syndromeand ii eosinophilic esophagitis avamysallermistglucocorticoid agonist allergic rhinitis iii seretideadvair beta agonistinhaled corticosteroid copd mortality claim iii seretide beta agonistinhaled corticosteroid asthma initial maintenance therapy submitted saug na serevent beta agonist asthma copd noncfc inhaler submitted sapr na ariflo pde iv inhibitor oral copd approvable aloct seretideadvair beta agonistinhaled corticosteroid asthma noncfc inhaler approved ajun aloct oct hepatitis vaccines hepatitis e recombinant hepatitis e prophylaxis ii fendrixextra strength recombinant extra strength hepatitis b prophylaxis prehaemodialysis approved anov afeb hepatitis b haemodialysis patients paediatric vaccines rotarix live attenuated oral rotavirus prophylaxis lll streptorix conjugated pneumoniae disease prophylaxis children iii n meningitidis conjugated meningitis prophylaxis submitted combinations priorixtetra live attenuated measles mumps rubella varicella prophylaxis submitted sapr vaccines hiv recombinant hiv prophylaxis fflu improved subunit influenza prophylaxis pneumoniae elderly recombinant pneumoniae disease prophylaxis varicellazoster recombinant varicella zoster prevention dengue fever attenuated tetravalent vaccine prophylactic use il epsteinbarr virus recombinant ebv prophylaxis ii mosquirix recombinant malaria prophylaxis ii staphylococcal antibodiesmonoclonal antibody prevention staphylococcal infections ii cervarix recombinant prophylaxis human papillomavirus hpv infections iil simplirix recombinant genital herpes prophylaxis iii boostrix subunit adolescentadult booster diphtheria tetanus approved aoct sjun pertussis pharmaccines breast cancer therapeutic recombinant treatment breast cancer neu p recombinant treatment prostate cancer l mage recombinant treatment lung cancermelanoma ii glaxosmithkline description business achieve commercial operational excellence glaxosmithkline undertakes range activities maximise glaxosmithkline also complies relevant industry codes commercial potential intellectual propertyby introducing practice training provided employees whose position innovative products many markets possible accelerating requires understanding group marketing requirements process bring new products market increasing brand particularly sales representatives monitoring process recognitionand ensuring patients access new marketing activities includes group internal audit medicines pharmaceutical consumer healthcare independent reviews approvals businessesfocus ways improve existing performance commercial operational excellenceinitiatives patient advocacy patientadvocacy initiative demonstrated significant worldwide sales force excellence progress since inception rationale strategy glaxosmithkline sales force always ranked high surveys centres enhancing access groupsmedicines healthcare professionalsworldwidesalesforceexcellence markets public private payers influence availability wsfe aims improve customer satisfaction even well improving reputation patientcentric group time available physicians learn new medicines initially launched usprogramme expanded clinical studies precious wsfe initiative sales critical initiative strategic plans throughout world representatives strengthen product knowledge learn deliver years patient advocacy leaders summit philadelphiawas patientspecific treatment options efficiently attended four hundred people representing twentythree effectively research shows sales visit highly effective countries six continents additionallypatient advocacy teams representative engages physician dialogue around patient us europe shared best practices types supports message visual aids illustrate established processesto optimise interactionwith patientgroups clinical results european centres excellence group introduced single global sales call model pharmaceuticals europehas introduced new business model focuses treating patient dialogue enhanceitsability compete increasingly challenging glaxosmithkline medicine appropriate effective environment model established centres excellence toadminister itsafely end year field key therapeutic areas respiratory metabolic people groups key markets trained new business capabilities ascommercial excellence portfolio approach management centres developpaneuropean strategies entire sales organisation immersed wsfe bring implemented consistently across region model cultural change raises ethical standards helps build driving swift adoption brand strategies campaigns longterm trusting relationships healthcare community reducing costs duplication new model also focuses ensuring new assets may launched europe marketing excellence optimal data support approval reimbursement goals global marketingexcellence initiative first help undiagnosed patients seek physicians help second procurement ensure receive appropriate treatment example glaxosmithkline annually spends around billion non uk officials estimate million people suffer type production related third party purchases worldwide covers diabetes yet per cent remain undiagnosed areas including media travel rd marketing diagnosed another per cent remain untreated purchases managed procurement behalf internal treated significant number undertreated customersandfocuson delivering best value group way patients achieve level health approach covers assurance supply service quality cost treatments could provide optimal circumstances andinnovation theprocess delivered savings excess glaxosmithklines marketing initiative implements programmes million per year since merger overcome barriers proper diagnosis treatment programmes begin show effects societal costs disease improving processes decrease extent glaxosmithkline product group ongoing improvements processesto increase chosen patients treatment thegroup benefit well quality goods services improve speed reliability performance deliver savings procurement function glaxosmithkline recognised industry initiates rigorous supplier selection monitoring processes across excellence marketing received variety awards key areas expenditureand compliance use acknowledging success campaigns award preferred suppliers high operational excellence experts programme independently judged experts globalmanufacturing andsupply supported number glaxosmithkline committed marketing ethical businesses functionsby helpingtosolve problems responsible patientcentred corporate policy rigorous controlled structured wayand focus efficiently governing marketing activities applies employees activities adding greatest value glaxosmithkline supplierscontractors agents policy requires marketing promotional activities based valid scientific project future evidence comply applicable laws regulations project future fundamental review consumer business sector policies include additional requirements healthcare business modelto increase competitiveness guidance thereby sales growth undertaken model implemented details given pagedescription business glaxosmithkline improve access medicines access healthcare developing world voluntarylicences glaxosmithkline grantedfivevoluntarylicencesto access healthcare developing countries remains major african generics companies manufacture sale arvs challenge global community problem rooted public private sectors subsaharan africa povertyand lack political willcontinues demand licencesbuild upon groups agreement aspen significant mobilisation resources true spirit partnership pharmacaresubsaharan africas largest generic companyfirst must tackled shared responsibility sectors global signed september demonstrate glaxosmithklines society group mandate expertise ongoing commitment increasing access essential medicines resources address underlying problems exist however innovative solutions glaxosmithkline continues play vital role commitment rd diseases particularly prevalent looking ahead developing world programme preferential pricing glaxosmithkline continue build products pricing antiretrovirals arvs antimalarials vaccines partnership commitments help improve healthcare willingness seek innovative solutions developing world however significant increase funding voluntary licencing arrangements global community still needed also important maintain incentives rd protection intellectual preferential pricing arrangements property example neither cure vaccine glaxosmithkline offered vaccines key organisations hivaids vaccination programmes developing countries preferential prices years group also sets single sustainable much achieved sustainable progress notforprofit price arvs antimalarials wide occur significant barriers stand way better range customers least developed countries undefinition access healthcare tackled shared responsibility subsaharan africa well projects fullyfunded sectors global society governments international agencies global fund fight aids tb malariaand us presidents charities academic institutions pharmaceutical industry emergency plan aids relief means notforprofit others prices offered total countries access healthcare developed world glaxosmithkline committed contributing health improvements sustainable manner prices arvs glaxosmithkline plays active role improving healthcare antimalarials therefore set levels profit made people limited access medicines direct costs covered allowing supply sustained groups bridges access commitment access programmes long required group undertaken reduce provided million worth medicines qualifying low prices whenever possible although two reductions income us residents medicare beneficiaries announced price reductions possible glaxosmithkline orange cardprogramme offers qualifying us senior citizens per cent discounts outpatient preferential pricing improving access group hassigned glaxosmithkline medicines individuals agreements coveringof worlds poorest countries signed programme group committed supply arvs preferential prices customers include governments maintaining programme medicare prescription benefit nongovernmental organisations ngos hospitals academic place institutions private employers group also founding member together rxa multi offer notforprofit prices requires sustainable framework company card programme seven major participating combining groups commitment preferential pricing pharmaceutical companies offer savings usa commitments governments developed world avoid widely prescribed medicines together rxparticipants save price referencing preferentially priced medicines per cent usual amount prescriptions help prevent product diversionglaxosmithkline taken steps end million people joined minimise threat diversion able supply programme countries combivir epivir trizivirin special access packs similar efforts underway secure widespread regulatory addition glaxosmithkline nine pharmaceutical approval retrovirand epivir syrupaccess packs register companies created together rx accessa savings programme differentiated red opposed traditional white combivirand qualified individuals usa lack prescription drug epivirtablets across number international markets coverage together rx access participating companies group successfully registered nine itsarvsunder offer savings per cent usual pharmacy european unions antidiversion regulation also continued cost medicines encourage countries take necessary steps ensure introductionand strict enforcement ofappropriate antidiversion measures glaxosmithkline description business best place best people best work glaxosmithkline people individuals developed global leadership positions targeted job moves different businesses geographies glaxosmithkline committed creating best place variety programmesare offered internally develop leaders best people best work managers innovate inspire execute well performance reward communication involvement reward philosophy programme development underscore senior management conference held february allowed glaxosmithklines commitment performance culture delegates briefed directly members performance based payshare awardsshare options corporate executive team key challenges facing group performance development planning contribute retention debate strategies addressing event also key talent superior performance accomplishment recognised individuals madeoutstanding contributions business targets annual performance development planning pdp may second global leadership survey conducted process ensures thatindividuals set business goals aligned among managers gauge opinion critical corporate strategies set behavioural goals create issues culture confidence groups future results development plan pdps reviewed throughout year showed significant improvement items compared culminating end year review factored results compared global benchmarks managers rate compensation decisions highly fostering alignment personal goals performance integrity central operating glaxosmithkline mission fostering environment ethics glaxosmithkline recent leadership survey showed integrity survey per cent managers proud per cent believe people department show part glaxosmithkline would gladly refer friend commitment performance integrity family member work glaxosmithkline commitment flexible working flexitime regard improvement areas managers report teleconferencing remote working flexible work schedules glaxosmithkline continue enhance environment recognises employees work best environment place people able best work engage helps integrate work personal lives managers making changes necessary compete effectively business function developed action plans address diversity areas improvement glaxosmithkline diversity initiative focuses improving group continually seeks ways improving efficiency performance responding diverse needs employees effectiveness employee communications order maximise customers external stakeholders second annual awareness critical information within diverse global audience multicultural marketing diversity awards entrants streaming video project underway whichwill allow senior five countries highlighted innovative activities demonstrated executives communicate frequentlywithemployees business impact global management population gender per cent male per cent female moredetails health wellbeing diversity measures see corporate responsibility report global policies employee health supported mandatory section employment practices standards integrate employee health safety group committed employment policies free environmental requirements standards applied discrimination potential existing staff grounds groupsfacilities operations worldwide age race ethnic national origin gender sexual orientation based first year data theglobal health experience faith disability glaxosmithkline committed offering people three health areas identified additional focus disabilities access full range recruitment career musculoskeletal mental health conditions related opportunities material handling multidisciplinary teams working set baselinesalign reporting develop interventions effort recruitment help reduce incidence impact conditions whilst voluntary turnover four per cent glaxosmithkline future iscommitted continuing enhanceitsrecruitment processes candidate care transforms recruitment process customer human resources services information systems experience aiming build positive relationships glaxosmithklines human resource delivery strategy designed seek join stay group make technology humanresources services information delivered low cost highly effective talent management leadership development channels make easy job candidates employees every individual creates development plan yearly part retirees access information employment compensation pdp process key talentisthen identified talent reviews benefits policies programmes include intuitive conducted business function individuals given personalised web based tools available employees many feedback development needs key talent developed locations new positions assignments courses pool successors identified vicepresidentpositions critical positions organisationdescription business glaxosmithkline invest communities success partnership glaxosmithkline operate single charitable foundation number small countrybased foundations canada glaxosmithkline continues build history community czech republic france italy romania spain north investment programmes support better healthcare delivery carolina usa grants made foundations education underserved communities around world included investment total group active engagement numerous external stakeholders including world health organization glaxosmithkline member percent club giving members notforprofit community funds oneper cent itsprofit tax good causes communityled initiatives across world donates medicines recognised largest giver ftse company support humanitarian efforts communitybased healthcare previous three years many programmes long term commitments help bring sustainable change communities globalhealthprogrammes eliminating lymphatic filariasis community investment groups effort help rid world disabling disease lymphatic filariasis lfcontinuedin close partnership glaxosmithklines global community investment activities governments ofendemiccountries partner valued atmillion equivalent per cent group organisations thegrouphas committed donate much profit tax comprised product donations antiparasitic drug albendazole requiredto treat one million cash giving million inkind donations million billion people risk countries costs millionto manage deliver community programmes thancountries sixth year programmemillion albendazole treatments worthmillion wholesale acquisition cost product donations follows donated tocountries since theglobal elimination programme productdonations total million started overmillion people havereceived donated albendazole cumulative total ofmillion treatments patient assistant programs egyptand several pacific islands completed minimum million five rounds mass drug administration preliminary results look impressive albendazole lf million addition donating albendazole tabletsthe group gave grants millionand staff expertise support activities humanitarian product donations million global alliance eliminate lf glaxosmithklines positive action hivaids positive action glaxosmithklines year pioneering global programme working communities affected aids glaxosmithklines cash givingwastargeted primarily health supportscommunitybased organisationstodelivereffective hiv education initiatives aids education prevention healthcare servicesnew programmes launched latin america asia central breakdown ofcashgiving total million easterneuropeto address emerging epidemic positive action worked partners support health programmes countries including education raising awareness aids among men kenya providing ukprisoners education preventing blood arts culture borne diseases environment training trainers health socialcare workers african organisations promoting partnerships asia improve patients understanding treatment providing support thousands community delegates regional international aids conferences uk glaxosmithkline contributed millionin continuing corporate programme charitable activities supporting glaxosmithkline african malaria partnership organisationsin health medical research science glaxosmithkline african malaria partnership supports three education arts environment addition group behavioural development programmes working eight african companies uk provided million community countries following addition senegal programme purposes corporate programmes north america focused group disbursed grants improving public education access better healthcare millionthree year commitment partners freedom children seniorcitizenswith funding ofmillionin hunger african medical research foundation amref addition nearlymillionwas donated groups usbased plan international programmes expected benefit businesses regional community activities nearly two million people focus particularly young children pregnant women encouraging effective prevention measures prompt treatment antenatal malaria management glaxosmithkline description business invest communities continued phase group supported british lung foundations baby breathe phase initiative personal hygiene sanitation education easy programme two year grant funding providing education thousands school children inkenya pilot scheme run nine regions across uk zambia nicaragua peru improve health hygiene thissupportsparents carers ofbabies children fight infectious diseasesin groupcommitted three fivewithrecurringchest problems year funding extendthe programmeintouganda partnership ministry health amref education initiatives achievements phase recognisedwith world groups efforts improve public science education business award support millennium development goals included three year grant national board industry award disease prevention education professional teaching standards increase number science teachers pursuing certification innorth carolina humanitarian product donations philadelphia glaxosmithkline donated essential products grant center corporate citizenship antibiotics nonprofit partners including americares us chamber commerce links department education map international project hope response humanitarian programme review education impacts economy relief efforts community healthcare example group philadelphia education fund received grant donated products following floods bangladeshhurricanes middle grade matterscampaign improve middlelevel education usa caribbean typhoons philippines children aged conflict sudan asian tsunami glaxosmithkline continued support inspire innovative total value groupshumanitarian product scheme postdoctoral researchers research education donations wasmillion excludes albendazole donated scheme developed partnership imperial college london lymphatic filariasis elimination programme product specialist schools trust milliondonation donations valuedat wholesale acquisition cost four years inspire places postdoctoral researchers specialist wholesale list pricenot including discounts standard science schools assist science teaching industry method science summer free librarybased science education community initiatives programme philadelphia area teaching basic scientific glaxosmithkline dedicated strengthening fabric concepts continued receive support grant communities whereit operatesthrough providing health th year children participated education initiatives support local civic cultural programme science across world awardwinning institutions improve quality life glaxosmithklines international education programme uses webbased resources contribution improve healthcare includes threeyear grant promote discussion science issues children millionwhich helped expand childrens schools inover countries received grant health funds referral management initiative rmi seven us states ensuring continuity specialist medical care highrisk employee involvement children often homeless glaxosmithkline employees encouraged contribute theirlocal communities employee volunteering schemes thegroup supported arthur ashe institute urban health support varies around world includes employee time grants totalling three years core funding cashdonations charities employeesvolunteerand community health empowerment programtoprovide matching gifts programme many countries glaxosmithkline health education lowincome neighbourhoods non offers taxefficientmethodsfor employee givingin accordance traditional venuessuch churches shops local taxation guidelines glaxosmithklinecontinues itsyear partnership barretstown usa group matched ireland lenvol france provide lifechanging activity employee retiree gifts value million programmes backed medical community foreuropean group also matched million employee donations children cancer lifethreatening illnesses helping themto glaxosmithklineand united way campaigngiving combined rediscover theirconfidenceselfesteemand participate fullyin contributionof million addition glaxosmithklines everyday lives received investment volunteer excellencegive programme provided respectively grants charitable organisationswhere employees annual impact awards recognise excellence work partners volunteered least hours year nonprofit community health organisations across uk glaxosmithklines making difference programme uk greater philadelphia area usa charities provided grants nonprofit organisations receivedunrestricted awards work dealing diverse registered charities based employee involvement issues domestic community violence sexual health young peopleand child abuse medical research provided uk medical charities breakthrough breast cancer cystic fibrosis trust debra ehlersdanlos support group motor neurone disease associationdescription business glaxosmithkline consumer healthcare current business five global brand concepts teams glaxosmithkline consumer healthcare manufactures markets aquafresh consumer brands healthcare industry organisation sensodyne structure responsibility global regional local levels dental care cold sore operations span majority worlds geography panadol sold principally across two major trade channels grocery smoking control pharmacy brands marketed across full regulatory future group also includes centres excellence global spectrum prescription free sale project management medical marketing emarketing support environment consumer healthcare business functions also reorganised effectively serve new operates become ever challenging model consumers demanding better quality better value lead market brands per cent global sales improved performance brands large marketed several territories retailers consolidated globalised therefore generally one anchor market lead development strengthened negotiation power businesses markets still enjoy central rd competitors finding conditions equally challenging resource include brands lucozade ribena horlicks therefore competing aggressively across elements tums anddr best marketing mix enterprise brands per cent global sales cycle times innovation reduced remaining valuable local brands managed new model retains local responsibility brand communications new strategy innovation enterprise brands also supported vision consumer healthcare business global regionallyfocused resources enable application fastest growing consumer healthcare group best practice crosspollination innovation innovation centred consumers delivered science success consumer healthcares new business model order conduct business effectively current reflected sales growth global lead market environment consumer healthcare business strategy enterprise brands operating model redesigned new model implemented operational targeted research development consumer healthcare deliver faster sales growth achieve vigorous focus delivering new product developments tightly aligned rd aligned closely new consumer healthcare consumer needs new model effectively welds operating model structure global brands together rd marketing commercial operating units mirrors commercial structure rd teams paired new culture providing future group teams located principal centres consumer healthcare rd weybridge uk greater focus alignment simplicity less proliferation parsippany usa colocation sites duplication bureaucracy termed innovation centres focus rd better faster ways working together dilution identification rapid development novel products local knowledge implementation power bring benefits consumers overthecounter otc oral care nutritional healthcare markets new structure focus new operating model brands growth opportunities consequently brands split three categories business structure centred global brands lead market brands enterprise brands global brands per cent global sales brands sales multiple markets similar positioning may developed effectively using global approach new team called future group created group assumes responsibility consumer market understanding brand equity strategy innovation pipeline communication future group comprises dedicated resources idea generation innovation development covering product packaging whole communications mix glaxosmithklinedescription business global manufacturing supply glaxosmithkline large portfolio products ranging regional pharma supply tablets toothpaste inhalers complex capsules regional pharma supply focuses several key activities different pack sizes presentations supply products key one regions supply products important particular market manufacture medicines begins development tailoring packaging meet specific local requirements key therapeutic active ingredient bulk active selected formulation focus regional pharma supply team reducing costs global manufacturing supply gms develops manufacturing glaxosmithkline compete effectively processes full scale volume production active compounds markets sites countries regional pharma primary manufacturing sites converting active compounds supply finished dosage formulation responsibility secondary manufacturing sites new product global supply gms operates single global network sites new product global supply focuses ensuring countries year gms produces around tonnes bulk appropriate technical competencies exist support rapid actives four billion packs packaged successful new product introduction works closely rds delivered sale countries throughout world development team also ensures secure supply also supports approximately new product line extension key brands sold across many markets global launches year distribution division focal point developing introducing new secondary manufacturing technologies gms adopting leading edge practices developing people gms coordinates primary supply operations ensure optimal expects derive benefits alignment two divisions full value stream secure source supply high quality products approach introducing new products eight sites six countries new product global supply compliance regulatory requirements customer expectations operational excellence best class cost gmshas developed set metrics common methodology driving improvement particular focused organisation increasing robustness manufacturing processes reduce waste maintain highest quality standards extensive supply divisions leadership education carried reinforce culture former five geographic supply chain structures continuous improvement staff empowered solve problems four supply divisions sites grouped together based upon rigorous controlled structured way given common business drivers areas expertise commercial capability drive stepchange performance implement activities support four divisions described improvements rapidly across manufacturing network since formation glaxosmithkline merger rationalisation primary supply andantibiotics operational excellence initiatives reduced number primary supply antibiotics focuses ensuring supply manufacturing sites per cent high quality competitively priced bulk actives driving improvements primary technologies processes also external suppliers supports delivery maximum value antibiotics manufacturing spends billion many external suppliers franchise combined primary secondary approach every year including purchase active ingredients chemical cost competitive supply response market opportunities intermediates partfinished finished products gms takes customer needs sites eight countries appropriate steps protect supply chains disruption primary supply andantibiotics resulting interrupted external supply appropriate stock levels contracting alternative registered suppliers consumer healthcare supply consumer healthcare supply focuses delivering highquality vaccines supply chain competitivelyproduced products offering capability vaccine manufacturing located primarily rixensart wavre rapid new product introduction highly innovative belgium three sites france germany hungary competitive business far shorter time frames two joint ventures china russia managing vaccine pharmaceuticals new technologies become fundamental supply chain involves anticipating market needs using flexible platform lowering costs providing flexibility operations approach able meet fluctuations demand sites countries consumer healthcare supply based forecasts different markets firm orders health authorities mass vaccination campaigns bulk filling packaging carefully balanced stocking vaccines helps manage shortterm increases demand increases prompted disease outbreaks increased demand public owing disease awareness campaignsdescription business glaxosmithkline products competition pharmaceutical products antivirals combivir combination retrovirand epivir consolidated glaxosmithklines principal pharmaceutical products presently position two reverse transcriptase inhibitors directed nine therapeutic areas analysis salesby cornerstone many multiple antihiv product regimens therapeutic areas description principal products physician acceptance clearly demonstrated value placed setout minimising pill burden faced patients turnover therapeutic area ziagenis reverse transcriptase inhibitor products potency respiratory ease use resistance profile allow play significant central nervous system role variety highly active well tolerated andsimplified hiv antivirals treatment regimens antibacterialsantimalarials triziviris combination combivirand ziagen combining three metabolic antihiv therapies one tablet twice daily administration vaccines oncology emesis epzicomkivexa approved fda august cardiovascular urogenital combination epivirand ziagenthat taken one tablet oncedaily dosing hivaids combination least one antihiv drug lexivatelzir protease inhibitor treatment hiv products versions may approved indications well tolerated convenient agenerase markets available supersedes lexiva may taken twice daily daily boosted ritonavir respiratory seretideadvair combination sereventand flixotide offers zeffixhas approved marketing usa europe china alongacting bronchodilator antiinflammatory single markets treatment chronic hepatitis b inhalerit approved treatment asthma copd valtrexis treatment episodic genital herpes well flixotidefloventand becotidebecloventare inhaled steroids long term suppression reduction transmission genital treatment inflammation associated asthma copd herpes zoster shingles cold sores chicken pox valtrex supersedes zovirax also used treat herpes infections sereventis longacting bronchodilator used treat asthma copd ventolinis selective shortacting bronchodilator used antibacterials antimalarials treat bronchospasm augmentinis broadspectrum antibiotic suitable flixonaseflonaseand beconaseare intranasal preparations treatment wide range common bacterial infections treatment perennial seasonal rhinitis particularly effective respiratory tract infections augmentin esis extra strength suspension specifically central nervous system cns designed treat children recurrent persistent middle ear seroxatpaxilis selective serotonin reuptake inhibitor ssrifor infections augmentin xris extra strength tablet form treatment depression panic obsessive compulsive disorder adults combat difficult treat infections post traumatic stress disorder social anxiety disorder premenstrual zinnatis oral antibiotic used primarily communityacquired dysphoric disorder general anxiety disorder infections lower respiratory tract wellbutrinis antidepressant available usa normal malaroneis oral antimalarial used treatment sustainedrelease sr daily formulations prophylaxis malaria caused plasmodium falciparum imigranimitrexis ht receptor agonist used treatment lapdapis effective well tolerated therapy treatment ofsevere frequent migraine cluster headache malaria developed become reference product sector naramigamergeis publicprivate collaboration newer migraine product lamictal well established treatment epilepsy also indicated bipolar disorder requipis specific dopamine dd receptor agonist indicated treatment ofparkinsons disease glaxosmithklinedescription business products competition continued metabolic cardiovascular urogenital avandiais potent insulin sensitising agent acts coregis alphabeta blocker proven underlying pathophysiology type diabetes effective intreating patients mild moderate severe heart failure heart attack hypertension glaxosmithkline sole avandametis combination avandiaand metformin hci marketing rights usa canada generic versions first medicine targets insulin resistance decreases product available canada glucose production one convenient pill levitrais pde inhibitor indicated male erectile dysfunction avandaryl fixeddosed combination avandia amaryl glaxosmithkline copromotion rightsin usaand sanofiaventis productwas approved canada markets october fda approvable letter received glaxosmithkline working fda bring avodartis ari inhibitor currently indicated benign prostatic resolution outstanding issues hyperplasia large clinical outcome study underway examining efficacy prevention prostate cancer vaccines arixtra fraxiparinewere acquired part glaxosmithkline markets range hepatitis vaccines havrix divestitures required merger sanofiand aventis protects hepatitis engerixbagainst hepatitis b arixtraa selective factor xa inhibitor indicated twinrixis combined hepatitis b vaccine protecting prophylaxis deep vein thrombosis may lead pulmonary diseases one vaccine available adult embolism hip fracture surgeryknee replacementand hip paediatric strengths replacement surgery also indicated treatment deep infanrix range paediatric vaccine combinations infanrix vein thrombosis andpulmonary embolism provides protection diphtheria tetanus pertussis fraxiparineis lowmolecular weight heparin indicated whooping cough infanrix pentapediarix provides additional prophylaxis thromboembolic disorders particularly deep vein protection hepatitis b polio infanrix hexa thrombosis pulmonary embolism general surgery adds protection haemophilus influenzae type b orthopedic surgery treatment deep vein thrombosis causes meningitis prevention clotting hemodialysis glaxosmithkline also markets priorix measles mumps european marketing rights tointegrilinwere acquired rubella vaccine typherix vaccine protection typhoid gp iibiiia inhibitor approved eu prevention fever varilrix vaccine varicella chicken pox early myocardial infarction addition group markets range vaccines prevent meningitis umbrella name mencevax category includes betnovate thehigher potency dermovate oncology emesis newer cutivatewhich antiinflammatory steroid zofranis used prevent nausea vomiting associated products used treat skin diseases suchas eczema psoriasis chemotherapy radiotherapy cancer available relafena nonsteroidal antiinflammatory drug treatment bothoral injectable forms also approved use arthritisand zantac treatment peptic ulcer disease prevention treatment postoperative nausea vomiting range ofgastric acid related disorders hycamtinis second line treatment ovarian cancer forsmall cell lung cancer bexxaris treatment patients cd follicular non hodgkins lymphoma without transformation whose disease refractory rituximab relapsed following chemotherapydescription business glaxosmithkline pharmaceuticals competition antivirals major competitors hiv market include gilead bristol myers pharmaceutical industry highly competitive squibb abbott merck pfizer glaxosmithklines principal competitors large international pharmaceutical companies substantial resources glaxosmithkline pioneering role hiv market companies major products mentioned retrovirand epiviracting cornerstone combination therapyand available combivirin single tablet launches pharmaceuticals may subject competition ziagen agenerasetrizivir lexiva andepizcom broadened products period patent protection thegroups portfolio hiv products patent generic versions manufacturers generic products typically donot bear significant research development valtrexhas strengthened groups position antiherpes costs consequently areable offer products area zoviraxfaces competition generic aciclovir valtrex considerably lower prices thebranded competitors research zoviraxcompete novartis famvir zeffixwas first development based pharmaceutical company normally antiviral market treat hepatitis b gileads hepsera seek achieve sufficiently high profit margin sales volume second glaxosmithkline marketing rights hepserain period patent protection repay original key markets investment generally substantial fund research forthe future competition generic products generally occurs antibacterials antimalarials patents major markets expire increasingly patent challenges generic versions augmentinand ceftinzinnatare available made prior patent expiry claiming innovator patent usa augmentinhas also lost patent protection various valid andor infringed generic product countries europe augmentinxrand augmentinescompete following loss patent protection generic products rapidly broad range branded generic antibiotics capture large share market particularly usa malarones safety profile convenient dosing regimen helped put product strong position versus mefloquine glaxosmithkline believes remaining competitive dependent malaria prophylaxis upon discovery development new products together effective marketing existing products within metabolic pharmaceutical industry introduction new products major competitor avandiais takeda chemicals actos processes competitors may affect pricing levels result copromoted eli lilly usa changing patterns product use assurance products may become outmoded notwithstanding patent vaccines trade mark protection addition increased government glaxosmithklines major competitors vaccine market include pressures physicians patients use generic sanofipasteur sp merck wyeth engerixband havrix pharmaceuticals rather brandname medicines may increase compete vaccines produced sp merck comvax competition products longer protected patent recombivax hb hepatitis b vaqta avaxim hepatitis infanrixsmajor competitor sps range dtpabased respiratory combination vaccines glaxosmithklines respiratory franchise driven growth seretideadvair gaining patients competitor products oncology emesis cannibalisation sereventand flixotideflovent major zofran presently provides glaxosmithkline leadership respiratory competitors singulair merck especially position antiemetic market competitor companies usa europe symbicort astrazeneca spiriva include roche sanofiaventis recently merck major pfizerboehringer ingelheim competitors diverse cytotoxic market include bristol myers squibb sanofiaventis pfizer novartis glaxosmithklines cns disorders cytotoxic portfolio led hycamtinand navelbine currently holds major competitors usa paxilareits generic formsas relatively small market position well generic fluoxetine generic form eli lillys prozac zoloft pfizer forest laboratories celexa lexapro cardiovascular urogenital principal competitors usa wellbutrinaregeneric forms glaxosmithkline markets coregin usa major bupropion generic forms ssris effexor xr wyeth competitors toprol xl generic betablockers avodart product paxil crand oncedaily wellbutrin xlhelp retain competes directly mercks proscar within bph market strong presence antidepressant market given glaxosmithkline copromotion rights usa availability generic paroxetinein usa generic competition countries levitrawhich faces competition seroxatpaxil also commenced uk number pfizers viagra lillyicos cialis markets glaxosmithklinedescription business products competition continued consumer healthcare products oral care leading oral care products toothpastes mouthwashes glaxosmithklines principal consumer healthcare products aquafresh sensodyne macleansand odolbrand three major areas analysis sales areas isset names range toothbrushes sold aquafresh dr bestnames addition denture care products available principally polident poligripand coregabrand names otc medicines nutritional healthcare oral care leading products category lucozade glucose energy nutritional healthcare sports drinks ribena blackcurrant juicebased drink rich vitamin c horlicks range milkbased malted food chocolate drinks sales three per cent higher cer terms declined one per cent sterling terms consumer healthcare competition glaxosmithkline holds leading global positions key major products necessarily sold markets consumer product areas worldwide second largest category product oral care third largest otc medicines nutritional overthecounter medicines healthcare holds leading position uk india analgesics panadol ireland dermatologicals zovirax main competitors include major international companies abreva colgatepalmolive johnson johnson pfizer procter gamble gastrointestinal tums unilever wyeth addition many companies citrucel compete glaxosmithkline certain markets respiratory tract contac beechams major competitor products otc medicines smoking control commit usa metamucil laxative pepcid indigestion nicorette private label smoking control products nicoderm cq niquitin cq uk lemsip cold remedy nurofen anadin nicabate cq analgesics nicorette nicotinell smoking control natural wellness support abtei treatments oral care aquafresh oral care major competitors colgatepalmolives colgate dr best procter gambles crest macleans nutritional healthcare major competitors horlicksare odol ovaltine milo malted food chocolate drinks odol med competitors ribenaare primarily local fruit juice products polident lucozadecompetes energy drinks poligrip sensodyne nutritional healthcare lucozade ribena horlicks overthecounter medicines leading products panadol widely available paracetamolacetominophen analgesic nicorettegum usa nicoderm niquitin cqandnicabaterange smoking control products tumsa calciumbased antacid citrucellaxative contac treatment colds abtei natural medicines vitamin range andzoviraxand abrevafor treatment cold sores group obtained otc marketing rights orlistat usa fda approved prescription product obesity management marketed roche xenicaldescription business glaxosmithkline regulatory environment regulation pharmaceuticals across international markets countries outside usa europe regulatory environment continues extremely glaxosmithkline operates within highly regulated environment varied challenging glaxosmithkline anticipates regional countryspecific laws regulations define data introduction new products continue require substantial required show safety efficacy pharmaceutical products effort time expense comply regulatory requirements well govern testing approval manufacturing labelling marketing drugs regulatory requirements major price controls factor determining whethera marketable product may manycountries prices pharmaceutical products successfully developedand amount time expense controlled law governments may also influence prices associated development control national healthcare organisations may bear large part cost supplying products consumers recent regulation process government healthcare reforms countries france spain glaxosmithklineadopted common technical germany may restrict pricing reimbursement document format marketing applications major supplements thisis single format registering product usa recent legislation healthcare reform crossborder accepted regulatory authorities many regionsthese trade acceleration generics market increased patient applications prepared submitted electronically contributions increased focus pricing currently government price controls private sector harmonisation activities global regional level purchases federal legislation requires pharmaceutical ongoing success standardisation however manufacturers pay prescribed rebates certain drugs order regulatory environment varied changes rapidly national eligible reimbursement medicaid federal regulatory authorities many jurisdictions high standards healthcare programmes technical appraisal consequently introduction new pharmaceutical products generally entails lengthy medicare approvalprocess us medicare prescription drug improvement european union currently two procedures modernization act provides limited immediate benefits obtaining marketing authorisations medicinal products medicare patients disabled years old form government sponsored discount cards centralised procedure applications made direct replaced comprehensive outpatient drug benefit theeuropean medicines evaluation agency leading benefit intended administered number private authorisation valid member states compulsory organisationsthatwill construct benefit structures consistent products derived biotechnology optional new federal law market benefit medicare patients activesubstances innovative medicinal products law provides strong incentives manufacturers mutual recognition procedure applicable negotiate prices plan sponsors bill provide majority conventional medicinal products operates explicit government price controls seniorcitizensalready mutual recognition national marketing authorisations drug coverage greatest increase demand likely agreement reached resolved tobe population lowincome seniorcitizenswho procedure binding arbitration coverage lowincome seniorcitizenswill receive subsidies new eu legislation implemented end premiums deductible copayments associated improve centralised procedure increase comprehensive benefit range products compulsory mutual law also changes way drugs administered insurgeries recognition procedure thedecentralised procedure clinics hospital outpatient departments reimbursed intended facilitate agreement member states instead reimbursement based prices published also amended implementation new legislation independent pricing servicesdoctorand clinic reimbursement bring number changes example increased based actual market prices reported manufacturers post marketing safety monitoring new types conditional audited government formula used hospital product approvals outpatient reimbursement change us grant marketing authorisation affords group protection government directed devise new costbased methodology period competitor rely confidential data beyond regulatory file basis marketing authorisation new eulegislation first time harmonise data protection period submission routes fda introduced new focus called critical path initiative thisis intended enable innovation drug development hopefully allowing rapid development approval needed medicines initiative investigate use pharmacogenomics surrogate markers efficacy among things manufacturing innovations tools rapidly developing producing safe effective drugs unmet medical needs glaxosmithklinedescription business regulatory environment continued value money basic patent position respect significant products becoming increasingly necessary demonstrate value follows money new products particular impacton drug budget augmentinthe patent key active ingredient potassium expenditure burden disease treated clavulanate expired markets except italy b markets need satisfy healthcare purchasers generic competition exists markets value money becoming additional hurdle product avandia avandametthe patent active ingredient acceptance regulatory tests ofsafety efficacy rosiglitazone due expire acin usa quality delay bringing effective improved bin europe patents commercial form active medicines market reduce effective patent ingredient rosiglitazone maleate due expire protection time usa bin europe litigation challenging validity many marketsespecially usa europe becoming patents protecting products ongoing usae increasingly difficult even significantly improved therapy avodartthe patent active ingredient dutasteride obtain premium price existing medication valuebased normal expiry usa bin europe pricing may difficult toapplyin circumstances although usa still possible price products reflect value combivirthe patent specific combination lamivudine possible predict whether extent zidovudine due expire usa groupsbusiness may affected future legislative bin europe regulatory developments relating specific pharmaceutical coregglaxosmithkline exclusive licensee us products price patent active ingredient carvedilol due expire regulation consumer healthcare epivirthe patent active ingredient lamivudine due consumer healthcare industry subject national regulation expire acin usa bin europe testing approval manufacturing labelling marketing flixotidefloventand flixonaseflonasein usa patent products many countries high standards technical active ingredient fluticasone propionate expired may appraisal entail lengthy approval process new product european countries protection expires march b launched imigranimitrexthe patent active ingredient sumatriptan national regulatory authorisation also required approve due expire cin usa bin europe switch products prescription otc requirements b italy litigation challenging validity patent include longterm experience quality safety efficacy protecting product ongoing usae product wide patient population data confirm relevant condition selflimiting easily lamictal patent active ingredient lamotrigine diagnosed consumer due expire acpaediatric extension pending usa bin countries europe litigation challenging intellectual property validity patent usa recently settlede intellectual property key business asset glaxosmithkline levitrad glaxosmithkline copromotion rights us effective legal protection intellectual property critical patent active ingredient vardenafil due ensuring reasonable return investment rd intellectual expire usa property protected patents trade marks registered lexivatelzirglaxosmithkline exclusive licensee designs copyrights domain name registrations patent patent active ingredient fosamprenavir due trade mark rights regarded particularly valuable expire usa bin europe many cases generic manufacturers launch attempt paxilseroxatthe patent commercial form active launch generic versions patented drugs prior normal patent ingredient paroxetine due expire cin usa expiry arguing relevant patents invalid andor europe litigation relating tothe validityand infringed product significant litigation concerning infringement patents protecting product ongoing challenges summarised innote financial statements usae generic competition commenced usa legal proceedings europe certain markets paxil cris protected formulation patent due expire patents glaxosmithklines policy obtain patent protection retrovirthere patents active ingredient zidovudine significant products discovered developed rd patents covering pharmaceutical formulations containing activities patent protection new active ingredients available zidovudine medical use due expire significant markets protection also obtained new usa europe pharmaceutical formulations manufacturing processes new medical uses special devices administering productsdescription business glaxosmithkline seretideadvairthe patent specific combination active responsibility environment health safety ingredients salmeterol xinafoate fluticasone propionate environment health safety ehsis key element corporate due expire usa bin europe responsibility group high priority responsibility application reissue us patent filed ehs highest level corporate group reporting glaxosmithklinee uk patent revoked uk general counsel overall responsibility providing courts patents individual ingredients expire governance leadership ehs issues head group uk usa patent salmeterol xinafoate makes regular reports corporate executive team cet expire audit corporate responsibility committees board sereventthe patent active ingredient salmeterol xinafoate directors within businesses operations managers due expire bin europe b responsible ehs supported sitebased ehs france b italy usa occupational health professionals trizivir patent specific combination lamivudine zidovudine abacavir due expire ehs strategy usaand europe glaxosmithkline tenyear strategic plan managing ehs sustainability throughout business ehs plan valtrex patent active ingredient valaciclovir due excellence aligned groups strategy year expire usa bin europe litigation special focus theme responding challenging validity patent protecting product external challenges time continued focus themes ongoing usae previous years continues drive improvements wellbutrin sr wellbutrin xl andzybanthe patenton theactive programmes key risk areas ingredient hasexpired generic competition sr instant release ir forms usa europe regulatory responding external challenges data exclusively provides protection least society expects glaxosmithkline take responsibility markets usa wellbutrin xlis protected environmental impact products well two formulation patents due expire operations focus attention expanded production litigationrelating tothe validityand infringement one products environmental impact arise stage patents ongoing theusae product life cycle theme ehs plan excellence responding external challenges focused three key ziagen thepatenton active ingredient abacavirisnot due areas pharmaceuticals environment chemicals policy expire acin usa bin europe climate change zofran thepatenton active ingredient ondansetronisnot due expire cin usa bin europe b completing core programmes france bitaly patents use treating emesis expire ehs plan excellence focus completing core litigationchallenging validity ofthe emesis use programmes measured improved audit scores patent ongoingin usae achievement performance targets set trade marks business drivers ehs glaxosmithklines pharmaceutical products protected new product development registered trade marks major markets general product stewardship environmental aspects sustainable mark used product market around world development principles introduced aspects may local variations example usa trade new product development entire life cycle impact mark paxilis used instead seroxatand advairis used instead product considered order address adverse impacts seretide optimise resources consumed reduce waste produced trade mark protection may generally extended long alternative chemistries processes reviewed build safety trade mark used renewing necessary processes improve mass productivity glaxosmithklines trade marks pharmaceutical products optimises resource consumption waste generation generally assume increasing importance patent also addresses triple bottom line considerations product expired particular country generic versions product become available product commercialisation ehs helps speed products market addressing regulatory consumer healthcare trade marks particularly important concerns development incorporating ehs business brand orientated many products decisionmaking design packaging labelling possible patent protection reduce costs differentiate products extend product life including patent term restoration hatchwaxman act b including extension term national european supplementary protection certificates c including extension term paediatric exclusivity aregistered trademark bayer ag e seenote financial statementslegal proceedings glaxosmithklinedescription business regulatory environment continued global competitor ehsimprovement competitive advantage may gained improving public trust objectives focused emerging issues based applying best business processes globally fostering pharmaceuticals environment chemicals policy climate culture continuous improvement optimising processes change theme responding external ehs challenges making economically viable potential created numerical targets ehs performance improvements set lowering price medicines contribute accomplished five years progress toward meeting social benefit allowing greater access global markets targets tracked every year published website wwwgskcom date significant progress made glaxosmithkline people towards achieving ehstargets many ehs programmes focused protecting people glaxosmithkline committed working towards designing glaxosmithkline selects measures performance improvement workplace minimises workrelated risks safety health based potential adverse impact people provides shirtsleeve environment personal safety environment business continuity business reputation equipment required routine basis protect measures selected similar reported employees health laboratory manufacturing operations companies recommended global reporting initiative longterm multistakeholder international undertaking ehs management develop disseminate globally applicable sustainability glaxosmithkline takes systematic approach managing ehs reporting guidelines risks impacts framework information programmes based global ehsstandards guides management sustainability key aspects impacts risks throughout organisation work towards eventual sustainability glaxosmithkline addressing economic environmental social issues research ehs audits manufacturing sales distribution medicines part governance responsibility glaxosmithkline conducts sustainability starts healthcare solutions found research ehs audits sites assessing performance ehs development continues sustainable solutions standards assigning quantitative performance scores manufacturing sales group currently looking sites audited part continuous improvement improving operational efficiency future investigate process progress monitored actions arising issues use renewable resources overall balance raised audits impact society environment group seeks dialogue external stakeholders considers views part commitment corporate social responsibility developing approaches sustainable development proactive management glaxosmithkline manufacturing information ehs programmes performance may found supply base key contract manufacturers website suppliers also assessed process evaluated management human rights ehs risks impacts based groups requirements contract manufacturers recommendations made improvements neededglaxosmithkline corporate governance section discusses glaxosmithklines management structures governance procedures contains companys reporting disclosures corporate governance required thecombined code corporate governance financial reporting council combined code including required statement compliance company reports compliance uslaws regulations apply board corporate executive team governance policy dialogue shareholders annual general meeting internal control framework committee reports combined code us lawand regulation glaxosmithkline corporate governance board dr ronaldo schmitz aged appointed rd may sir christopher gent aged nonexecutive director dr schmitz formerly nonexecutive appointed st june director glaxo wellcome plc nonexecutive director chairman sir christopher wasthe chief executive officer legal general group plc member board directors vodafone plc retirement july anon rohm haas company cabot corporation executivedirector lehman brothers holdings incadirector international advisory board hakluyt coand senior dr lucy shapiro aged adviser bain co appointed rd may nonexecutive director dr shapiro formerly nonexecutive dr jeanpierre garnier aged director smithkline beecham plc ludwig professor appointed rd may cancer research department developmental biology chief executive officerdr garnier appointed executive director beckman center molecular genetic director smithkline beecham plc became chief medicine stanford university school medicine executive officer april nonexecutive director nonexecutive director anacor pharmaceuticals inc holds united technologies corporation member board phd molecular biology albert einstein college trustees eisenhower exchange fellowships holds medicine phd pharmacology university louis pasteur france mba stanford university usa sir robert wilson aged appointed st november john coombe aged nonexecutive directorsir robert nonexecutive chairman appointed rd may retiring st march bggroup plc economist group previously chief financial officermr coombe formerly executive executive chairman rio tinto plc director glaxo wellcome plc responsible finance investor relations member supervisory drtachiyamadaaged board siemens ag code committee uk appointed st january takeover panelandwas appointed nonexecutive director chairman research development dr yamada wasa non hsbc holdings plconst march executive director subsequently executive director smithkline beecham plc prior joining smithkline beecham lawrence culp aged chairman department internal medicine appointed st july university michigan medical school physicianinchief nonexecutive director mr culp president chief executive university michigan medical center member officer danaher corporation prior joining danaher held board directors diadexus inc december positions accenture previously andersen consulting isa trustee rockefeller brothers fund sir crispin davis aged chief financial officer designate appointed st july julian heslop aged nonexecutive director sir crispin chief executive reed mr heslop succeed mr coombe chief financial officer elsevier plc prior chief executive aegis group effect st april whenhe also join board plc joined guinness plc member mr heslop joined glaxo wellcomeas financial controllerin april main board group managing director united january following merger appointed distillers spent early career procter gamble senior vicepresident operations controller prior joining sir deryck maughan aged glaxowellcomehe held senior finance roles grand appointed st june metropolitan plc nonexecutive director sir deryck formerly chairman directors ceo citigroup international salomon brothers inc dr michle barzach mr donald mchenry mr john mcarthur serves boards directors carnegie hall lincoln center allnonexecutive directors retired board following nyumedical center also international advisory conclusion agm th may sir christopher board member british american business incand board hogg former chairman sir peter job nonexecutive member ofthe american academy berlin trilateral directors retired board st december commission served asvice chairman new york stock exchange details membership board committees may found sir ian prosser aged page appointed rd may senior independentdirector sir ian formerly nonexecutive director smithkline beecham plc chairman chief executive bass plclatterly intercontinental hotels plcand chairman world travel tourism council nonexecutive deputy chairman bp plc nonexecutive director saralee corporation also member cbi presidents committeecorporate governanceglaxosmithkline corporate executive team cet david stout presidentpharmaceutical operations jp garnier mr stout responsible global pharmaceuticals vaccines chief executive officer businesses joined smithkline beecham head chief executive officer dr garnier responsible us sales marketingand president uspharmaceuticals management group oversees operational aspects current appointment january group includingestablishingpolicies objectives initiatives directs longterm strategy formerly chief executive chris viehbacher officer smithkline beecham joined group presidentuspharmaceuticals mr viehbacher responsible uspharmaceuticals since rupert bondy january joined wellcome became director senior vice president general counsel continental europe glaxo wellcome mr bondy responsible legal matters across group responsible glaxosmithklines european pharmaceuticals together environmental health safety issues insurance business current appointment security lawyer private practice joining smithkline beecham andrew witty presidentpharmaceuticals europe ford calhoun mr witty responsible groups pharmaceuticals chief information officer operations europe since january joined glaxo dr calhoun responsible information technology global glaxosmithkline senior vice president asia pacific function enables key business processes across parts current appointment group doctoral postdoctoral training microbiology genetics biomathematics computer science joined smith tachiyamada kline french chairmanresearch development dr yamada leads groups complex business drug discovery john coombe developmentcreating new medicines research chief financial officerretiring st march joined smithkline beecham nonexecutive member head finance function mr coombe responsible board became chairman rd pharmaceuticals activities financial reporting control tax treasury appointed board directors st january investor relations finance systems internal audit real estate joined glaxo group financial controller jennie younger appointed group finance director senior vice presidentcorporate communications community partnerships marc dunoyer mrs younger responsible groups internal external presidentpharmaceuticals japan communications image partnerships global mr dunoyer appointed president pharmaceuticals japan communities joined glaxo wellcome director march joined group senior vice investor relationsand appointed current position president regional director japan current european women achievement appointment award business russell greig jack ziegler presidentpharmaceuticals international presidentconsumer healthcare dr greig leads pharmaceutical operations outside usa mr ziegler head global consumer healthcare business europe covering countries joined produces oral healthcare overthecounter medicines group senior vice president worldwide nutritional healthcare products joined smithkline beecham business development rd prior current appointment appointed president consumer march healthcare business dan phelan julian heslop senior vice presidenthuman resources chief financial officer designate mr phelan responsible benefits compensation recruitment mr heslop succeed mr coombe chief financial officer organisation development leadership development succession effect st april whenhe also join cet planning human resource information systems employee health management lawyer private practice mr heslop joined glaxowellcomeas financial controllerinapril joining smith kline french appointed following completion merger appointed senior vice president director human resources smithkline senior vice president operations controller beecham members david pulman mr ingram continues work parttime vice chairman presidentglobal manufacturing supply pharmaceuticals acting special advisor group dr pulman responsible theglobalmanufacturing andsupply attendingcet meetings capacity organisation global procurementhe joined glaxo responsible north american supply network manufacturing strategy logistics current appointment glaxosmithkline corporate governance governance policy board process board authority accountable shareholders board corporate executiveteam ensuring company appropriately managed directors listed board page achieves strategic objectives sets board discharges board responsible groups system corporate responsibilities annual programme meetings governance ultimately accountable groups activities includes approval overall budgetary planning strategy financial performance business strategy chief executive officerceo responsible executive board reviews companys internal controls risk management group assisted cetthe management policies approves governance structure cet meets times per year otherwise necessary code ethics board appraises approves major financing members responsibilities listed corporate investment contractual decisions excess defined executive team page thresholds addition matters board evaluates monitors performance group whole includes board comprises three executive andeightnonexecutive directors whilst board considers nonexecutive directors engaging board meetings ceo executive independent character judgementit determined directors members cet appropriate one nonexecutive directordr shapiroshould financial operating performance glaxosmithkline considered independent combined codedr shapiro external issues material groups prospects considered independent due remuneration evaluating progress toward achievement groups receives groupas member ofthe glaxosmithkline financial business objectives annual plans scientific advisory board sir christopher gentwas appointed boardas deputy chairmanhe determined monitoring reports received directly various board independent upon taking chairmanship committees thesignificant risks facing group boardon st january accordance board overall responsibility succession planning combined codehe excluded determination ceo executive directors board given whether least half board independent nonexecutive ceo broad authority operate business group directors neither dr shapironor sir christopher gent hold ceo accountable reports board positions board committee independence required business performance combined code cet members make regular presentations board board considers mr culp sir crispin davissir deryck areas responsibility board meets cet maughan sir ian prosser dr schmitz sir robert wilson members annual basis discuss collectively groups independent accordance recommendations strategy primary element induction process new combined code nonexecutivedirectors undertaken members cet following directors whoretiredduring year allnonexecutivedirectors encouraged separate considered board independent accordance informal discussions discretion cetmembers combined code dr barzachbecause received board met six times member attending remunerationfrom group subsidiaryas healthcare consultant follows andmr mchenry andsir christopher hoggdue length number meetings number service mr mcarthurand sir peter jobwho also retired name held whilst board member meetings attended yearwere bothconsidered independent sir christopher gent dr jpgarnier date publicationand throughout majority mr j coombe board members excluding chairman independent dr yamada nonexecutive directors mr l culp sir christopher hogg chairman throughout sir crispin davis retired board st december may sir deryck maughan sir christopher gent appointed deputy chairman effect sir ian prosser st june board agreed sir christopher gent dr r schmitz would succeed sir christopher hogg chairman effect dr l shapiro st january dr garnier isceo sir robert wilson sir christopher hogg chairman leads board represents board dr barzach ceo cet members necessary board sir peter job meetings ceo manages group implements mr jmcarthur strategy policies adopted board chairman mr mchenry chairmen board committeescommunicate regularly ceo cet members division responsibilities addition six scheduled meetings referred role chairman ceo set board also met quorate basis oneoccasion writing agreed board appears full thewebsite sir ian prosser senior independent director sid throughout corporate governanceglaxosmithkline independent advice chairman company ceo responsible board recognises may occasions one evaluating making recommendations board directors feel necessary take independent legal remuneration nonexecutive directors andor financial advice companys expense agreed procedure enable procedure nominations committee followed explained corporate governance section nominations committee reviews structure size companys website composition board appointment members board cet makes recommendations board company secretary appropriate committee also monitors planning company secretary responsible board available succession board senior management committee individual directors respect board procedures consists entirely nonexecutive directorsof majority company secretary simon bicknell appointed may independentand meets least year consider barrister joined group succession planning otherwise necessary thenominations secretary board committees committee report given page board committees corporate responsibility committee board established number committees provides corporate responsibility committee consists entirely sufficient resources enable undertake duties nonexecutive directors provides boardlevel forum current membership committees given table regular review external issues potential serious impact upon groups business oversight reputation management committee also responsible governance corporate audit remuneration nominations responsibility oversight groups worldwide donations community support committee meets formally three times year sir christopher gent c c meetings consultations asnecessary dr jpgarnier mr j coombe financial results committee dr yamada financial results committee reviews approves behalf mr l culp board annual report form f annual review sir crispin davis convening annual general meeting together sir deryck maughan preliminary quarterly statements trading results sir ian prosser director member committee quorum dr r schmitz c meeting three members quorate meeting must dr l shapiro include chairman chairman audit committee sir robert wilson c ceo cfo committee meets necessary key c chairman member addition director member corporate administration transactions financial results committees corporate administration transactions committee corporate administration transactions committee reviews following summary role terms reference approves matters connection administration committee current full terms reference groups business andcertain corporate transactions committee obtained company secretary committee consists directors cetmembers corporate governance section companys website company secretary committee meets necessary audit committee evaluation board board committees directors audit committee reviews financial internal reporting performance evaluation board committees process system internal controls management risks directors normally undertaken chairman external internal audit process committee also implemented collaboration committee chairmen proposes shareholders appointment external auditors support company secretary following directly responsible remuneration oversight appointment sir christopher gent june deputy work committee consists entirely independent chairman decided deputy chairman would nonexecutive directors meets least four times year undertake performance evaluation board otherwise necessary theaudit committee report given committees directorsincollaborationwith committee page chairmen company secretary remuneration committee board evaluation conducted wayof remuneration committee determines terms service questionnaire followed aprivate discussion remuneration executive directors members deputy chairman directorsincluding cet assistance external independent advisors chairmanan external consultant appointed assist evaluates makes recommendations board overall evaluation audit committee executive remuneration policy committee consists entirely independent nonexecutive directors meets least four times year otherwise necessary information remuneration directors given remuneration report pagesto glaxosmithkline corporate governance dialogue shareholders may company authorised purchase amaximum ofmillion shares million shares financial results announced quarterly purchased cancellation andmillion purchased company reports formally shareholders twice year held astreasurysharessee noteto financial statements halfyear fullyear results announced fullyear share capital share premium account exact amount results included companys annual report annual timing future purchases extent repurchased reviewwhich issued shareholders companys halfyear shares held astreasuryshares rather cancelled results published national newspaper shortly determined company dependenton market released ceo cfo give presentations fullyear conditions factors results institutional investors analysts media london new york addition teleconferences donations political organisations eu political release first second third quarter results institutional expenditure investors analysts media annual report annual agm may shareholders first authorised reviewand quarterlyresultsmay also accessed company make donations eu political organisations companys website incur eu political expenditure provisions political parties elections referendums act annual general meetingagm takes place london year authority since renewed annually formal notification sent shareholders least one month although company notmake intendto advance meetinga business presentation made makesuch payments donations political parties within shareholders directors able attend available formally normal meaning expression definitionin legislation meeting informally afterwards questions ofeu political organisationis wide itcan extend bodies committee chairmen ordinarily attend agm respond company subsidiaries might wish support shareholdersquestions dr schmitz chairman audit includingthose concerned policy review law reform committee unable attend companys agm may representation business community special interest convalescingsir crispin davis groupssuch concerned environment thegroup mr mcarthur also unable attend meeting due made donations noneu political organisations totalling commitments resolutions agm decided poll donations required companys articles association results madetoeu political organisations pollare announced london stock exchange posted companys website details agm annual general meeting set section annual general meeting see agm held pm wednesday th may ensure nonexecutive directors aware queen elizabeth ii conference centre broad sanctuary understand views major shareholders company westminster london swp ee business transacted board place process focusing sectorspecific issues meeting include well general shareholder preferences ceo cfo maintain dialogue institutional receiving adopting glaxosmithkline 's annual shareholders performance plans objectives report programme regular meetings speak regularly external conferences presentations approving remuneration report remuneration report pagestosets groups investor relations department offices london remuneration policies operated glaxosmithkline philadelphia acts focal point contact investors disclosures directors remunerationincluding throughout year required companies act directors chairman remuneration committee meets remuneration report regulations resolution major shareholders discuss executive remuneration policy proposed approve remuneration report nonexecutive directors including new appointees available meet major shareholders requested retirement election reelection directors sir christopher gent sir deryck maughan mr heslop companys website gives access current financial appointed directors since business information group agm offer election board share buyback programme dr garnier sir ian prosser drschmitz anddrshapirowill october following completion billion share retire offerthemselvesfor reelection board buyback programme announced company article companys articles association announced plans billion share buyback programme programme million accounted reappointment remuneration auditors million million resolutions proposed reappoint programme covers purchases companyof shares pricewaterhousecoopers llp auditors authorise cancellation held astreasuryshares accordance audit committee determine remuneration authority given shareholders companys agm corporate governanceglaxosmithkline special business risk oversight compliance council rocc company seekauthority rocc council senior executives authorised board assist audit committee oversee risk management make donations eu political organisations incur internal control activities group membership comprises eu political expenditure several cetmembers heads departments give directors authority disapply preemption rights internal control risk management auditandcompliance allotting new shares connection rights issues responsibilities direct reporting line audit committee otherwise maximum five per cent provides mechanism bypassing executive management current issued share capital need ever arise purchase ordinary shares toa maximum ten per cent current issued share capital rocc meets regular basisto review assess significant amendthecompanys articles associationto enablethe risks mitigation plans rocc responding company certain circumstances meetcosts incurred group policy referred provided business units company associated resolutions requisitioned framework risk management upward reporting shareholdersto bring thearticles ofassociation line significant risks mitigation planning identification new legislation regarding indemnification directors manager overall responsibility management clarify circumstances adr holder given risk requirement speak company meetings risk management compliance boards rmcbs internal control framework risk management compliance boards rmcbs established major business units membership often board recognises responsibility present balanced comprises members senior executive team respective understandable assessment groups position prospects business unit augmented specialists appropriate structure accountability audit operated rmcbs oversee management risks considered glaxosmithkline follows important respective business units including risks board accountability reviewing approving designated significant glaxosmithklineas whole adequacy effectiveness internal controls operated thus increasing number risks actively managed company including financial operational compliance controls acrossthe group risk management board delegated responsibility rmcb regularly reports status regarding significant review audit committeewhich receives reports risks rocc individuals identified committees report pages responsibility managementthrough compliancefunctions cetto implement board policies risk control cet number risk areas specific standards meet exceed responsible identifying approving monitoringand enforcing requirements applicable law established specialist key policies go heart group conducts audit compliance groups example corporate environment business internal control framework includes central direction healthsafety global quality assuranceand worldwide resource allocationand risk management key activities regulatory compliance assist dissemination implementation research development manufacturing marketing sales audit standards legal human resources information systemsand financial practice corporate ethics compliance cec part framework comprehensive planning rocc also supported corporate ethics compliance system annual budget approved board results department responsible supporting development operating units reported monthly compared implementation practices facilitate employees budget forecasts prepared regularly year compliance laws group policy extensive financial controls procedures selfassessment exercises thrust groups compliance effort due diligence riskactivities reviewed groups internal auditors preventing detecting misconduct noncompliance commercial financial responsibility however isclearly law regulation promoting ethical behaviour compliance delegated local business units supported regional laws regulations corporate responsibility levels management structure principles designed provide effective compliance systems environment central leadership coupled local operating autonomy framework exercise accountability cec managed corporate compliance officerwho control within group reports directly ceo corporate compliance officer chairs roccand provides summary reports roccs group also attaches importance clear principles activities groups significant risks cet procedures designed achieve appropriate accountability auditcommittee regular basis control agrouppolicy risk management legal compliance mandates business units establish processesfor managing areas potentially significant risk monitoringrisks significant businesses group details risks affecting group see noteto financial statements legal proceedings risk factors internal control frameworkalsorelies following pagesto overseeing reporting risk compliance issues glaxosmithkline corporate governance effectiveness controls accordinglytheboard chosen nominate one internal control framework operation committee member recent relevant financial whole year review continues operate experienceas defined combined code date approval report system internal controls arriving conclusionthe board considered following designed manage rather eliminate risk ofnot points drschmitz chairman committee achievingbusiness objectives providereasonableand since april prior appointment nonexecutive absolute assurance material misstatement loss director companyhe nonexecutive director audit committee receivesreports onareas significant risk glaxo wellcome plcwhere served audit committee group related internal controls following consideration dr schmitz also member executive board reports theaudit committee reports annually directors deutsche bank ag retired board board effectiveness controls controls may mitigate charge investment bankingdr schmitz eliminate risks addition areas formerly member executive board directors groups business necessary take risks achieve basf including cfo satisfactory return shareholders investment rd holds mba inseadsir ian prosser cfo later acquiring new products businesses cases ceo ofbassplc member instituteof chartered thegroupsobjective apply expertise prudent accountants england wales sir robert wilson began management rather elimination riskthe directors review professional career economist chairman bggroup relates company subsidiaries extend plc held senior management positions rio tinto plc material associated undertakings joint ventures culminating appointment executive chairmanfrom investments retired sir deryck maughan appointed member committee st january board audit committee reviewed chairman chief executive officer citigroup international assessment risks internal control framework vice chairman citigroup incprior creation operates glaxosmithkline considered effectiveness citigroup waschairman cochief executive officer system internal control operationin group salomon smith barneyhe also chairman chief executive year covered reportand date approval officer salomon brotherssir peter jobwho retired boardthe process followed board reviewing board st december ceo reuters plc system internal controls accords guidance internal andbroughtconsiderable industrial experience control issued turnbull committee role member committee committee reports committee supported company secretary attends committees meetings available audit committee report financial resources take independent professional advice audit committees role flows directly boards considered necessary meetings committee attended oversight function authorised board investigate chairman ceo cfo general counsel head global activity within terms reference committee internal audit gia corporate compliance officerand written terms reference approved external auditors board committee reports regularly board performance activities assigned committee worked structured programme committees main responsibilities include reviewing corporate activities withstanding items committee required accounting financial reporting process monitoring consider meetingtogether matters focused integrity companys financial statements evaluating coincide key events annual financial reporting cycle system internal control management risksoverseeing external auditors reported committee critical activities eachofthe groups compliance audit functionsand accounting policies practices used company overseeingcompliance laws regulations ethical codes alternative accounting treatments discussed practice committees oversight role requires address management resultant conclusion external regularly relationships management internal auditors material written communications management external auditors understand monitor reporting restrictions access information relationships tiers accountability parties committee receives regular reports members cfo reported financial performance company cet senior managers covering key compliance activities technical financial accounting matters group including concerning rd manufacturing general counsel reported material litigation sales marketing ehs company secretary reported corporate governance committee entirely composed independent nonexecutive directors committee members bring considerable financial heads groups compliance audit groups accounting experience committees work members reported auditscope annual coverage audit resources past employment experience either finance accounting roles results audits conducted throughout year comparable experience corporate activities corporate compliance officerreported activities board determined combined qualifications undertaken rocc experience committee members taken together modus operandi givethe committee collectively financial expertise necessary discharge responsibilitiescorporate governanceglaxosmithkline company secretary aschairman disclosure recruiting nonexecutive directorsthe committee considers committeereported matters affectedthe quality particular skills knowledge experience would benefit timely disclosure financial material information board significantly appointmentbroad selection board public markets shareholders criteriaareused focuson achieving balance enabled committee review clarity completeness representation uk us markets individuals disclosures published annual financial statements ceo experience skills developed various sectorsand interim reports quarterly preliminary results specialitiesprofessional search agencies engaged specialising announcements formal announcements relating recruitment high calibre nonexecutive directors dossiers financial performance prior release board potential nonexecutive appointeesareprovided committee candidatesareshortlisted interview audit committee management internal auditorsand considering relevant qualificationsnew nonexecutive full boardwork together ensure quality companys directorsoffer election companysnext corporate accounting financial reporting committee agm appointmentsareannouncedpublicly serves primary link board external internal auditors facilitates necessary independence acustomised induction process conducted management encourages external internal new nonexecutive directors focusing particular experience auditors communicate freely regularly committee taking account different backgrounds process committee met collectively separately included meeting key members cet andother senior external auditors head giawithout members executives cases visiting particular operational management present facilities group committee primary responsibility making case appointment new cfothecommittee recommendation shareholders appointment considered particular skills knowledge experience required reappointment removal external auditors annually cfo glaxosmithkline committee considered assessing qualifications expertise resources independence number potential external internal candidates external auditors effectiveness audit process recommending board approve appointment mr heslop board approved mr heslops appointmentwhich making assessment committee considers papers publicly announcedin october mr heslopwill offer detail relevant regulatory requirements required external election thecompanys agm may auditors evaluates reports external auditors compliance requirements external auditors committee metthree timesduring full session provide nonaudit services committee ensures auditor twiceon quorate basis members present full objectivity independence safeguarded policy meetings requiring preapproval audit committee services expenditure audit nonaudit services set remuneration report page remuneration report found pagesto guidelines set companys policy engaging combined code external auditors provide nonaudit servicesinclude ascertaining skills experience external auditors make throughout company complied thecode provisions suitable supplier nonaudit services adequate safeguards combined codeexcept follows place objectivity independence audit b designing schemes performancerelated compromised fee levels relative annual remuneration theremunerationcommittee follow audit fee within limits set committee provisions schedule code item company also wellestablished policies including code schedule states thatin general basic salary ethics available onitswebsite helpline facility pensionable companys position explainedin reporting investigation unlawful conductno remuneration report pages waivers codewere made c board satisfy least one member committee met full session five times five theauditcommittee recent relevant financial times quorate basis full session attended experience companys position explained page membersexcept sir peter jobwho unable attend two thechairman arrange thechairmen meetings auditremuneration andnominationscommittees available answer questions agm directors nominations committee report attend companys position explained page nominations committees terms reference include responsibility proposing appointment board us law regulation committee members committee made recommendations board appointment number provisions us law regulation apply sir christopher gent sir deryck maughan andmrheslop glaxosmithkline companys shares quoted new york stock exchange nyse form adss case chairman committee focused identifying individual calibre experience required tochair complex global organisation glaxosmithkline corporate governance nyse rules based knowledgetheffinancial statements generalthe nyse rules permit company followuk financial information fairly present materialrespects corporate governance practices instead apply financial condition results operations cash flowsas usaprovided company explains significant variations dates andfor periodspresented inthe annual report explanation provided companys website form f responsible establishing maintaining disclosure sarbanesoxley act controls procedures ensure material information following number corporate accounting scandals made known evaluatedthe effectiveness usa congress passed sarbanesoxley act controls procedures theyear end results sarbanesoxley sarbanesoxley established newstandards evaluation contained annual reportand corporate accountability companies listed usa although form fand disclosedin annual report form companys corporate governance structure believed f changes ininternalcontrols financial reporting robust line best practice certain changes period covered annual report form f necessary ensure compliance sarbanesoxley havematerially affectedor reasonably likely toaffect recommended securities exchange commission materiallythe companys internal controlover financial sec glaxosmithkline established disclosure committee reporting committee reports ceo cfo audit disclosedbased ontheirmost recentevaluation committee chaired company secretary internal control financial reporting external auditors members consist senior managers finance legal audit committee significant deficiencies compliance corporate communications investor relations material weaknesses design operation internal external legal counsel external auditors invited control financial reporting reasonably likely attend meetingsperiodically responsibility considering affect adversely companys ability record process materiality information andon timely basis determining summarise report financial informationand fraud disclosure treatment information also regardless materiality involving persons responsibility timely filing reports sec significant role companys internal control financial formal review annual report form f reporting committee meteighttimes ceo cfo completed certificationswhich sarbanesoxley requires annual report contains filed sec part groups form f statement whether member companys audit committee audit committee financial expert controls procedures group carried evaluation supervision board reviewed qualifications backgrounds participationof groups management including members audit committee determined ceo cfo effectiveness design operation although one member companys audit committee groups disclosure controls proceduresas audit committee financial expert combined qualifications st december inherent limitations experience audit committee members taken effectiveness system disclosure controls procedures together modus operandi give audit committee including possibility human error circumvention collectively financial expertise necessary discharge overriding controls procedures responsibilities explanation basis boards judgement refer page accordingly even effective disclosure controls procedures provide reasonable assurance achieving control accounting periods ending thjuly objectives based upon groups evaluation ceo cfo sarbanesoxley requires companysform fcontain concluded thatas atst december disclosure report stating responsibility management establishing controls procedureswereeffective provide reasonable maintaining adequate internal control financial reporting assurance information required disclosed reports assessing effectiveness companys internal control group files submits us securities exchange act financial reporting although company required amended recorded processed summarised report compliance form fmanagement reported required undertaken process ensure position report compliance due date nochanges groups internal control financial reporting duringthat materially affectedor sarbanesoxley also introduced requirement ceo reasonably likely affect materiallythe groups internal cfo complete formal certifications confirming control financial reporting reviewed annual report form f based knowledgeit contains material misstatements omissionsglaxosmithkline remuneration report remunerationreport sets remuneration policies operated glaxosmithkline respect directors corporate executive team cet members together disclosures directors remuneration including required directors remuneration report regulations regulations accordance regulations following sections remunerationreport subject audit annual remuneration nonexecutive directors remuneration share options incentive plansperformance criteria onperformance share plansand share options andpensions remaining sections subject auditneither pages referred within auditedsections thisreport submitted shareholders board approval annual general meeting referenced thenoticeof annual general meeting throughout remunerationreport executive directors cetmembers referred executives references glaxosmithkline shares adss mean respectively ordinary shares glaxosmithkline plc p american depository shares glaxosmithkline plc ads represents two glaxosmithkline shares introduction remuneration policy executive director terms conditions remuneration nonexecutive directorterms conditions fees directors senior managementremuneration annualremuneration nonexecutive directorsremuneration directors interests share options incentive plans pensions directors senior management directors interests contracts glaxosmithkline remunerationreport remuneration report introduction remuneration policy remuneration committee committee responsible principles making recommendations board companys thefourcore principles underpin remuneration policy remuneration policy within terms agreed policy glaxosmithkline determining total individual remuneration packages securing outstanding executive talent executives pay performance performance remuneration policy set report finalised robust transparent governance structures undertaking extensive consultation process shareholders commitment leader good remuneration practice institutional bodies course pharmaceutical industry glaxosmithklines remuneration policy designed establish formulating policy committee also decided framework remunerationthatis consistent companys remuneration structure must support needs scale scope operations meetsthe recruitment needs businessin competitive market place business closely aligned uk shareholder guidelines uk shareholder guidelines willbe followed maximum st december company thesecondlargest extent consistent needs business pharmaceutical company world revenue operations company would maintain regular dialogue shareholders five continentswith products sold overcountries global pharmaceutical companies primary pay around per cent sales generated usa comparator group performance conditions would based measurable remuneration committee delivery strong financial performance delivery composition committee changed year superior returns shareholders compared mr mcarthur retired board may pharmaceutical companies sir robert wilson appointed chairman committee high proportion total remuneration opportunity members committee sir crispin davis based performancerelated remuneration sir peter job mr culp board deemed members delivered medium tolong term committee independent nonexecutive directors remuneration would determined using projected value accordance combined code method see explanation committee metseventimes member one remuneration structure executive directors attending follows cet particular performance conditions apply equally longterm incentive awards number meetings number meetings held whilst attended exgratia payments willbe made name committee member committee member pay structures would simple consistent sir robert wilson business needs chairman fromth may overallthe policy intended provide median total mrlculp remuneration median performance poor performance sir crispin davis result total remuneration significantly pay comparator mr j mcarthur group median opportunity earn upper quartile total chairman untilth may remuneration exceptional performance sir peter jobretired st dec strong alignment performance demonstrably onequorate meetingwasheld toapprovethe formal grant interests shareholders provides executives share options performance share awards give effect unambiguous signals importance delivering success committees decisions companys shareholders exception company secretary employees commitment company involved conduct committee committee apply policy consistent meetings dr garnier ceo senior vice president human transparent basis significant changes measures used resources invited attend part meetings assess performance discussed shareholders committee required use comparators pay benchmarking committee deloitte touche llpdeloitte appointed use discretion ensure remuneration levels reasonable committee provide independent adviceon executive believes changes may cause concern amongst remuneration shareholders position discussed shareholders prior implementation deloitte provided consulting services glaxosmithkline year provide advice executive remuneration matters committee towers perrinprovides market data data analysisto committeeremuneration reportglaxosmithkline pay performance comparators individual elements remuneration following table sets companies used pay balance fixed base salary variable annual performance comparison bonus longterm incentive elements remuneration changes market cap performance chart shows anticipated normal company country range mix fixed variable payat differentlevels abbott laboratories usa performance ceo typical case astrazeneca uk executive directorsedin years ranges may bristolmyers squibb usa higher lower depending theperformance thecompany eli lilly usa andtheindividual number shares subject longterm glaxosmithkline uk incentive awards executive directors unchanged johnson johnson usa merck usa novartis switzerland ceo ed pfizer usa roche holdings switzerland sanofiaventis france scheringplough usa takeda pharmaceutical company japan base salary annual bonus longterm incentives wyeth usa base salary merger aventis sanofisynthelabo reduced base salaries set reference median relevant size comparator group companies market executives pharmaceutical pay comparator glaxosmithklinethecommittee subsequently determined group actual salary levels reviewed annually may vary number reasons including focus operation market depending executives experience responsibility market capitalisation suitable company add value changes usually take effect st aprilbase salaries group dr garnier dr yamada changed mr coombes base salary increased bythreeper cent benchmarking dr garnier receivedmr coombe benchmarking purposestotal remuneration incorporates base anddr yamada salary annual bonus longterm incentives setting pay committee due regard executives pension annual bonus arrangements bonuses determined basis formal review global pharmaceutical industry used primary pay annual performance stretching financial targets based comparator executives appropriate marketplace profit interest tax subject detailed companys senior executive talent first instance assessment individual business unit group achievements pay benchmarked publicly available remuneration data objectives bonus payable financial performance companies less per cent target performance individual performance objectives increaseordecrease bonus provide context information reference made level factor range zeroto bonuses towers perrin annual global pharmaceutical pay survey subject upper limits executives pharmaceutical human resources association phra ceorange per cent per cent base salary ensure global pharmaceutical industry benchmark ceos limit per cent subject scrutiny review committee also considers pay data global businesses primarily consumer annual bonus paid basis ontarget business manufacturing sectors performance together base salary provides annual cash line median pay comparator group prior determining annual longterm incentive opportunity committee considers range vesting levels may case ceothe bonus targets set board achieved based different assumptions share price following end financial year committee reviews growth performance levels etc performance line ceos performance determines bonus payable expectations total remuneration targeted median recommended board approval ceo makes comparator group longterm incentive opportunity set recommendations committee regarding performance way provides positioning total remuneration level achieved objectives executives median recommendations considered committee determine resultant bonus ensure stable benchmark developed reduce impact shortterm fluctuations incentive policies executives also choose invest bonus glaxosmithkline global pharmaceutical companies assessed number shares minimum three years annual investment years planor equivalent usplan end threeyear holding periodexecutives entitled matching award valuation method per cent deferred shareholding match projected value method used benchmark total subject performance conditions plan open remuneration method projects future value approximately senior executives terms remuneration package different performance scenarios committee believes arrangements encourage whilst moderating impact market fluctuations theshort shareholding amongst senior executives considers term strengthening focus performance appropriate executives participate onthe terms glaxosmithkline remunerationreport setting bonus awards committee took tsr rank companies percentage account achievement management maintaining growth glaxosmithkline award vesting cer basis whilst absorbing billion oflost sales generics longterm incentives executives eligible performance share awards share options remuneration policy provides annual longterm incentive awards normally made performance share award share option award committee considers performance shares provide tsr measured prorata basis glaxosmithklines stronger alignment shareholder valueand thereforethe performance falls two comparators level vesting remuneration policy places greater emphasis use determined actual relative level tsr rather simple performance shares longterm incentive awards determined ranking ontarget performance half provide closer link shareholder returns payments longterm incentive reward derived performance shares executives notional dividends reinvested paid grant annual awards using one plan consistent proportion vesting award receipt dividends practice pay comparator group leading incorporated benchmarking award levels ukcompanies longterm incentives cetare provided addition performance shares earned executives basis asthe executive directors sold except meet related tax liabilities two years following end vesting period committee believes performance share awards share options delivered us aligns interests executives resident executives form adss awards delivered longterm interests shareholders form ordinary shares executives resident uk countries awards made plans vesting table performance share awards granted incorporate dilution limits consistent guidelines provided december performance period st january association british insurers national association st december given page pension funds shareholder representative bodies current estimated dilution existing awards b share options glaxosmithkline employee share schemes made since merger share options allow holder buy shares future date approximatelyfiveper cent companys share capital share price prevailing time grant share options st december granted thanmanagers glaxosmithkline including executives share options granted performance shares executives linked achievement compound executives level performance shares vesting based annualeps growth performance period companys total shareholder return tsrrelative committeeconsideredthat eps key measure performance comparator group see page threeyear performance business also fully reflected measurement period tsrwas chosen appropriate business measures extended throughout group ensuring comparative measure since focuses return organisational alignment shareholders wellunderstood tested mechanism measure performance allows comparison companies setting eps targetsthe committee considers companys operating different countries internal projections analysts forecasts glaxosmithklines eps performanceas well analysts forecasts tsr measured sterling performance period pharmaceutical industry represents change value share together value reinvested dividends paid order remove impact following key principles govern use eps varying tax treatments dividends different jurisdictions performance measure dividends reinvested gross adjustments considered major items respect performance share awards granted december adjustments judgement committee performance period st january purpose adjustments ensure stdecember glaxosmithkline ranked position performance measurement fair reasonable seventhe midpointof performance comparator group participants shareholders per cent shares vestany ranking point discretion exercised committee disclosed result shares vestingonly glaxosmithkline one shareholders annual report top two companies shares vest committee set basis decision considers determining vesting levels committee regard appropriate make adjustment companys underlying financial performance grant vesting increases straightline basis eps performance hurdles set tableon following remunerationreportglaxosmithkline annualised percentage sharesave plan sharereward plan inland revenue growth eps award vesting approved plans open uk employees terms mr coombe member sharesave plan rpi contributes month provides option rpi buy shares end threeyear savings period line rpi opportunity available uk employees rpi mr coombe also contributes per month buy shares performance condition substantially consistent uk sharereward plan company matches number shareholder guidelines expectations isdemanding shares bought month compared thoseoperated global pharmaceutical companies consistent policy providing pay executives also receive benefits including healthcare performance performance medical dental personal financial adviceandlife assurance cash value benefits received executive directors performance measured three financial years following shown page grant option committee decided grant performance retesting executive director terms conditions remuneration performance condition metafter threeyear periodthe option lapse executive director contracts policy regarding executive directors contracts pensions subject extensive review change thepolicy executives participate glaxosmithkline senior executive provides framework contracts executive directors pension plans pension arrangements structured appointed future accordance plans operated executives country key aspects glaxosmithklines contractual framework executives likely retire benefits normally payable age details individual arrangements aspect policy executive directors set pagein response notice period calendar months future pensions regimein uk committee carefully termination consider impact change legislation decide employing company best move forward regulation clearer market executive consensus emerges view implementation april termination payment x annual salary x annual ontarget bonus share ownership requirements mitigation required align interests executives shareholders executives required maintain significant holdings shares benefits governed benefits policy glaxosmithkline requirements important part including aligning interests executives shareholders ceo healthcare medical dental required hold shares value four times base salary personal financial advice executive directors required build shareholding life assurance contributions value three times base salary members cet vesting longterm rules relevant equity incentive required build shareholding value two times base incentives plan salarythe top executives groupare required pension based existing arrangements build shareholding value one times base salary terms relevant pension plan executives required continue satisfy shareholding noncompete clause months termination requirements minimum twelve months following notice date retirement company order shares qualify share ownership dr garniers target bonus per cent salary mr coombes per cent salary dr yamadas isper cent salary requirements must held personally executiveor imposition month noncompete period executives considered spouse minor childrenor earned deferred vitally important company order protect groups intellectual one share programmes operated company property light noncompete clause competitor practice committee believes would appropriate provide mitigation unexercised share options included calculationas contracts reviewing level severance payments committee st december dr garniers shareholding considered investor dti guidance however determined line adss mr coombes wasordinary shares dr yamadas competitive practice appropriate provide payment salary wasadss holdings excess share target bonus termination approved shareholders glaxosmithkline glaxo wellcome smithkline ownership requirements beecham appropriate remuneration elements dr garnier mr coombe dr yamada agreed changes executives participate various legacy glaxo wellcome previous contractual terms without compensation come broadly smithkline beecham allemployee share plans either uk line new contractual framework including usa glaxosmithkline plans replaced reduction contractual notice period calendar months however order honour certain aspects old contractual termsthere number individual features retained glaxosmithkline remunerationreport dr garniers case include entitlement benefits accrued glaxo wellcome uk pension reimbursement excise tax change control related arrangements augmented trustees plans five payments life insurance benefit funded company age per cent reflect distribution surplus augmentation following provisions relating vesting oflongterm apply element ofmr coombes pension earnings incentives st march pre awards entitlements termination company cause addition contractual provisions outlined retirement resignation good reason ie resignation event dr garnier dr yamada mr coombes service due elected retained director agreements terminated employing companythe company merged company result change following would apply control provided resignation occurs within days first anniversary change control case awards glaxosmithkline annual options vest full remain exercisable full investment plan provided agreement terminated option term performance shares vest end cause deferred amountany incomeand performance period subject performance gains automatically distributed soon administratively timeapportioned practicable termination resign retire termination causethen deferredamount thereafter distributed end minimumthreeyear deferral provisions apply options subject period performance testing circumstances options performance share awards made months prior line policy applicable us senior executives termination notice date lapse dr garnier dr yamada entitled receive continuing medical dental insurance mr coombe remains entitled termination cash equivalent months benefits continuing medical dental following merger participants legacy share insurance option schemes elected exchange legacy options options glaxosmithkline shares receive additionthe current executive directorsareentitled receive additional cash benefit equal per cent grant price one years worth pension contributions termination original option additional benefit triggered dr garniers mr coombes contracts executed new option exercised lapses qualify rd march took effect st january additional cash benefitparticipants retain options dr garniers contract expire st october least second anniversary effective date mr coombes st march last day merger monthin reach th birthday dr yamadas contract executed th july took effect outside appointments executive directors st january expires onth june last outside appointments must approved chairman day monthin reaches nd birthday behalf board isthe companys policy remuneration earned appointments may kept individual termination payments made respect part executive director notice period extending beyond contract expiry dates nonexecutive directorterms conditions fees individual pensionarrangements uk plan provides pension based twothirds final nonexecutive directors glaxosmithkline service salary age us cash balance plan provides annual contracts instead letters appointment company contribution interest sum accumulated cash aims provide nonexecutive directors fees balance plan contractual promise provide specific competitive companies equivalent size levels retirement income complexity year chairman sir christopher hogg ceo recommended board approved glaxosmithkline makes annual contributions per cent new fee structure effective st october dr garniers annual salary bonus per cent nonexecutive directors follows dr yamadas annual salary bonus fund increases interest rate based yield year treasury bonds standard fee per annum company liability beyond making annual supplemental fees follows contributions per annum sid audit committee prior usemployees including dr garnier chairman dr yamada moved final salary pension arrangement per annum chairman remuneration current cash balance structure employees us corporate responsibilitycommittees cash balance plan contributions based combined annual per meeting nonexecutive director salary annual bonus undertaking intercontinental travelto meetings mr coombe participates glaxo wellcome defined benefit fees paid us dollars converted rate plan retirement age entitled receive annual usbeing exchange rate applied pension oftwothirdsof final salary twothirdswidows newfee arrangements approved pension inflation proofing fee arrangements sir christopher gent described pageremunerationreportglaxosmithkline enhance link directors shareholders following table shows date letter appointment set table glaxosmithkline requires nonexecutive applicable thedate leaving board directors receive significant part fees form nonexecutive date letter shares effect st october least per cent director appointment date leaving nonexecutive directors total fees paid form mrlculp shares allocated share account nonexecutive sir crispin davis directors may also take opportunity invest part sir deryck maughan balance fees share account sir ian prosser prior st october nonexecutive directors dr rschmitz allocated number shares dependent position dr lshaprio part theirfees could elect invest part balance sir robert wilson offees share account shares paid dr barzach directors retirement board later date sir peter job paid basis dividends reinvested interim mr j mcarthur mr mchenry fee arrangements prior st october follows chairman tsrperformance graph board board deputy following graph sets performance company member committee chairman chairman relative ftse index company cash fees constituent performance comparator group since merger th december graph prepared percentage cash fees may accordance regulations indication taken shares likely vesting awards granted companys maximum share incentive plans election automatic share ordinary shares allocation adss ordinary ordinary shares shares adss adss nonexecutive directors entitled compensation appointment terminated glaxosmithkline total return tsef total return index chairman glaxosmithkline pharma peers return index sir christopher hogg retired chairman effect st december sir christopher hoggs letter appointment directors senior managementremuneration board dated th june amended st september record appointment aschairman following tables set directors glaxosmithkline effect th may sir christopher gents letter plc remuneration earned interests shares appointment board dated th may underwhich glaxosmithkline plc interests share options incentive agreed serve company asdeputy chairman plans pension benefits members cet st december st january aschairman company secretary known senior management also conclusion annual general meeting following participate remuneration plans executive third anniversary appointment may extended directors aggregate remuneration interests term three years mutual agreementhe received directors senior management also provided fees rate per annum plus allocation glaxosmithklineshares value per annum whilst deputy chairman receives per annum plus allocation glaxosmithklineshares value per annum chairman nonexecutive directors appointment nonexecutive director provided letter appointment agreed serve company nonexecutive director conclusion annual generalmeeting following third anniversary appointment case extended term three years mutual agreement directors serve term longer three years without offering reelection shareholders glaxosmithkline remunerationreport annual remuneration total total fees annual annual fees annual annual salary benefits bonus remuneration salary benefits bonus remuneration footnote executive directors dr jp garnier abc dr yamada bc mr jcoombe bcd total executive directors current nonexecutive directors mrl culp sir deryck maughan dr l shapiro e sir christopher gent sir crispindavis sir ian prosser dr r schmitz sir robert wilson total current nonexecutivedirectors former nonexecutive directors mr j mcarthur mr mchenry mr pallaire dr barzach f sir christopher hogg sir roger hurn sir peter job sir richard sykes ag total former nonexecutive directors total nonexecutive directors total remuneration remunerationfor directors us payrollisreported dollarsamounts converted sterling average rates year following merger participants legacy share option schemes elected exchange legacy options options glaxosmithkline shares granted additional cash benefit equal per cent grant price original option additional benefit known exchange offer incentive eoi payable new option exercised lapses market value qualify additional cash benefitparticipants retain options least second anniversary effective date merger year dr garnier received relating options exercised page sir richard sykes received result options lapsing market value amounts included benefits table b dr garnier nonexecutive director united technologies corporationin respect hereceived form deferred stock units andstock options grant price mr coombe member supervisory board siemens ag respect hereceivedandstock appreciation rights grant price dr yamadawasa member board directors diadexusincin respect whichin hereceivedstock appreciation rights grant price amounts excluded table retained executive directors c following mergerdr garniermr coombe dr yamadawere awardeda oneoff special deferred bonusas members ceteach awarded anamount equivalent hissalary st december notionally invested glaxosmithkline shares adss onth february deferred three years atst december value shares adss notionally acquired respect dr garnier anincrease offiveper cent year includes dividends reinvested year shares notionally acquired respect mr coombe valued st december adecrease ofoneper cent year includes dividends reinvested year shares notionally acquired respect dr yamada valued atas st december increase offiveper cent yearthis includes dividends reinvested year deferred bonus vested th february andthe amounts paid equivalent value shares oradss notionally acquired february plus dividends reinvested period dr garnier received dr yamada received mr coombe waived hisdeferred bonusof company make acontribution pension plan enhance pension entitlements amounts included table aboveremunerationreportglaxosmithkline mr coombe waived annualbonus thecompany make acontribution pension plan enhance pension entitlementsthis amount included within fees salary e dr shapiro member glaxosmithklines scientific advisory board received fees form adss included within fees salary f dr barzach received fees fromglaxosmithkline francefor healthcare consultancy provided included within fees salary g addition remuneration received former director set abovesir richard sykes received period st january th may relating appointment senior advisor none directors received expenses year requiring separate disclosure required regulations nonexecutive directors remuneration total cash sharesadss total cash sharesadss fees salary current nonexecutive directors mrlculp sir deryck maughan dr l shapiro sir christopher gent sir crispin davis sir ian prosser dr r schmitz sir robert wilson former nonexecutive directors mr jmcarthur mr mchenry mr pallaire dr barzach sir christopher hogg sir roger hurn sir peter job total table sets remuneration received nonexecutive directors glaxosmithkline accordingly include dr barzachs fees received glaxosmithkline france healthcare consultancy provided dr shapiros fees received member glaxosmithklines scientific advisory board st january th september nonexecutive directors required receive part fees form sharesor adsswith balance received cash st october st december nonexecutive directors required take least per cent total fees form shares allocated share account cases could elect receive either part cash payment form sharesoradss total value shares adss date awardtogether cash payment forms total feeswhich included within annual remuneration table fees salary table sets value fees received form cash shares adss shares adss notionally awarded nonexecutive directors allocated interest accounts included within directors interests tables page accumulated balance shares adss together notional dividends subsequently reinvested paid nonexecutive directors retirement upon retirement nonexecutive directors receive either shares adss cash amount equal value shares adss date retirement glaxosmithkline remunerationreport table sets accumulated number shares adss held nonexecutive director st december together movements account year number shares adss dividends nonexecutive directors share arrangements allocated elected reinvested paid current nonexecutive directors sir christopher gent mrlculp adss sir crispin davis sir deryck maughan sir ian prosser dr r schmitz dr l shapiro shares adss sir robert wilson former nonexecutive directors dr barzach sir christopher hogg sir roger hurn sir peter job mr jmcarthur adss mr dmchenry adss mr jyoung shares adss table sets settlement former nonexecutive directorsshare arrangements ontheir leaving board value awards value awards payments date ofleaving onallocation onleavinga b dr barzach sir christopher hogg sir peter job mr jmcarthur mr dmchenryd prior years sir roger hurnc mr jyoungc change value awards allocation leaving attributable dividends reinvested change share price dates ofaward dates ofleaving b awards sirchristopher hogg sir peter jobunder nonexecutivedirectors sharearrangements weresettledin full transfer shares january c leaving board sir roger hurn mr young elected receive settlement nonexecutive directorssharearrangements quarterly three annual cash payments respectively addition payments disclosed mr mchenry received payment deferred fees relating period mr mchenry director smithkline beckman prior merger beecham group deferred fees indexed total return glaxosmithkline adssand payable following mr mchenrys retirement nonexecutive director glaxosmithklinethe total accumulated value deferred fees paid equivalent glaxosmithkline adssremunerationreportglaxosmithkline directors interests following beneficial interests directors company shown register maintained company accordance companies act shares adss th february st december stjanuary th february st december st january footnote dr jp garnier mr jcoombe b dr yamada sir christopher gent cd mrl culp c sir crispindavis c sir christopher hogg ce sir peter job ce sir deryck maughan cd sir ian prosser c dr r schmitz c dr l shapiro c sir robert wilson c one glaxosmithkline ads represents two glaxosmithkline shares includes equivalent number ofadsspurchased glaxosmithkline stock fund within k plan b includes shares purchased glaxosmithkline sharereward plan totallingshares st december andshares thfebruary c includes shares adss received part fees described nonexecutive directors share arrangements dividends received shares adss converted shares adss st december also included directors interests sir christopher gent sir deryck maughan shares date appointment board e sir christopher hogg sir peter job left board st december therefore interests company th february included table interests abovementioned directors atthfebruary reflect changes end financial year date glaxosmithkline remunerationreport share options options adss granted date grant exercise period grant price number exercised dr jp garnier dr yamada options shares granted date grant exercise period grant price number exercised mr jcoombe na na na na options outstanding st december earliest latest vesting lapse dates market price glaxosmithkline share year end given table belowmr coombewasexcluded grant options onnd december retires company within months date grant weighted average vestingdate lapse date dr jpgarnier grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total ads options st december weighted average vestingdate lapse date dr tyamada grant price number earliest latest earliest latest market price underwater year end vested options market price year end vested options unvested options total ads options st december weighted average vestingdate lapse date mr jcoombe grant price number earliest latest earliest latest market price underwater year end vested options unvested options market price year end unvested options total share options st december glaxosmithkline grants share options executive directors senior managers annual basis generally november initial grant made following completion merger march measurement period options granted march commenced st january measurement periods options granted november december commenced onst january respectively directors hold options various share option plans referred innoteto financial statements employee share schemes none directors interest option companys shares following merger directors elected exchange outstanding options legacy share option plans options glaxosmithkline shares directorsand participants legacy schemes made election receive additional benefit cash sum equal per cent grant price original option additional benefit given new option exercised lapses prior share options granted executive directors subject performance condition order options vest full business performance eps growth excluding currency exceptional items average least three percentage points per annum increase uk retail prices index threeyear performance period options granted executive directors subject performance conditions described pages remunerationreportglaxosmithkline respect grant performance condition met threeyear measurement period performance measured four financial years following date grant options performance conditionis met end four years option lapse options granted executive directors subject performance condition set extent performance conditions met end threeyear performance period option lapse retesting permitted grant market options exercised date number price price gain gain dr jpgarnier average exchange rate year gain made dr garnier amounted eoi benefit paid dr garnier exerciseof options benefit included table page onth february dr garnierexercised options exercise price giving rise gain dr garnier also received respect exchange offer incentive benefit arising exercise options mr coombe exercise share options dr yamada exercise options highest lowest closing prices year ended st december glaxosmithkline shares respectively highest lowest prices glaxosmithkline adss year ended st december respectively market price glaxosmithkline share st december st december glaxosmithkline ads st december thepricesonth february wereper glaxosmithkline share per glaxosmithkline ads incentive plans performance share planawards dr jpgarnier ads market additional number price vested exercised ads vested unvested granted date vested market dividends unvested deferred performance period grant deferred number price gain lapsed reinvested value awards deferred drgarnier vesting dr tyamada ads market additional number price vestedexercised ads unvested granted date vested market dividends unvested performance period grant deferred number price gain lapsed reinvested mr jcoombe shares market additional number price vested exercised sharesby unvested granted date vested market dividends unvested performance period grant deferred number price gain lapsed reinvested glaxosmithkline remunerationreport average exchange rate year gainsby dr garnieranddr yamadaamounted respectivelymr coombewasexcluded thegrant awards made nddecember retires company within months date grant performance share plan psp mediumterm incentive scheme introduced psp replaces longterm incentive plan midterm incentive plan operated respectively glaxo wellcome smithkline beecham terms psp number shares actually vesting determined following end relevant threeyear measurement period dependent glaxosmithklines performance period described page share awards aregranted annually november december measurement period commences following st january ending threeyears onst december threeyear measurement period theawards performance periodcommencingst january ended st december based performance glaxosmithkline period per centof theaward vested february beginning withthe award performance period beginning st january dividends reinvested psps awarded members cetunder terms psp us participants may defer receipt part vested awards dr garnier elected defer receipt awards vested untilretirement prior performance period beginning st january awards two parts halfcanbe earned reference glaxosmithklines tsr performance compared ftse company constituent half award isdeliverable companys business performance eps growth excluding currency exceptional itemsison average least three percentage points per annum increase uk retail prices index threeyear performance periodfor awards glaxosmithklineisrankedin top ftse based tsr performance sharesin part awardwill vest th position ftse per cent shares vest glaxosmithkline ranked th position none sharessubject part awardwill vest th th positions vesting occur sliding scale following vesting table appliesto theawards performance period st january st december tsr rank companies glaxosmithkline percentage award vesting performance comparator group theseawardscomprised companies glaxosmithkline aventis sanofisynthelabo comparator groupprior merger form sanofiaventis purposes calculating tsrover performance period awards granted december starting price shares two individual companies compared price merged company end performance period adjusted merger ratio dividends treated reinvested performance period tsr measured prorata basis glaxosmithklines performance falls median two comparators level vesting determined median actual relative level tsr rather simple ranking vested vested deferred dividends deferred participations reinvested participations midterm incentive plan adss dr jp garnier midterm incentive plan mtip share award scheme operated smithkline beecham plan closed new entrants upon completion merger participations granted final award adss made receipt award may deferred directordr garnier deferred receipt full amounts vestedin deferred awards together additional adss subsequently received dividend reinvestment arenot included directors interests table pagesincethey retained mtip paid average stock appreciation rights sars adss grant price dr l shapiro sars held drshapiro grant price market price glaxosmithkline ads year end dr shapiro member glaxosmithklines scientific advisory board sab dr shapiro member smithkline beechams sab completion merger glaxo wellcome along members sab received annual grants smithkline beecham sars general vested three years date grant expire years date grant grants sars sab members ceased sars entitle holder cash sum future date based share price growth date grant date exercise full provision made financial statements accrued gains sars date grant connection merger previously granted sars became immediately exercisableremunerationreportglaxosmithkline pensions accrued annual pension benefits transfer values executive directors retirement set regulations require disclosure accrued benefit end year change accrued benefit year transfer value beginning end year change transfer value year listing rules require additional disclosure change accrued benefit net inflation transfer value change change change change accrued transfer value accrued accrued accrued transfer transfer year benefit change benefit benefit benefit value value transfer year net accrued year value inflation benefit pa pa pa pa dr jp garnier mr jcoombe dr tyamada change transfer value shown net contributions made individual pensions executive directors disclosed currency pension payable dr garnier dr yamada members employee us cash balance pension plan glaxosmithkline makes annual contributions calculated percentage employees base salary bonusthe fund increases interest rate set annually inadvance based year treasury bond rate provide cash sum retirement cash sum used purchase pension retirement based annuity rates applicable time neither entitlement spouses pension pension increases otherthan reducing initial pension normal retirement age plan years age drgarniers pension arrangements brought line termsof service agreement assumed retirement age reduced similarly dr yamadas assumed retirement age reducedto transfer value cash sum dr garniers plan increased byover year result phased transfers previous scheme accumulation interest contributions paid thecompany transfer value cash sumof dr yamadas plan increased year result accumulation interest contributions paid company dr garnier dr yamada alsomembers usretirement savings plan money purchase scheme open usemployees contributions invested range funds value accumulated funds paid retirement contributions paid scheme company respect dr garnier invested glaxosmithkline shares stock ownership account respect dr yamada contributions paid scheme invested glaxosmithkline shares stock ownership account shares held account included within directors interests tables page mr coombes transfer value calculated basis actuarial advice accordance actuarial guidance note gn transfer value represents present value future payments made pension plan whilst mr coombes annual accrued benefit increased excluding effects inflation transfer value increased year increase arisen primarily result following factors mr coombes pensionable salary increased accounted increase accrued benefit increase transfer value accrued benefit st december annual increases transfer values become larger closer individual retirement terms mr coombes service agreementhe retire age stmarch mr coombe approaches retirementthe transfer value pension increaseto reflect level funds required meet annual accrued benefit payments mr coombe waived annual bonus special deferred bonus company make contribution pension plan enhance pension benefits discretionary increase applied uk pension plan uplifting increase uk retail price indexlevel plan members result sir richard sykes received adiscretionary increase accrued benefit glaxosmithklineremunerationreport directors senior management us reporting purposes necessary provide information compensation interests directors senior management asagroup group purposes disclosure group defined directors members cet company secretary respect financial year total compensation paid members group periods served capacity aggregateincrease accrued pension benefits aggregate payment defined contribution schemes members group granted options overshares adss awardedsharesadss performance share planand shares restricted share plan atth february thencurrent members group comprisingpersons ownedshares andadss constituting less one per cent issued share capital company group also held date options purchase shares andadssshares andadss awarded performance share plan including shares adss vested deferredshares andadss legacy smithkline beecham midterm incentive planincluding shares adss vested deferredadss awarded legacy smithkline beecham stock appreciation rightsand shares awarded restricted share planthese holdings issued various executive share option plansdescribed note financial statements employee share schemes directors interests contracts except described noteto financial statements related party transactions end financial year director connected person material interest contract significance relation groups business group company directors remuneration report approved board directors signed behalf sir christopher gent chairman ndmarch glaxosmithkline operating financial review prospects operating financial review prospects discusses operating financial performancethe financial outlook financial resources group results year compared primarily results preceding year following headings financial trends ratios year results year st december compared year st december financial position resources st december outlook risk factors additionally accordance us requirements year results year st december compared year st december exchangerates group multinational business operates many countriesand earns revenues incurs costs many currencies results reported sterling affected bymovements exchange rates sterling overseascurrencies average exchange rates prevailing period areused translate results cash flows overseas subsidiary associated undertakings joint ventures sterling period end ratesare used translate net assets undertakings currencies influence translations usdollar euro japanese yen order illustrate underlying performance groups practice discuss results terms constant exchange rate cer growth represents growth calculated exchange rates used determine results overseas companies sterling remained unchanged used previous year cer represents growth constant exchange rates represents growth actual exchange rates business performance years business performance primary performance measure used management presented excluding merger items integration restructuring costs disposals businesses management believesthat exclusion items providesa better comparison way business managed givesan indication performance group terms elements revenue expenditure local management able influence completion programmes group reporting results statutory basis growth rates presented comparing results business performance results statutory results management considers comparison statutory results business performance results gives appropriate indication groups performance period review therefore commentaries presented basis unless otherwise stated information provided addition statutory results prepared uk gaap appear pagesand assist shareholders gain clear understanding underlying performance business increase comparability periods presented glaxosmithkline operating financial review prospects financial trends ratios statutory results growth restated growth restated cer cer turnoverpharmaceuticals consumer healthcare total cost sales selling general administration research development trading profit profit taxation earnings basic earnings per share pence p p p merger restructuring disposal subsidiaries cost sales selling general administration research development trading profit profit taxation earnings business performance results turnover cost sales selling general administration research development trading profit profit taxation adjusted earnings adjusted earnings per share pence p p p research development statutory pharmaceuticals consumer healthcare total interest net interest payable interest cover times times times interest cover calculated statutory profit interest divided net interest payable tax rate business performance statutory results borrowings net debt gearing gearing ratio calculated net debt percentage shareholders funds net debt minority interestsoperating financial review prospectsglaxosmithkline year world economy world market pharmaceuticals record oil pricesthe continued threat terrorismand tightened global pharmaceutical sales increased bynineper cent monetary policies major economies features billion global economy despite continued strong growth china usa signs economic world market value growth recovery main economies europe albeit slower geographic region bn total cer usa growth usawasper cent although wide europe predictions wouldsee expansion kept less four germany per cent federal reserve board raised interest ratesfive times france stave inflationary pressures uk continued concern countrys budget deficit effect italy global economy whatever corrective actions japan adopted nevertheless usa remained main driver asia pacific global growth strong support asia despite adverse latin america impact higher oil prices middle east africa japans economydeclinedper cent however recovery canada economy anticipated mid althoughin china official total measures moderate pace countrys economic expansionweretaken growthof nineper centwas achieved growth theus markethas slowed remains double digits emerging economies elsewhere asia hit oil price rises represents per cent global prescription although reasonable growth continued countries taiwan pharmaceutical market compared toper cent decade ago thailand singapore th september glaxosmithkline heldsecondposition eugdp grew per centwheregrowth larger world pharmaceutical market market share economies varied fromper cent uktoper cent percent behind pfizer market share ofper cent germany interest rates unchanged european central glaxosmithkline hadeightproducts worlds top bank oil prices expected adverse impact pharmaceutical products areaugmentin avandia main european economies continued modest imigranimitrexlamictalseretideadvair seroxatpaxil wellbutrin growth predicted zofran ukincreases government consumer spending fuelled world market value growth initial expansionthat wasdampened later concerns top five therapeutic classes bn total cer interest rates house prices nevertheless final growth rate cardiovascular met government forecasts bank england raised interest central nervous system ratesfourtimes year held per cent alimentary tract metabolic signs emerged slowing economy concerns antiinfectives bacterial inflation receded viral fungal excluding vaccines respiratory following substantive recovery global equity markets share price indices showed subdued advances note data based months thseptember despite positive economic corporate news year pharmaceutical turnover exchange growth rates included review turnover constant currencies influence groups results us exchange rates cer unless otherwise stated sterling growth dollar euro japanese yen rates may found tables pharmaceutical turnover pound hit highest level dollar therapeutic area pageand geographic region fouryears climbing yearend euro gained page one per cent sterling eightper cent dollar total pharmaceutical turnover wasmillion thesecond consecutiveyear dollar compared million increase ofone fallen value eurodue tothe impact continued per centcerin sterling terms turnover declined six per cent unrest iraq tension elsewhere world concerns principally due tothe weakness us dollar us economy within groups portfolio turnover new products first launched major market within last five years accounted forper cent total turnover grew byper cent million turnover established franchise products amounted tomillion representingper cent total turnover declined fiveper cent compared last year turnover older products less actively promoted million decline ofsevenper cent representingper cent total turnover glaxosmithkline operating financial review prospects year continued global pharmaceutical turnover fourth quarter strong growth glaxosmithklines epilepsy bipolar increased threeper cent reflecting us turnoverincreaseof disorder treatment lamictalcontinues sales per cent fourper cent tomillion whereas europe turnover million ongoing us growth per cent million grewtwoper cent tomillion international turnover driven indication maintenance treatment grewfiveper cent tomillionturnover usawas bipolar disorder received last year impactedby generic competitionfor wellbutrinand paxil excluding sales products turnover grew per cent antivirals usa global hiv product sales rose four per cent billionand sales usa increased four per cent million pharmaceutical turnover therapeutic area glaxosmithkline continues grow hiv franchise despitethe launch several new products competitors glaxosmithklines ability continue deliver pharmaceutical turnover growth despite generic competition several hiv performance enhanced launch epzicom new products primarily due exceptionally broad product combination product epivirziagen usa august portfolio fastgrowing highvalue products eu name kivexa january include therespiratory product seretideadvairup per sales herpes treatment valtrex exceeded millionfor cent billionthe diabetes treatment avandiaavandamet first time per cent million per cent billionlamictalfor epilepsybipolar disorder performance driven usa per cent per cent billionvaltrexfor herpes billionup million product clear market leader per cent coregfor heart diseaseup per cent billion treatments genital herpes andvaccinesup per cent billion antibacterials glaxosmithkline products sales antibacterial sales declined nine per cent worldwide million per cent usa reflecting generic competition regions respiratory metabolic glaxosmithkline continues global leader respiratory thediabetes treatments avandiaavandametcontinueto perform pharmaceuticals sales three key products strongly overall sales billion per cent seretideadvair flixotidefloventand serevent amounting billion nine per cent sales seretideadvair groups sales theusagrew per cent million encouragingly largest product grew per cent billion although avandiaavandametarealso growing verystronglyin europe contributed declines sereventand flixotide constituent international markets sales per cent per cent products respectively strong performance markets isdriven growing acceptance amongst opinion leaders physicians usa advairsales grew per cent billion growth benefits new products improving control ofseretidein europe also strong per cent diabetic patients million although reported growth fourth quarter adversely impacted oneoff rebate adjustment germany vaccines wholesaler destocking italyinternational sales grew thevaccines business strong year sales per cent per cent reflecting good growth geographic areas billion several key products driving growth older respiratory products ventolinand becotidecontinued pediarixinfanrixup per cent million priorixup per decline patients converted newer products cent millionandfluarixup per cent million central nervous system cns oncology emesis cns sales declined per cent billion sales declined sales zofrangrew eight per cent million driven regions us performance per cent million total sales paxilfranchise per cent cardiovascular urogenital billion result generic competition paxil ir sales coregfor heart disease sales grew per cent declined per cent million mitigating decline million strong performance product japanup per cent millionand performance paxil crwhich generated therapeutic areas sales million per cent sales zantac fell per cent million declines total sales wellbutrinproducts fell per cent million regions wellbutrin irand sr sales fell per cent million result generic competition impact partially offset however exceptionally strong performance wellbutrin xl new oncedaily product achieved sales million first full year marketoperating financial review prospectsglaxosmithkline pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer respiratory serevent seretideadvair flixotideflovent seretideadvair flixotideflovent serevent flixonaseflonase cns depression seroxatpaxil paxilir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl migraine imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccines hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascularand urogenital coreg levitra avodart zantac cer represents turnover growth constant exchange rates represents growth actual exchange rates analysis turnover quarter given financial record pagesto glaxosmithkline operating financial review prospects year continued regional analysis parallel trade occurs occasionally elsewhere world sufficiently material affect significantly turnover data turnover reported table represents sales invoiced market presented invoiced basis glaxosmithklines local entity customers local market plus copromotion income within market pharmaceutical turnover europe region turnover created basis pharmaceutical turnover geographic region invoiced basis turnover market within europe adjusted effects parallel trade show turnover basis country region growth major markets total cer product finally consumed product sold glaxosmithkline usa europe region invoiced adjustment created invoiced adjustment created france major markets uk europe italy france germany uk spain italy poland germany europe spain international poland asia pacific europe japan middle east africa pharmaceutical turnover geographic region latin america turnover created basis canada region growth major markets total cer cer represents turnover growth constant exchange rates represents growth usa actual exchange rates europe individual governments determine pricing medicines france countries within europe result wide price variations uk product parallel trade occurs third parties italy exploit price differential purchasing products market germany low prices enforced selling governments spain purchasers markets higher prices poland agreed parallel trade permitted single europe market rules european union glaxosmithkline international derive benefit profit resale higher price asia pacific japan result management believes within european region middle east africa turnover market invoiced basis presented latinamerica properly represent consumption products within canada market glaxosmithklineemployeesbased market instrumental promotion groups products within market thereby creating product sale final consumption cer represents turnover growth constant exchange rates represents growth market following tablegives adjustments made actual exchange rates analysis turnover quarter given financial record pagesto orderto restate turnover markets within europe turnover created basis adjustments glaxosmithklines estimates based recent data independent external sources valued sterling relevant exchange rates management believes turnover created basis reporting turnover market provides better reflection performance businesses market within europe total turnover europe region unaffected restatementoperating financial review prospectsglaxosmithkline usa international usa reported flat turnover year despite significant internationalregion reported year year turnover growth impact generic competition paxiland wellbutrin excluding three per centstrong growth asia pacific upeight percent sales products turnover grew per cent us latin america upeightper centwasoffset flat sales australia business represented per cent total pharmaceutical turnover declines five percent subsahahraafricaeightper cent middle eastnorth africa percent canada canada sales decline due generic erosion paxil ir advairmaintained strong growth sales million excluding element canada grew per cent per cent however adversely affected sales constituent products floventand sereventwhich showed japan recorded turnover growth five per cent despite routine declines flonase indicated treatment perennial rhinitis government price reductions implemented paxilup grew nine per cent per cent sereventup per cent valtrexup per cent performed particularly well offsetting small declines zantacand sales wellbutrinproducts fell per cent million zovirax wellbutrin ir srsales fell per cent million result generic competition impact partially offset across markets international key products driving however exceptionally strong performance wellbutrin xl growthwere seretide grew per cent record sales new oncedaily product achieved sales million million avandiaavandamet grew per cent first full year market million vaccines franchisewhich recorded growth per cent achieved sales million total sales paxil franchise per cent million result generic competition paxil irsales consumer healthcare sales declined percent million mitigating growth decline performance paxil cr generated sales cer million per cent otc medicines analgesics sales antivirals therapeutic area grew per cent hiv dermatological products four per cent valtrex herpes grew per cent gastrointestinal driven bypatients switching suppression therapy respiratory tract sales ofavandiaavandametincreased per cent anti smoking control bacterial sales declined per cent result generic natural wellness support competition began third quarter coregsales increased per cent continued benefit wide oral care range indications nutritional healthcare vaccines grew six per cent reflecting good performance pediarix growth consumer healthcare sales ofthreeper cent billioncomprised otc medicines sales increase oftwo europe per cent nutritional healthcare sales increase offiveper cent discussion individual market performance europe oral care sales increase offourper cent region aturnover created basisrather aturnover invoiced basis otcmedicines europe region contributed per cent pharmaceutical turnover otcmedicine sales billion two per cent sales although overall turnover growth region two per growthfrom smoking control products usaup per cent cent good growth recorded spain andsouthernand europeup per centhelped offset decline eastern europe government healthcare reforms including pricing dermatological products weredown per cent due reimbursement restrictions adversely affected turnover generic competition cutivate usa expansion france italy germany panadol brand international markets helpedanalgesics grow seven per cent seretide glaxosmithklines largest selling product europe grew per cent reported notable growth inspain uk july glaxosmithkline obtained theotcmarketing rights seretideand constituent products sereventand flixotidegrew usa orlistat fdaapproved prescription product obesity eight per cent management marketed roche xenical decline sales theherpes franchise mainly result oral care generic competition zoviraxpartially offset patients oral care sales billion four per cent strong switching newer product valtrex growth internationalofnineper cent led seroxatsales per cent reflecting generic competition sensodyne polidentand poligripbrands inthe ukand france nutritional healthcare antibacterial sales declined six per cent due generic sales nutritional healthcare products grew five per cent competition throughout region billion lucozade grew seven per cent million vaccines grew seven per cent driven thehepatitis franchise andinfanrix glaxosmithkline operating financial review prospects year continued trading profit statutory results trading profit overall trading margin declined percentage points group reporting results statutory basis trading profit million declined six per cent sterling analysis trading profit subsequent discussion terms constant exchange rates trading profit increased compares results statutory results five per cent margin decreased percentage points reflecting completion merger manufacturing restated growth restructuring programme lower charges relating cer programmes deliver future cost savings offset higher turnover legal provisions increased rd expenditure cost sales selling general profit taxation statutory results administration analysis discussion profit taxation relates research statutory performance development trading profit operating incomeexpense royalties income group adopted uitf abstract revised operating expense abstract relating shares held esop trusts share options awards comparative information income equity investments restated accordingly trading profit profit tax disposals reduced million net assets st december million operating expense includes litigation costs provisions cost sales relating legal claims withdrawn products product cost sales percentage turnover remained line withdrawals antitrust matters claims respect sales prior year reduced merger manufacturing restructuring marketing reimbursement income equity investments costs offset significant weakening us dollar disposals includes equity investment carrying value relative last year loss higher margin paxil irand adjustments arising stock market changes product disposals wellbutrin srsales generics adverse product mix equity investment sales merger manufacturing restructuring costs nil million operating expense million year compared million charge reflects provisions selling general administration related litigation matters legal matters partly offest selling general administration sga costs declined two minor product divestments sales equity investments per cent seven per cent sterling terms reflecting savings income net charge legal provisions gain general administration partly offset increased sales equity investments lower compared advertising promotion selling costs latter costs last year increased three per cent accounted one percentage point increase total sga general administration costs share profitslosses joint ventures associated declined eight per cent accounted three percentage undertakings point reduction total sga due lower charges share profits associates arises principally related programmes deliver future cost savings equal groups holding inquest diagnostics inc two percentage point reduction total sga general expense reductions equal three percentage point decline disposal ofinterest associates total sga reductions partly offset higher group disposed million shares provisions legal matters equivalent two percentage point investment quest diagnostics inc cash proceedsof increase total sga net currency movements million reducing groups shareholding overall reduction percentage points relative st december per cent recognising forexpenses expressed percentage turnover chargeof millionfor goodwill previously written reservesa profit million recognised higher provisions legal matters include charge million inquarter related introduction ibnrincurred reported actuarial technique determine net interest payable reasonable estimate groups exposure unasserted interest payable claims relation number product liability matters investment income research development share interest payable associate rd expenditure increased seven per cent reflecting increased clinical trial activity pharmaceuticals rd expenditure represented per cent pharmaceutical turnover year net interest payable increased compared largely result higher average effective group interest rate higher borrowingsoperating financial review prospectsglaxosmithkline profit ordinary activities taxation statutory research development results research development rd increased eight per cent taking account net operating incomeexpenses reflecting increased clinical trial activity pharmaceuticals rd contribution associates business disposals net interest expenditure represented per cent pharmaceutical payable statutory profit tax million compared turnover year million increase eight per cent three per cent decline sterling trading profit trading profit million one per cent decrease trading profit business performance per cent decline sterling terms compared business performance trading margin declined two percentage points years business performance compared net currency movements primary performance measureused management margin declined percentage points reflecting higher rd presented excluding merger items integration expenditure higher cost ofsales due less favourable product restructuring costs disposal businesses management mixand higherprovisionsfor legal matters partially offset cost believesthat exclusion items providesa better comparison savings initiatives general administration lower charges business performance periods presented related toprogrammesto deliver future cost savings completion programmes group reporting results statutory basis analysis trading profit taxation business performance profit subsequent discussion compares results business performance results accordingly information analysis discussion profit taxation provided supplement contained inthe consolidated relates tostatutory performance business statement profit loss pagesandprepared performance accordance ukgaap operating incomeexpense restated growth royalties income cer operating expense turnover cost sales income equity investments selling general disposals administration research development operating expense includes litigation costs provisions trading profit relating legal claims withdrawn products product withdrawals antitrust matters claims respect sales marketing reimbursement income equity investments cost sales disposals includes equity investment carrying value cost salesincreasedas percentage turnover result adjustments arising stock market changes product disposals significant weakening usdollar relative loss equity investment sales higher margin paxil ir wellbutrin sr sales generics andan adverseproduct mix operating expensewasmillion year compared million charge reflects provisions selling general administration related tolegal matters partly offset minor product sgacosts declined twoper centseven per cent sterling terms divestments sales equity investments income reflecting savings general administration partly offset increased advertising promotion selling costs share profitslosses joint ventures associated latter costs increased three percent accounted one undertakings percentage point increase total sga general share profits associates arises principally administration costs declined eight percent accounted groups holding inquest diagnosticsinc three percentage point reduction total sga due lower chargesrelated programmes deliverfuture cost savings disposal ofinterest associates equal two percentage point reduction total sga group disposed million shares general expense reductions equal three percentage investment quest diagnostics inc cash proceeds point decline total sga reductions partly offset million reducing groups shareholding higherprovisionsfor legal matters equivalent two percentage st december per cent recognisinga point increase total sga net currency movements charge million goodwill previously written overallreduction percentage points relative reservesa profit million recognised forexpenses expressed percentage turnover higher provisions legal matters include charge million quarter related introduction ibnrincurred reported actuarial technique determine reasonable estimate groups exposure unasserted claims relation number product liability matters glaxosmithkline operating financial review prospects year continued irs claimsfor years upheld group net interest payable would additionally liable interest late paymentestimated interest payable amount billion net federal tax reliefat investment income st december giving totalof billionfor years group expects filea petition thetax share interest payable associate claims april including claim refund taxes ask tax court consolidate irs claims years single triala provisional trial date claims set october net interest payable increased compared largelyas result higher average effective group interest rate higher similar tax issues remain open date borrowings glaxosmithkline expects receive substantial claims irs yearsglaxosmithkline continues believe profit ordinary activities taxation business profits reported us subsidiaries period date performance paid taxes usa sufficient taking account net operating incomeexpense reflect activities us operations contribution associates net interest payablestatutory thegroupis continuing discussions inland revenue proffit taxwasmillion compared withbusiness respect uk transfer pricing disputes performance profit tax million increase oftwoper centdecline sterling terms nine per cent glaxosmithkline uses best advice determining transfer pricing methodology seeking manage transfer pricing merger manufacturing restructuring issues satisfactory conclusion basis ofexternal merger manufacturing programmes substantially professional advice continues believe made adequate completed consequently group reporting provision liabilities likely arise open assessments statutory results costs programmes million million tax however continues wide difference views group irs inland revenue relevant taxation taxationauthorities open issues exist ultimate liability matters may vary amounts provided restated dependent upon outcome litigation proceedings business performance negotiations relevant tax authorities merger restructuring disposal except shown annual report provision subsidiaries made taxation would arise distribution profits total retained overseas subsidiary associated undertakings grounds remittance profit retained st december integrated nature groups worldwide operations required way incremental tax arise involving significant investment research strategic manufacture limited number locations consequential earnings growth crossborder supply routes numerous endmarkets gives rise restated cer complexity delay negotiations revenue authorities statutory earnings profits individual group companies liable basic earnings per share p p tax disagreements revenue authorities basic earnings per ads intragroup transactions particular price goods transferred group companies different tax adjusted earnings jurisdictions produce conflicting claims revenue adjusted earnings per share p p authorities profits taxed individual territories adjusted earnings per ads resolution issues continuing fact life weighted average number glaxosmithklinethe group open issues revenue shares millions authorities usa uk japan canadaby far largest relates glaxo heritage products respect us adjusted earnings adjusted earnings per share presented internal revenue service irs uk inland revenue made order illustrate business performance competing contradictory claims years business performance glaxosmithkline attempted settle us dispute first primary performance measure used management direct discussion irs subsequently presented excluding merger items integration discussions us uk authorities terms restructuring costs disposals businesses management double tax convention two countries believesthat exclusion items providesa better comparison discussions terminated july th january ofbusinessperformancefor periods presentedfor irs issued notice deficiency years completion programmes group reporting claiming additional taxes billion nd april results statutory basis group filed petition us tax court disputing irs claim seeking refund billion taxeson th january irs issued notice deficiency years claiming additional taxes billionoperating financial review prospectsglaxosmithkline adjusted earnings increased one per cent adjusted earnings groups largest business us pharmaceuticals per share increased two per cent reflecting reduction us market complex arrangements rebates weighted average number shares resulting groups discounts allowances following briefly describes share buyback programme interest cost programme nature arrangements existence groups us also impacts groups earnings pharmaceuticals business actual rates exchange adjusted earnings per share us medicaid programme stateadministered declined nine per cent adverse currency impact eps programme providing assistance certain poor percentage pointsreflects significant weakening us vulnerable patients medicaid drug rebate dollar relative compares six per cent adverse programwas established reduce state federal currency impact turnover difference principally arises expenditure prescription drugs glaxosmithkline different mix currencies profits compared turnover participates providing rebates states provisions medicaid rebates calculated based specific statutory eps pence compared terms individual state agreements using combination pence sterling based decline statutory eps historical experience product population growth three per cent reflected significant weakening dollar anticipated price increases impact contracting excluding effects ofcurrency statutory eps grew eight per cent strategies reflecting completion groups merger restructuring programmesin well underlying business growth glaxosmithkline arrangements certain key parties whereby party able buy products wholesalers dividend lower prices chargeback represents difference board declared fourth interim dividend ofpence invoice price wholesaler indirect customers per share making total year ofpence per share contractual discounted price provisions estimating compares total dividend pence per share chargebacks calculated based thetermsofeach equivalent dividend receivable adr holders iscents agreement historical experience product growth rates per ads based exchange rate dividend customer rebates offered key managed care group exdividend date th february purchasing organisations direct indirect paid th april shareholders adr holders record customers arrangements require customer th february achieve certain performance targets relating value product purchased formulary status predetermined critical accounting policies market sharesrelative competitors provision consolidatedfinancial statements prepared accordance rebates estimated based specific terms ukgenerally accepted accounting principles following agreement historical experience product growth rates accounting policies approved board described cash discounts offered customers encourage noteto financial statements accounting policies prompt payment accrued time management required make estimates assumptions invoicing adjusted subsequently reflect actual affect amounts assets liabilities revenue expenses experience reported thefinancial statements actual amounts results could differ estimates following considered historical experience customer returns critical accounting policies adopted glaxosmithkline records provision estimated sales returns applying historical experience customer returns turnover amounts invoiced together market related information revenue recognised title risk loss passed stock levels wholesalers anticipated price increases customerand reliable estimates made relevant andcompetitor activity deductions gross turnover reduced rebates discounts reconciliation gross turnover net turnover us allowances product returns given expected given pharmaceuticals business follows vary product arrangements buying groups arrangements purchasing organisations dependent upon submission claims time initial gross turnover recognition saleprovisions aremade time sale estimated rebates discountsor allowancespayable usgovernment state programmes returnsto made based available market information chargebacks historical experience amounts estimated managed care group purchasing may fully reflect final outcomeandtheamounts organisation rebates subject change dependent upon amongst things cash discounts types buying group product sales mix level provision customer returns reviewedand adjusted quarterlyin light historical experience actual rebates discounts allowances given total deductions returns made changes arrangements future events net turnover could cause assumptions theprovisionsare based change could affect future results group glaxosmithklineoperating financial review prospects year continued total provisions rebates discounts allowances returns intangible assets us pharmaceuticals business st december intangible assets acquired glaxosmithkline st december wereas follows third parties costs acquisition capitalised licences compounds development amortised estimated st st december december useful lives exceeding years estimated useful lives reviewed annually impairment reviews undertaken events occur call question carrying values usgovernment state programmes assets brands acquired businesses capitalised chargebacks independently separable longterm managed care group purchasing value group brands amortised estimated organisation rebates useful lives exceeding years except end cash discounts useful economic life foreseen brands customer returns amortised subject annual impairment reviews impairment reviews based riskadjusted future cash flows total discounted using appropriate riskfree interest rates future cash flows based business forecasts therefore amonthly process operated monitorstock levels inherently judgemental future events could cause values wholesalersfor abnormal movements process usesgross intangible assets impaired would sales volumes prescription volumes based third party data adverse effect future results group sources information received key wholesalersthe aim maintain stocks consistent level year year pensions postretirement benefits based pattern consumption costs providing pensions postretirement benefits charged profit loss account accordance ssap basis us pharmaceutical stock levels wholesalers period benefit derived distribution channels st december estimated employees services costs assessed accordance amount less one month ofturnover calculation advice received independent actuaries basis uses third party information accuracy assumptions selected management assumptions include totally verified believed sufficiently reliable future earnings pension increases discount rates expected purpose long term rates return assets disclosed noteto financial statements employee costs expected long term legal disputes rates return assets determined based long term glaxosmithkline provides anticipated settlement costs government bond rates adjusted risk current market reasonable estimate may made likely outcome expectations note also gives additional disclosures dispute andlegal otherexpenses arising fromclaims required frs retirement benefits selection different thegroupthe companys directors taken legal advice assumptions could affect future results group established provisions taking account insurance agreements regard relevant facts product rights goodwill circumstances matter accordance accounting addition critical accounting policies outlined requirements provisions product liability claims certain accounting policy product rights goodwill deemed products made anincurred reported basis important respect balance sheet prepared sufficient history claims made settlements accordance us accounting principles usgaap available provisions made unasserted merger glaxo wellcome smithkline beecham claims claims reasonable estimate likely accounted acquisition gave rise product rights outcome yet made ultimate liability pending billion goodwill billion recognised unasserted claims may vary amounts provided goodwill product rights determined indefinite dependent upon outcome litigation proceedings lives amortised rather reviewed annually investigations possible settlement negotiations impairment impairment reviews assess business projections prepared part groups annual budgeting planning impairment fixed assets process determine whether impairment value carrying values fixed assets subject depreciation goodwill occurred business projections include amortisation reviewed impairment assumptions future events changes future events could indication values assets might impaired cause assumptions business projections change impairment determined reference higher net consequent adverse effect future results group realisable value value use measured reference risk reported usgaap adjusted future cashflows discounted using appropriate riskfree interest rates future cashflows based business forecasts therefore inherently judgemental future events could cause assumptions used impairment reviews change consequent adverse effect future results groupoperating financial review prospectsglaxosmithkline financial position resources financial position group observes stringent procedures uses specialist skills manage environmental risks activities environmental restated issues sometimes dating operations modified discontinued reported responsibility environment goodwill health safety page noteto financial intangible fixed assets statements legal proceedings glaxosmithkline believes tangible fixed assets facilities adequate current needs investments investments fixed assets glaxosmithkline heldinvestmentswith carrying value st december ofmillion million equity investments market value st december million stocks million investments include associates debtors joint ventures mainly equity shares holding liquid investments derives directly groups business investments cash bank include stakes companies group research current assets collaborations provide access biotechnology loans overdrafts developments potential interest interests companies creditors arise business divestments creditors amounts due within one year debtors net current assets debtors increased reflecting timing yearend total assets less current liabilities receipts higher deferred tax asset insurance receivables additional cash contributions ukpension plan loans creditors provisions creditors amounts due one year group carried provisions million st december provisions liabilities charges respect estimated future liabilities million related legal disputes net assets million related pensions postretirement called share capital benefitsfor employees share premium account provision made tax legal disputes reserves indemnified disposal liabilities costs manufacturing profit loss account restructuring merger integration extent equity shareholders funds balance sheet date actual constructive obligation existed could reasonably estimated nonequity minority interests equity minority interests net debt capital employed group net debt st december comprised tangible fixed assets total costof groups tangible fixed assets cash liquid investments st december billion net book value borrowings repayable within one year billion land buildings represented billion borrowings repayable one year plant equipment billion computer software billion net debt assets construction billion glaxosmithkline invested million new andrenewal property plant net debtincreasedby million million equipment mainly related large number projects primarily due tothe negative impact foreign exchange improvement expansion facilities various worldwide operating cash flows redemption preference shares sites property mainly heldfreehold new investment financed issued subsidiary settlement legal matters group liquid resources st december group acquisition fraxiparine arixtra business capital contractual commitments future expenditure sanofisynthelabo million operating lease commitments million pensions glaxosmithklines business sciencebased technologyintensive group continues account pension arrangements highly regulated governmental authorities allocates accordance ssap transitional provisions significant financial resources renewal maintenance frs disclosed pension assets liabilities group property plant equipment minimise risks interruption st december show net deficit allowing deferred production achieve compliance regulatory taxation million millionspecial cash standards number processes use chemicals hazardous contributions million made reduce materials funding deficits uk us plansthis position reviewed annually andfurther contributions made appropriate glaxosmithklineoperating financial review prospects financial position resources continued shareholders funds commitments contingent liabilities summary movements equity shareholders funds financial commitments summarised noteto set financial statements commitments contingent liabilities obligations respect short longterm debt set restated noteto financial statements contingent liabilities noteto financial statements net debt beginning yearas previously reported amounts provided pensions postretirement benefits prior period adjustmentimplementation restructuring integration plans legal environmental uitf revised uitf disputes set innoteto financial equity shareholdersfunds beginning statements provisions liabilities charges ofyearas restated profit year contractual obligations commitments dividends following table sets groups contractual obligations shares issued exercise share options commitments fall due payment shares purchased investment esopshares total yr yrs yrs yrs exchange movements goodwillwrittenback loans unrealised lossprofit ondisposal finance lease obligations intellectual property operating lease tax exchange movements commitments unrealised gains intangible fixed assets end year tangible fixed assets commitments equity shareholders fundsincreasedfrom million total st december million st december increase arises retained earningspartly offset shares group entered number research collaborations purchased cancelledor held astreasury sharesand develop new compounds pharmaceutical exchange movements overseas net assets companies terms arrangements include front fees equity investments loans commitments fund share purchases specified levels research addition group often esop trusts make market purchases agree make payments future milestones shares glaxosmithkline plc nil shares held achieved agreements relate compounds trusts satisfy future exercises options awards early stages development milestone payments group share option award schemes proportion continue number years compounds move shares held trusts respect awards rules successfully development process generally scheme require company satisfy exercises closer product marketing approval greater market purchases rather issue new shares shares possibility success payments shown represent held trusts matched options awards granted maximum would paid milestones achieved diminish dilutive effect new share issues shareholders ' number commitments made licensing capital earnings agreements principally withtheravance inc tanabe rd october glaxosmithkline announced second seiyaka co ltd exelixis inc human genome sciencesinc share repurchase programme billion annual pension commitments provided note financial general meetingshareholders renewed approval statements employee costs glaxosmithkline make market purchases shares exact amount timing future purchases depend contingent liabilities market conditions factors glaxosmithkline following table sets contingent liabilities comprising purchased total million shares cost billion discounted bills performance guarantees items arising programme total shares purchased million normal course business expected shares costing million cancelled remaining expire million shares costing million held treasury shares total yr yrs yrs yrs st december esop trusts held million guarantees glaxosmithkline shares carrying value million contingent liabilities market value million future exercise share options share awards total operating financial review prospectsglaxosmithkline normal course business group provided various investment appraisal indemnification guarantees respect business disposals glaxosmithkline formal process assessing potential legal disputes subsequently arisen investment proposals order ensure decisions aligned provision made reasonable estimate made groups overall strategy process includes analysis likely outcome dispute included note impact profitand assessment return based financial statements provisions liabilities discounted cash flows discount rate used perform financial charges analysis decided internallyto allow determination extent investments cover groups cost capital specific groups policy provide settlement costs investments discount rate may adjusted take account asserted claims environmental disputes reasonable country risk weightings estimate may made prior point liability recorded legal environmental costs discussed risk factors capitalexpenditure financial investment pagesto cash payments fortangible intangible fixed assets amounted glaxosmithkline uses best advice determining transfer million milliondisposals realised pricing methodology basis external professional million million cash payments acquire equity advice continues believe made adequate provision investments ofmillion million madein liabilities likely arise open taxation assessments year sales equity investments realised million ultimate liability matters may vary significantly million amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities future cash flow discussed noteto financial statements group expects future operating cash flow taxation sufficient fund operating debt service costs satisfy normal levels capital expenditure meet obligations cash flow existing licensing agreements meet routine outflows including tax dividends subject risk factors discussed summary consolidated cash flow statement set pages group may time time additional demands finance acquisitions restated group access sources liquidity banks financial institutions addition cash flow net cash inflow operating activities operations forsuch needs dividends joint ventures associated undertakings payment policies returns investment servicing finance group companies responsible monitoring managing taxation paid working capital terms sales collections supplier capital expenditure financial investment paymentsreflect local commercial practice acquisitions disposals equity dividends paid uk company uk subsidiaries net cash inflowbefore management policies ensure suppliers paid time particular liquid resources financing uk companies seek management liquid resources settle terms payment suppliers agreeing shares purchased terms transaction financing ensure suppliers made aware agreed terms increasedecreasein cash year ofpayment abide terms payment reconciliation net cash flow movement net debt policy includes arrangements accelerated payment small suppliers net debt beginning year payment performance increasedecreasein cash year st december average number days purchases cash outflowfrom management represented trade fixed asset creditors parent liquid resources company wasnil nil respect company net increase longterm loans uk subsidiaries aggregate wasdays days net repayment shortterm loans exchange movements net debt end year net cash inflow operating activities million adecreaseof million arising thenegative impact foreign exchange settlement legal matters glaxosmithklineoperating financial review prospects financial position resources continued treasury policies liquid assets surplus immediate operating requirements group companies generally investedand managed glaxosmithkline plcreportsin sterling paysdividends centrally corporate treasury requirements group sterling profits role corporate treasury glaxosmithkline companies operating finance met whenever possible manage monitor groups external internal central resources funding requirements financial risks support group corporate objectives treasury activities governed policies external borrowings mainly managed centrally corporate procedures approved board monitored treasury comprise portfolio long mediumterm treasurymanagement group instruments shortterm finance glaxosmithkline maintains treasury control systems procedures glaxosmithkline hold issue derivative financial monitor foreign exchange interest rate liquidity credit instruments trading purposes groups treasury policies financial risks specifically prohibit activity transactions financial instruments undertaken manage risks arising liquidity underlying business activities speculation group operates globally primarily subsidiary companies established markets group trades funding maturity counterparty risk due nature groups business patent protection group invests centrally managed liquid assets ingovernment many ofthe products groups portfolio groups bonds shortterm corporate debt instruments minimum products compete largely product efficacy rather price shortterm credit rating ap money market funds selling margins sufficient cover normal operating costs credit rating aaaaaa fully collateralised preference share groups operating subsidiaries substantially cash generative investments credit ratings shown standard poors operating cash flow used fund investment research moodys investors services respectively development new products well routine outflows capital group manages net borrowing requirements expenditure tax dividends repayment maturing debt portfolio long mediumterm borrowings including bonds group may time time additional demands together shortterm finance us billion finance share purchases acquisitions commercial paper programmein april million glaxosmithkline operates high level interest cover year per cent coupon bond million year low levels net debt relative itsmarket capitalisation per cent coupon bond amillion year per cent addition tothe strong positive cash flow normal trading coupon bond issued theusshelf registration activities additional liquidity readily available via itscommercial established march paperprogramme shortterm investments group also groups mediumterm borrowings mature dates uncommitted euro medium term note programme billion private financing matures long million issue st december dated sterling bond matures longdated dollar march group established usshelf registration bond matures private financing may redeemed billion st december million glaxosmithkline time particular event issue accelerating event would increase cost funding group glaxosmithklines longterm debt rating aa treasury operations standard poors aa moodys investors services objective treasury activity manage posttax net agencies shortterm ratingsfor paper issued costincome financial operations benefit group groups commercial paper programmearea p earnings corporate treasury operate profit centre respectively glaxosmithkline uses variety financial instruments including derivatives finance operations manage market risks foreign exchange risk management operations financial instruments comprise cash glaxosmithklineforeign currency transaction exposure arising liquid resources borrowings spot foreign exchange contracts normal trade flowsin respect external intragroup tradeis hedged glaxosmithklines policy minimise number derivative financial instruments used manage exposure overseas operating subsidiaries transaction risk market risks treasury operations derivative instruments bymatching local currency income local currency costs principally comprising forward foreign currency contracts interest forthispurpose intragroup trading transactions matched rate currency swaps used swap borrowings liquid centrally intragroup payment terms managed reduce assets currencies required group purposes risk exceptional foreign currency cash flows hedged selectively manage exposure funding risks changes foreign management corporate treasury exchange rates interest rates significant proportion group borrowings including glaxosmithkline balances use borrowings liquid assets commercial paper programme us dollars benefit regard cash flow operating activities liquidity us dollar denominated capital markets certain thecurrencies earned tax cost intragroup borrowings swapped currencies distributions currencies business assets required group purposes group seeks denominate denominated posttax cost borrowings compared borrowings currencies principalassets totheposttax return liquid assetsoperating financial review prospectsglaxosmithkline borrowings denominated swapped foreign currencies financial assets liabilities match investments overseas group assets treated analysis net debt given noteto financial hedge relevant net assets statements net debt analysis financial assets liabilities carrying value fair value reconciliation net debt based composition net debt st december given innoteto financial statements financial instruments per cent appreciation sterling major currencies related disclosures together discussion derivative would result reduction groups net debt financial instruments quantitative disclosures market approximatelymillion per cent weakening sterling riskin accordance requirements financial reporting major currencies would result increase standard groups net debt approximately million group continues benefit strong positive cash flow interest rate risk management group net debt would decreased significantly year glaxosmithklines policy interest rate risk management requires st december groups purchase amount net borrowings fixed rates increases shares market billion ratio forecast net interest payable trading profit financial assets liabilities st december group uses limited number interest rate swaps representative treasury policies strategies redenominate external borrowings intothe interest rate coupon glaxosmithkline applied consistently year required group purposes duration swaps matches significant changes policies throughout year duration theprincipal instruments interest rate derivative instruments accounted hedges relevant assets liabilities possible group manages centrally shortterm cash surpluses borrowing requirements subsidiary companies uses forward contracts hedge future repayments back originating currency sensitivity analysis considers sensitivity groups net debt hypothetical changes market rates assumes variables remain constant based composition net debt st december one percentage point basis points increase decrease average interest rates would result negligible change groups annual interest expense equity risk management equity investments classified current assets available sale group manages disposals meet overall business requirements arise group regularly monitors value equity investments enters hedges selectively approval board glaxosmithklineoperating financial review prospects outlook risk factors outlook see noteto financial statements legal proceedingsfor discussion patentrelated proceedings group sales growth existing products launch newproducts involved arekey driversof glaxosmithklinesbusiness performanceit anticipated number new products launched generic drug manufacturers seeking market generic versions typically sales existing products declinedramatically many groups important products including generic competition introduced eitheron patent expiry seretideadvair avandiazofran wellbutrin xl imitrexlamictal earlier successful challenge groups patent andvaltrex prior expiration groups patents glaxosmithkline engaged legal proceedings regarding exhibited readiness products validity infringement groups patents relating many future generic products competitive augmentinpaxil productsthese discussed inrisk factorsbelow wellbutrin sr launched usa noteto financial statements legal proceedings respectively significantimpact groups overall turnoverand earnings based reporting international financial reporting standards ifrs glaxosmithklines published earnings guidance weakness intellectual property protection certain group expected todeliver eps percentage countries growth constant exchange ratesin low doubledigit range countries group operates patent group net debt billion low relative protection may significantly weaker usa itsmarket capitalisationand positions take advantage european union addition effort control public health opportunities might arise build business crises developing countries south africa brazil considered plans substantial reductions scope risks uncertainties inherent business patent protection pharmaceutical products particular may affect future performance including expected earnings countries could facilitate competition within markets growth discussed risk factors generic manufacturers would otherwise unable introduce competing products number years loss risk factors patent protection including abrogation patent rights risks uncertainties relevant groups business compulsory licensing likely affect adversely groups factors listed among group thinks operating results national markets expected could cause groups actual results differ materially material group overall absence adequate patent expected historical results protection could limit opportunity look markets future sales growth risk rd deliver commercially successful new products risk substantial adverse outcome litigation continued development commercially viable new products government investigations critical groups ability replace sales older products see noteto financial statements legal proceedings decline upon expiration exclusive rights increase overall discussion proceedings governmental investigations sales developing new products costly lengthy uncertain group currently involved unfavourable resolution process new product candidate fail stage similar future proceedings investigations mayhave process one latestage product candidates could amaterialadverse effect onthe groups financial results fail receive regulatory approval group made material provisions related legal proceedings investigations reduced earnings new product candidates may appear promising development group may also makeadditional significantprovisions related significant investments fail reach market legal proceedingsandinvestigations future would limited commercial success result efficacy safety reduce earnings many cases practice plaintiff bar concerns inability obtain necessary regulatory approvals claim damages compensatory punitive statutory difficulty excessive costs manufacture infringement amounts bear relationship underlying harm patents intellectual property rights others inability accordingly potentially misleading quantify potential differentiate product adequately exposure claims proceedings investigations type competes successful development groups research described note development pipeline particular importance light recent anticipated expiration patent data exclusivity recent insurance loss experience including pharmaceutical product number groups largest selling products liability exposures increased cost ofandnarrowed coverage afforded insurance pharmaceutical companies risk loss expiration patents marketing exclusivity generally including group patent infringement litigation order contain insurance costs inand group efforts generic manufacturers may involve challenges continued adjustits coverage profile accepting greater validity patent orassertions thatthe alternative compounds degree uninsured exposurein addition future claims infringe groups patents group successful aremade insurance policies insurersmayreservethe right patent protectionor data exclusivity periodsin deny coverage various groundsif denial coverage maintaining exclusive rights market one major ultimately upheldon claims could result material products particularly usa group highest additional chargestothe groups earnings turnover margins groupsturnoverand margins would adversely affectedoperating financial review prospectsglaxosmithkline product liability litigation group hadproducts millionin annual preclinical clinical trials conducted development global sales among products arepaxilirand potential products determine safety efficacy augmentinir respect group faces products use humans following approval regulatory generic competition andzofran imitrex valtrex lamictaland bodies notwithstanding efforts drugs vaccines avandia respect group currently defending introduced marketplace unanticipated side effects may intellectual property rights usa flonase became evident group currently defendant number fda yet approved generic version following expiry product liability lawsuits including class actions involve us patent mid substantial claims damages related groups groups major products pharmaceutical products become subject problem loss patent protection litigation particularly usa inherently unpredictable unexpected side effects regulatory proceedings publicity affecting excessive verdicts justified evidence occur doctor patient confidence pressure competitive class actions sweep together persons prescribed products new effective treatment groups products inflate potential liability force introduced adverse impact groups revenues numbers claims pain suffering punitive damages operating results could significant particular group faces frequently asserted product liability actions allowed intense competition manufacturers generic pharmaceutical represent potentially openended exposure products major markets generic products often enter market upon expiration antitrust litigation patents data exclusivity periods groups products usa become increasingly common following introduction generic products typically leads dramatic loss adverse outcome prosecution patent infringement actions sales reduces groups revenues margins defendants direct indirect purchasers payers proprietary products expiration dates patents initiate antitrust actions well claims direct indirect groups major products set pages legal purchasers payers typically filed class actions proceedings involving patent challengesare setoutin note relief sought may include treble damagesand restitution thefinancial statements legal proceedings claimsdamages adverse antitrust verdicts subject automatic trebling usa governmental payer controls pharmaceutical products subject price controls pressures governmental investigations restrictions many markets including japan germany groupoperates globally complex legal regulatory france italy governments intervene directly setting environments often vary among jurisdictions failure prices addition markets major purchasers comply applicable laws rules regulations pharmaceutical products whether governmental agencies jurisdictions may result incivil andcriminal legal proceedings private health care providers economic power exert usa example group responding federal substantial pressure prices terms access formularies state governmental investigationsinto pricing marketing reimbursement ofitsprescription drug products group predict whether existing controls increase investigations could result related restitution civil false claims new controls introduced reduce groups act litigation behalf federal state governments margins affect adversely ability introduce new products well asrelated proceedings initiated againstthe groupby profitably behalf consumers private payers proceedings may example usa group highest margins result trebling damages awarded fines respect sales country pricing pressures could significantly violation law criminal proceedings may also initiated increase upon implementation pharmaceutical benefit group companies individuals medicare event state programmes control cost ofpharmaceuticalare adopted medicare risks competition price controls limitations sales programme initiates outpatient pharmaceutical coverage third party competition beneficiariesin us government private insurers group operates highly competitive businesses coverage offered enormous pharmaceuticalsbusiness faces competition purchasing power programmecould demand discounts proprietary products large international manufacturers may implicitly create price controls prescription drugs producers genericpharmaceuticals significant product additionally number states proposed implemented innovations technical advances intensification price various schemes control prices senior citizens drug competition competitors could adversely affect groups programmes including importation countries bulk operating resultscontinued consolidation pharmaceutical purchasing drugs growth number patients covered industry could adversely affect groups competitive position large managed care institutions usa islikely continued consolidation among groups customers may increase implementation medicare amendments increase pricing pressures also increases pricing pressures groups products trends may adversely affect groups revenues margins sales usa terms implementation medicare pharmaceutical benefit finalised possible quantify impact benefit groups financial results glaxosmithklineoperating financial review prospects outlook risk factors continued regulatory controls reliance information technology group must comply broad range regulatory controls group increasingly dependent information technology testing approval manufacturing marketing many systems includinginternetbased systems internal pharmaceutical consumer healthcare products particularly communication well communication customers usa countries european union affect suppliers significant disruption systems whether cost product development also time required due computer viruses outside incursions could reach market uncertainty successfully materially adversely affect groups operations stricterregulatory controls also heighten risk withdrawal taxation regulators ofapprovalspreviously granted would reduce effective tax rate groups earnings benefits revenues result product recalls product liability fact portion earnings taxed favourable rates lawsuits addition cases group may voluntarily jurisdictions outside ukchanges tax laws cease marketing product example withdrawal application respect matters transfer pricing lotronexshortly initial launch usa face declining risk double taxation relate portion sales based concerns efficacy safety whether groups earnings taxed favourable rates could increase scientifically justified even absence regulatory action groups effective tax rate adversely affect financial developmentofthe postapproval adverse event profile resultsthe group open issues revenue authorities product product class may major impact usa uk japan canada far largest relates marketing sale product glaxo heritage products respect us internal revenue service uk inland revenue made competing risk interruption product supply contradictory claimsthese matters discussed note manufacture pharmaceutical products constituent financialstatements taxation materials requires compliance good manufacturing practice regulations groups manufacturing sites subject review global political economic conditions approval fda regulatory agencies group conducts substantial portion operations compliance failure suppliers key materials groups outside theuk groups management foreign exchange manufacturing facilities could lead product recalls rates discussed operating financial review prospects seizures interruption production delays approvals foreign exchange risk management fluctuations exchange new products pending resolution manufacturing issues rates betweensterling currencies especially us noncompliance also result fines disgorgement dollarthe euro japaneseyen materially affect profits interruption supply fines disgorgement remedy groups financial results could materially adversely affect groups financial results groups cidra puerto rico facility currently subject group control changes inflation interest fdaobservations possible deficiencies manufacturing rates foreign currency exchange rates controls practicesas referred innoteto financial statements economic factors affecting businesses possibility legal proceedings group undertakes business political unrest legal regulatory changes nationalisation continuity planning single sourcing certain components bulk jurisdictions group operates factors could active materials finished products creates risk failure materially affect groups future results operations supply event regulatory noncompliance physical disruption manufacturing sites accounting standards new revised accounting standards rules promulgated risk concentration ofsales wholesalers time time bythe uk us internationalaccounting standard usa line pharmaceutical companies setting boards could material adverse impact groups group sells products small number wholesalers reported financial results adoption international addition hospitals pharmacies physicians groups financial reporting standards ifrs changes market sales three largest amounted approximately valuation certain financial instruments equity collar per cent groups us pharmaceutical sales group linked groups investment questdiagnostics put exposed concentration credit riskin respectofthese call options linked groups strategic alliance theravance wholesalers one affected impairments equity investments reflected financial difficulty could materially adversely affect groups reported results gains losses actually groups financial results realised could significant impact profit loss statement given periodthe group believes complies environmental liabilities appropriate regulatory requirements concerning environmental laws various jurisdictions impose actual financial statements disclosures however companies potential obligations group remediate contaminated experienced investigations potential noncompliance sites group also identified potentially accounting disclosure requirements resulted responsible party us comprehensive environmental significant penalties response compensation liability act number sites remediation costs relating groups use ownership human resources sitesfailure tomanage properly environmental risks could grouphasapproximatelyemployeesaround result additional remedial costs could materially world subject laws regulations concerning adversely affect groups operations see noteto employees ranging discrimination harassment financialstatements legal proceedingsfor discussion personal privacy labour relations vary significantly environmentalrelated proceedings group involved jurisdiction jurisdiction failure comply applicable requirements could significant adverse affect groupoperating financial review prospectsglaxosmithkline year accordance ussec disclosure requirements following pharmaceutical turnover discussion compares results year st december growth rates included review turnover constant results year st december exchange rates cer unless otherwise stated sterling growth growth rates included review turnover constant rates may found tables pharmaceutical turnover exchange rates cer unless otherwise stated sterling growth therapeutic area page rates may found table pharmaceutical sales total pharmaceutical turnover million therapeutic area page compared million increase five per cent approximately one per cent overall growth came exchange price increases growth sterling terms one per cent currencies influence groups results us significantly impacted weakness us dollar dollar euro japanese yen currencies pound hit highest level dollar within groups portfolio turnover new products launched three years climbing euro gained per cent major market within last five years accounted per dollar first year dollar fallen cent total turnover grew per cent million value euro investors weighed impact turnover established franchise products amounted continued unrest iraq tensions elsewhere world million representing per cent total turnover concerns us economy grew one per cent compared last year turnover older products less actively promoted million world market pharmaceuticals decline eight per cent representing per cent total turnover global pharmaceutical sales increased almost nine per cent cer five per cent sterling billion global pharmaceutical turnover fourth quarter declined two per cent reflecting us turnover decline world market value growth six per cent million whereas europe turnover grew geographic region bn total cer two per cent million international turnover usa grew four per cent million turnover us declined europe due generic competition paxilwhich began september germany france uk pharmaceutical turnover therapeutic area italy glaxosmithklines ability continue deliver pharmaceutical japan turnover growth despite generic competition several asia pacific products primarily due exceptionally broad product latin america portfolio fastgrowing highvalue products middle east africa canada include respiratory product seretideadvair billion total per cent diabetes treatment avandiaavandamet billion per cent wellbutrinfor depression us market although less buoyant maintained billion per cent emesis treatment zofran double digit growth represents per cent global billion per cent lamictalfor epilepsy billion prescription pharmaceutical market compared per cent per cent trizivir hiv billion per cent decade ago valtrexfor herpes billion per cent coregfor heart disease billion per cent pediatric vaccine th september glaxosmithkline held second position infanrixpediarix billion per cent world pharmaceutical market market share per cent behind pfizer market share per cent central nervous system cns glaxosmithkline seven products worlds top cns sales grew four per cent million sales usa pharmaceutical products augmentin avandia europe grew three per cent international sales grew imigranimitrex seretideadvair seroxatpaxil wellbutrinand per cent zofran sales seroxatpaxil glaxosmithklines leading product world market value growth depression anxiety disorders declined four per cent top five therapeutic classes bn total cer million us sales declined nine per cent million cardiovascular following launch generic paroxetine september central nervous system glaxosmithkline 's innovative new product paxil cr increased alimentary tract metabolic share total paxil prescriptions branded generic since antiinfectives bacterial generic launch per cent per cent paxil crsales viral fungal excluding vaccines million europeseroxatsales declined eight respiratory per cent million reflecting competition pricing pressures international sales grew per cent million note data based months thseptember led continued strong growth japan glaxosmithkline operating financial review prospects year continued sales wellbutrin depression grew per cent metabolic million reflecting increased physician awareness worldwide sales metabolic category billion products outstanding efficacy favourable sideeffect profile per cent avandiafranchise avandiaand avandamet new oncedaily formulation wellbutrin xl launched grew per cent year us sales per cent september formulation accounted per cent million branded wellbutrinprescriptions early february avandamet combination avandiaand metformin hci seven per cent sales expanded avandiametabolic franchise us launch limited generic competition wellbutrinbegan usa fourth quarter europe avandiahas benefited january mg dose increasing physician acceptance sales million per cent franchise benefit eu glaxosmithklines medicine epilepsy lamictal continued approval avandametin december avandiaalso grow across regions achieving sales million well international markets sales million per cent june fda approved lamictalfor long per cent term maintenance treatment bipolar disorder vaccines respiratory sales vaccines grew two per cent billion supported glaxosmithkline continues global leader respiratory infanrixpediarix franchise per cent million pharmaceuticals sales three key products hepatitis franchise declined per cent million reflecting seretideadvair flixotidefloventand serevent amounting competitive pressure usa europe billion per cent sales seretideadvair groups largest product grew per cent billion although usa glaxosmithklines new pediarixvaccine launched contributed declines sereventand flixotide constituent january pediarixadds protection hepatitis b products seretideadvairis one top ten pharmaceutical poliomyelitis theinfanrixcombination results six brands world usa sales grew per cent fewer injections infants million cardiovascular urogenital seretide also continued perform strongly europe coregsales grew per cent million benefiting per cent international markets per cent recent data showed highly significant statistical growth prospects advairwere strengthened difference survival coregand metoprolol patients fda approval use treatment ofcopdin fourth heart failure quarter levitra vardenafil new agent treatment erectile older respiratory products ventolinand becotidecontinued dysfunction launched usa august decline patients converted newer products europe first half year levitrawas researched developed bayer agand copromoted glaxosmithkline antivirals hiv medicines grew across regions totalled billion oncology emesis sales six per cent sales trizivir glaxosmithklines triple sales zofrangrew per cent million driven combination therapy grew per cent million lexiva astrong us performance per cent million hiv launched december initial sales million therapeutic areas global sales valtrex received fda approval august sales zantacfell per cent million declines reduce risk transmission genital herpes rose inall regions per cent million antibacterials antibacterial sales declined per cent worldwide per cent usa augmentinsussales per cent year result generic competition began third quarter usa glaxosmithklines two new antibiotics augmentin es children augmentin xrfor adults recorded combined sales million spite generic competitionoperating financial review prospectsglaxosmithkline pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major products total cer cer cer cer cns depression seroxatpaxil wellbutrin migraine imigranimitrex naramigamerge lamictal requip zyban respiratory serevent seretideadvair flixotideflovent seretideadvair flixotideflovent serevent flixonaseflonase ventolin becotide antivirals hiv trizvir combivir epivir retrovir ziagen agenerase herpes valtrex zovirax zeffix antibacterials augmentin zinnatceftin fortum amoxil metabolic avandiaavandamet vaccines hepatitis infanrix oncology emesis zofran hycamtin cardiovasular urogenital coreg levitra avodart zantac cer represents turnover growth constant exchange rates represents growth actual exchange rates glaxosmithkline operating financial review prospects year continued usa international usa reported five per cent turnover growth year eight per cent turnover growth international region business represents per cent total pharmaceutical reflected mixture good growth middle east africa turnover canada japan asia pacific latin america also grew strongly mexico rebounded following poor economic conditions advairmaintained strong growth sales million realignment wholesaler stock levels driving overall respiratory growth per cent however adversely affected sales constituent products flovent overall international growth driven seretide seroxatpaxil serevent showed declines flonaseindicated avandia partly offset declines zantacand zovirax treatment perennial rhinitis grew strongly per cent asia pacific area grew due performance seretide sales growth three per cent central nervous system avandia strong growth number markets partly products included sales wellbutrinup per cent reflecting offset decline one per cent largest market australia performance new day formulation wellbutrin xl reflecting reduced sales zybanzantacand older antibiotics paxil sales declined nine per cent due launch generic growth japan reflected strong growth paxil serevent paroxetine september glaxosmithkline 's innovative new valtrexpartly offset declines zovirax zantac product paxil cr increased share total paxilprescriptions government price reductions branded generic since generic launch per cent per cent paxil crsales million middle east africa area followed trends markets growth seretide avandia vaccines sales antivirals therapeutic area grew four per cent canada growth driven seretide avandia hiv led strong performance trizivirup per cent partially drew sales constituent products valtrex consumer healthcare sales herpes grew per cent driven fda approval growth reduced risk transmission genital herpes cer sales avandiaincreased per cent benefiting otc medicines analgesics launch avandametin november antibacterial sales dermatological declined per cent result generic competition began gastrointestinal third quarter coregsales increased per cent respiratory tract reflecting benefit recent data showed highly smoking control significant statistical difference survival betweencoregand natural wellness support metopropol patients heart failure oral care europe discussion individual market performance europe nutritional healthcare region turnover created basis rather turnover invoiced basis see pages details growth consumer healthcare sales four per cent europe region contributed per cent pharmaceutical turnover million comprised otc medicines sales increase although overall turnover growth region two per two per cent nutritional healthcare sales increase nine cent good growth recorded italy central eastern per cent oral care sales increase three per cent europe government healthcare reforms including pricing reimbursement restrictions adversely affected turnover france otcmedicines spain germany seretide glaxosmithklines largest selling overthecounter medicine sales billion two per cent product europe reported notable growth france italy sales smoking control gastrointestinal products uk although partly offset expected declines significantly usa primarily due flat market conditions sereventand flixotide trizivirshowed strong growth private label competition growth smoking control major markets region decline sales herpes products recently launched europe sales dermatological franchise mainly result generic competition zovirax products acquired earlier year helped offset declines partially offset patients switching newer valtrexproduct oral care oral care sales billion three per cent glaxosmithkline 's sensodyne brand continues grow regions nutritional healthcare nutritional healthcare products grew nine per cent billion lucozade sportand lucozade hydroactivecontinued drive growth categoryoperating financial review prospectsglaxosmithkline trading profit statutory results profit taxation statutory results statutory results include merger items integration analysis discussion profit taxation relates restructuring costs disposal subsidiaries statutory performance restated restated growth operating incomeexpense cer royalties income turnover operating expense cost sales selling general income equity investments administration disposals research development trading profit operating incomeexpense includes litigation costs provisions relating legal claims withdrawn products product withdrawals antitrust matters equity investment cost sales carrying value adjustments arising stock market price cost sales reduced percentage turnover result changes royalty income product disposals equity benefits arising merger manufacturing restructuring investment sales savings favourable product mix small pricing benefit offset adverse exchange impact merger operating expenses million year manufacturing costs incurred million million compared million year year lower movement reflects higher provisions product liability antitrust claims partially offset higher selling general administration proceeds product disposals equity investment sales selling general administration sga costs declined two per cent reflecting reduced merger integration costs operational business disposals excellence cost savings initiatives partly offset profit disposal businesses million reflects increased selling costs support new product launches charges final settlements regarding disposal healthcare relating cost saving programmes increased pension costs services businesses without merger integration costs sga grew four per cent driven selling cost increases accounted three share profitslosses joint ventures associated percentage point increase charges relating operational undertakings excellence pension cost increases individually added one share profits associates arises principally percentage point cost savings reduced growth one groups holding inquest diagnosticsinc percentage point together produced reduction percentage points relative expenses expressed net interest payable percentage turnover interest payable investment income research development rd declined one per cent reflecting reduced merger integration share interest payable associate costs partly offset increased clinical trial inlicensing activity reinvestment merger synergies pharmaceuticals rd expenditure represented per cent pharmaceutical turnover net interest payable increased compared largely year result unwinding discounts provisions longterm receivables trading profit statutory trading profit million growth profit ordinary activities taxation statutory per cent stronger turnover growth five per cent results demonstrating improved trading margin percentage taking account net operating incomeexpenses points principally due lower merger integration costs contribution associates business disposals net interest cost savings derived merger integration manufacturing payable statutory profit tax million compared initiatives partly offset charges relating operational million increase per cent excellence cost saving programmes higher pension costs glaxosmithkline operating financial review prospects year continued trading profit business performance profit taxation business performance illustrate glaxosmithkline performance analysis analysis discussion profit taxation trading profit subsequent discussion excludes relates business performance merger items integration restructuring costs disposal businesses management believes exclusion operating incomeexpense items provides better reflection way royalties income business managed accordingly information provided operating expense supplement contained consolidated statement profit loss pagesandprepared accordance income equity investments ukgaap disposals restated restated growth cer operating incomeexpense includes litigation costs turnover provisions relating legal claims withdrawn products cost sales product withdrawals antitrust matters equity investment selling general carrying value adjustments arising stock market price administration changes royalty income product disposals equity research investment sales development operating expenses million year trading profit compared million yearonyear movement reflects higher provisions product liability cost sales antitrust claims partially offset higher cost sales reduced percentage turnover result proceeds product disposals equity investment sales benefits arising merger manufacturing restructuring savings favourable product mix small pricing benefit share profitslosses joint ventures associated offset adverse exchange impact undertakings share profits associates arises principally selling general administration groups holding inquest diagnosticsinc selling general administration sga costs grew four per cent reflecting increased selling costs support new product net interest payable launches charges relating operational excellence cost saving interest payable programmes increased pension costs partly offset cost investment income saving initiatives cost saving initiatives relatively small restructuring activities estimated without operational excellence charges sga would share interest payable associate grown three per cent driven principally selling cost increases pension cost increases added one percentage point offset cost saving initiatives together produced net interest payable increased compared largely reduction percentage points expressed percentage result unwinding discounts provisions long turnover term receivables research development profit ordinary activities taxation business research development rd increased four per cent reflecting performance increased clinical trial inlicensing activity reinvestment taking account net operating incomeexpense merger synergies pharmaceuticals rd expenditure represented contribution associates business disposals net interest per cent pharmaceutical turnover year payable business performance profit tax million compared million increase trading profit eightper cent business performance trading profit million growth ofeightper cent stronger turnover growth five per cent demonstrating improved trading margin points per cent compared principally due cost savings derived merger integration manufacturing initiatives partly offset charges relating operational excellence cost saving programmes higher pension costs focus operational excellence value creation elimination waste bureaucracy programme become integral part way business managed charges booked business performanceoperating financial review prospectsglaxosmithkline merger items restructuring costs disposal businesses group received claim additional taxes irs asserts legacy company glaxo wellcome owes years merger manufacturing restructuring statutory notice deficiency billion glaxosmithkline made good progress merger billion tax principally relates allocation profits manufacturing restructuring plans merger programmes glaxo heritage products usa weresubstantially complete end combined countries extent irs successful claim programmes produced annual savings exceeded interest would payable glaxosmithkline estimates published target billion interest full claim date would approximately costs million incurred year respect billion billion net federal tax relief similar tax merger manufacturing restructuring aftertax relief issues remain open date glaxosmithkline expects million net charge million costs receive claims irs years include severance asset writedowns professional fees site since glaxosmithkline exhausted administrative remedies closure open thegroupplans contest claim additional taxes filing petition ustax court trial block drug company inc expected sometime glaxosmithkline acquired block drug january costs incurred integrating business million glaxosmithkline continues believe profits reported including redundancies asset writedowns site closures us subsidiaries period date paid taxes usa sufficient reflect disposal businesses activities usoperations profit disposal businesses million reflects glaxosmithkline uses best advice determining transfer final settlements regarding disposal healthcare pricing methodology seeking manage transfer pricing services businesses issues satisfactory conclusion basis external professional advice continues believe made taxation adequate provision liabilities likely arise open restated restated assessmentshowever continues wide difference views group irs ultimate liability business performance matters may vary significantly amounts provided merger restructuring disposal dependent upon outcome litigation proceedings subsidiaries negotiations relevant tax authorities total credit taxation merger restructuring items amounting million reflects actual tax rate applicable integrated nature groups worldwide operations transactions territories arise involving significant investment research strategic latest position taxation see taxation theyear manufacture limited number locations operating financial review prospects page consequential crossborder supply routes numerous endmarkets gives rise complexity delay negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities intragroup transactions particular price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits fall taxed individual territories resolution issues continuing fact life glaxosmithkline group open issues revenue authorities usa uk japan canada far largest relates glaxo heritage products usa usa number years glaxosmithkline significant open issues relating transfer pricing glaxosmithkline attempted settle dispute first direct discussion usinternal revenue service irs subsequently discussions usa uk authorities terms double tax convention two countries glaxosmithkline understands views two tax authorities different unable reach agreement discussions terminated july glaxosmithklineoperating financial review prospects year continued earnings growth restated restated cer statutory earnings basic earnings per share p p basic earnings per ads adjusted earnings adjusted earnings per share p p adjusted earnings per ads weighted average number shares millions adjusted earnings adjusted earnings per share presented order illustrate business performance primary measure used management adjusted earnings increased seven per cent adjusted earnings per share increased per cent reflecting reduction weighted average number shares resulting groups share buyback programme interest cost programme also impacts groups earnings adjusted earnings per shareincreased four per cent sterling terms compared per cent cer terms adverse currency impact eps six per cent year reflected significant weakening us dollar relative compares four per cent adverse currency impact turnover difference principally arises different mix currencies profits compared turnover taken together expenses taxation business disposals resulted basic eps pence compared pence diluted eps pence compared pence merger manufacturing restructuring costs lower result sterling based growth basic eps per cent significantly higher cerbased growth adjusted eps despite overall negative impact currencies dividend board declared fourth interim dividend pence per share making total year pence per share compares total dividend pence per share glaxosmithkline expects similar increase total dividend declared allocation quarterly dividends rebalanced glaxosmithkline intends increase first three interim dividends nine pence pence remainder total dividend year allocated fourth quarter dividendglaxosmithkline financial statements section comprises directors statements responsibility independent auditors report financial statements financial statements consisting principal financial statements supporting notes directors statements responsibility independent auditors report financial statements consolidated statement profit loss consolidated statement total recognised gains losses consolidated statement cash flow consolidated balance sheet reconciliation movements consolidated equity shareholders funds company balance sheet notes financial statements presentation financial statements accounting policies new accounting policies future requirements exchange rates merger glaxo wellcome smithkline beecham segment information merger items restructuring costs divested businesses operating incomeexpense operating profit joint ventures associated undertakings net interest payable taxation earnings per share dividends goodwill intangible assets tangible fixed assets fixed asset investments equity investments stocks debtors creditors provisions liabilities charges contingent liabilities net debt commitments share capital share premium account nonequity minority interests reserves legal proceedings post balance sheet event related party transactions acquisitions disposals financial instruments related disclosures employee costs employee share schemes reconciliation us accounting principles principal group companies glaxosmithkline directors statements responsibility directors statement responsibility relation internal control financial statements board audit committee reviewed directors assessment risks internal control framework operates glaxosmithkline considered effectiveness responsible ensuring maintenance proper accounting system internal control operation inthegroup records disclose reasonable accuracy financial year covered report date approval position group time financial board directors statements beprepared comply companies act thecombined code required law prepare financial statements board considers glaxosmithkline plc applies principles financial period give true fair view state thecombined codeon corporate governance financial affairs company group end reporting council asdescribed corporate governance financial period ofthe profit loss period pagesto complied itsprovisionsexcept responsible also ensuring operation systems described page internalcontrol taking reasonable steps safeguard required listing rules financial services authority assets group preventing detecting auditors haveconsidered directors statement fraud irregularities compliance relation points thecombinedcode financial statements year ended st december specified theirreview comprising principal statements supporting notes set infinancial statements onpages report annual report directors confirm suitable accounting policies annual report year ended st december consistently applied preparation financial statements comprising report directors remuneration report supported reasonable prudent judgements estimates financial statements additional information investors asnecessary applicable accounting standards followed approved board directors signed financial statements prepared going behalf concern basis responsibilities auditors relation financial statements set independent auditors report pageopposite financial statements year ended st december included annual report published sir christopher gent hardcopy printed form made available website chairman directors responsible maintenance integrity ndmarch annualreport website accordance uk legislation governing preparation dissemination financial statements access website available outside uk comparable legislation may different directors remuneration remuneration report pages report sets remuneration policies operated glaxosmithkline disclosures directors remuneration disclosable information relating directors officers interests prepared accordance companies act complies section b thecombined codeon corporate governance going concern basis making enquiries directors reasonable expectationthat group company adequate resources continue operational existence foreseeable future forthis reason continue adopt going concern basis inpreparing financial statementsglaxosmithkline independent auditors report members glaxosmithkline plc audited financial statements comprise basis audit opinion consolidated statement profit loss consolidated statement conducted audit accordance withauditingstandards total recognised gains losses consolidated statement issued theauditing practices board audit includes cash flow consolidated company balance sheets examination test basis evidence relevantto amounts related notes prepared historical cost disclosures financial statements andthe auditable part convention accounting policies set statement thedirectorsremunerationreport also includes accounting policies also audited disclosures assessment significant estimates judgements made required part schedule companies act thedirectors preparation financial statements contained thedirectorsremunerationreport auditable whether accounting policies appropriate part companyscircumstances consistently applied adequately disclosed respective responsibilities ofdirectors andauditors planned performed audit obtain thedirectors responsibilities preparing theannualreportand information explanations considered necessary thefinancial statements accordance applicable united order provide us sufficient evidence give reasonable kingdom law accounting standards set assurance thefinancial statements auditable part statement ofdirectors responsibilities thedirectors also directorsremunerationreport free material responsible preparing thedirectorsremunerationreport misstatement whether caused fraud irregularity responsibility audit financial statements error forming opinion also evaluated overall auditable part thedirectorsremunerationreport accordance adequacy presentation information financial relevant legal regulatory requirements united statements kingdom auditing standards issued auditing practices board report including opinion prepared opinion companys members body accordance opinion section companies act purpose giving opinion accept assume responsibility financial statements give true fair view state purpose person report affairs company group st december shown whose hands may come save expressly andthe profit cash flows group theyear agreed prior consent writing ended financial statements properly prepared report opinion whether financial accordance companies act statements give true fair view whether financial parts thedirectorsremunerationreport required statements auditable part thedirectorsremuneration part schedule companies act report properly prepared accordance properly prepared accordance companies act companies act also report opinion thedirectorsreportis consistent financial statements company kept proper accounting records received information explanations require audit information specifiedby law regardingdirectors remuneration transactions disclosed pricewaterhousecoopers llp read information contained theannualreport chartered accountants registered auditors consider implications report become aware embankment place apparent misstatements material inconsistencies london england financial statements information comprises financial summary description business unauditable part directorsremunerationreport joint statement ndmarch chairman chief executive officer operating financial review prospects corporate governance statement review whether corporate governance statement reflects companys compliance thenineprovisions frc combined codespecified review listing rules financial services authority report required consider whether theboards statements internal control cover risks controls orform opinion effectiveness companys groups corporate governance procedures risk control procedures glaxosmithkline consolidated statement profit loss year ended st december statutory notes turnover cost sales gross profit selling general administrative expenditure research development expenditure trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings profit disposal interest associates product divestments lossprofiton disposal businesses profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p adjusted earnings per share p diluted earnings per share p profit attributable shareholders dividends retained profit consolidated statement total recognised gains losses year ended st december profit attributable shareholders exchange movements overseas net assets unrealised lossprofit disposal intellectual property tax exchange movements unrealised gains total recognised gains losses relating year prior year adjustment implementation uitf revised uitf total recognised gains losses consolidated statement profit lossglaxosmithkline merger merger business restructuring business restructuring performance disposal statutory performance disposal statutory restated subsidiaries restated restated subsidiaries restated p p p p p p restated restated glaxosmithkline consolidated statement cash flow year ended st december reconciliation operating profit operating cash flows restated restated notes operating profit depreciation impairment assets written amortisation goodwill intangible fixed assets loss sale tangible fixed assets profit sale equity investments increasein stocks increase trade debtors increasedecreasein trade creditors decreaseincrease provisions net cash inflow operating activities cash flow statement net cash inflow operating activities dividends joint ventures associated undertakings returns investment servicing finance taxation paid capital expenditure financial investment acquisitions disposals equity dividends paid net cash inflowbefore management liquid resources financing management liquid resources financing increasedecreasein cash year reconciliation net cash flow movement net debt net debt beginning year increasedecrease cash year cash outflowinflow management liquid resources net increase longterm loans net repayment shortterm loans net repayment obligations finance leases net noncash funds subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year consolidated statement cash flowglaxosmithkline analysis cash flows notes restated restated returns investment servicing finance interest received interest paid dividends paid minority shareholders dividends paid preference shares capital expenditure financial investment purchase tangible fixed assets sale tangible fixed assets purchase intangible assets product divestments purchase equity investments sale equity investments acquisitions disposals purchase businesses disposal businesses investment joint ventures associated undertakings disposal interests associates financing issue share capital redemption preference shares issued asubsidiary share capital purchased cancellation share capital purchased held treasury shares proceeds shares employee share options financing cash flows increase longterm loans repayment longterm loans net repayment shortterm loans net repayment obligations finance leases analysis changes net debt exchange cash flow cash bank overdrafts debt due within one year commercial paper eurobonds mediumterm notes debt due one year eurobonds mediumterm notes private financing management liquid resources liquid investments net debt information significant changes net debt see notenet debt glaxosmithkline consolidated balance sheet st december restated notes goodwill intangible assets tangible assets investments fixed assets equity investments stocks debtors liquid investments cash bank current assets loans overdrafts creditors creditors amounts due within one year net current assets total assets less current liabilities loans creditors creditors amounts due one year provisions liabilities charges net assets capital reserves called share capital share premium account reserves profit loss account equity shareholders funds nonequity minority interests equity minority interests capital employed approved board nd march sir christopher gent chairman reconciliation movements consolidated equity shareholders funds year ended st december restated notes equity shareholders funds previously reported prior period adjustment implementation uitf revised uitf equity shareholders funds beginning ofyearas restated total recognised gains losses period dividends ordinary shares issued ordinary shares purchased cancelled ordinary shares purchased held treasury shares proceeds shares employee share options employee share schemes goodwill written back exchange movements goodwill written reserves equity shareholders funds end year glaxosmithkline company balance sheet st december notes shares subsidiary companies cost fixed assets amounts owed group undertakings taxation cash bank current assets dividends payable amounts owed group undertakings creditors amounts due within one year net current liabilities net assets capital reserves called share capital share premium account reserves profit loss account equity shareholders funds approved board nd march sir christopher gent chairman glaxosmithkline notes financial statements presentation financial statements additional information accordance requirements usgenerally accepted accounting principles us gaap included description business notes financial statements notea statement glaxosmithkline major global healthcare group differences reconciliations net income shareholders engaged creation discovery development manufacture equity uk us gaap provided marketing pharmaceutical products including vaccines overthecounter otc medicines healthrelated consumer presentation statement profit loss products glaxosmithklines principal pharmaceutical products years acolumnar presentationwas include medicines following therapeutic areas adopted statementof profit loss order illustrate central nervous system respiratory antivirals antibacterials underlying business performanceas thiswasthe primary measure vaccines oncology emesis metabolic cardiovascular used management purpose certain itemswere urogenital identified separately andexcluded business performance comprised merger integration items including product financial period divestments costs relating previously announced manufacturing financial statements cover financial year restructuring theeffect disposals subsidiaries st january stdecember comparative figures management believes exclusion items provideda financial years st january st december better reflection years way business st january tost december wasmanaged gives indication performance group terms elements revenue expenditure composition group local management able influence list subsidiary associated undertakings opinion directors principally affected amount profit completion programmes group net assets group given principal group reporting results statutory basis growth rates companies note presented comparing results business performance results statutory results management composition financial statements considers comparison statutory results consolidated financial statements drawn accordance business performance results gives appropriate indication uk generally accepted accounting principles ukgaap groups performance period uk accounting presentation trading profit reflects turnover less cost sales comprising financial statements comprise costs ofmanufacture external royalties selling general administrative expenditure comprising costs selling consolidated statement profit loss distribution medical support currently marketed products consolidated statement total recognised gains losses costs administration costs research consolidated statement cash flow development create future products sale consolidated balance sheet reconciliation movements consolidated equity accounting convention shareholders funds financial statements prepared using historical company balance sheet cost convention notes financial statements permitted section companies act accounting standards profitand loss account company presented financial statements comply withapplicable uk accounting standards consolidated statement total recognised gains losses includes accounting principles policies realised profit attributable shareholders reflected preparation financial statements conformity theconsolidated statement profit loss generally accepted accounting principles requires management unrealised gain loss value groups make estimates assumptions affect reported overseas net assets less related foreign currency borrowings amounts assets liabilities disclosure contingent attributable currency movements period assets liabilities date financial statements tax items reported amounts revenues expenses reporting period actual results could differ estimates reconciliation movements equity shareholders funds comprises items contributing increase decrease financial statements prepared accordance period shareholders funds items include companys accounting policies approved board described note total recognised gains losses period dividends paid proposed proceeds shares issued period cost shares purchased treasury shares cancellation theshare buyback programme changes goodwill arising acquisitions prior st january set directly reservesnotes financial statements glaxosmithkline accounting policies foreign currency transactions foreign currency transactions group companies booked consolidation inlocal currency exchange rate ruling date consolidated financial statements include transaction forward rate hedged forward assets liabilities results cash flow exchangecontract foreign currency assets liabilities company subsidiary undertakings including employee translated local currency rates exchange ruling share ownership plan esop trusts balance sheet date forward rate exchange differences groups share net assets results joint ventures areincluded trading profit associated undertakings revenue financial statements undertakings consolidated made revenue recognised profit loss account goods st december supplied made available external customers orders undertakings group material interest receivedandwhen title risk loss passesto customer accounted subsidiaries group exercises dominant turnover represents net invoice value deduction influence joint ventures group exercises joint control discounts given point sale accruals estimated associates group exercise significant future rebates returns methodology assumptions influence used estimate rebates returns monitored adjusted regularly light ofcontractual historical information interests acquired undertakings consolidated past experience turnover also includes copromotion income effective date acquisition interests sold consolidated group records share revenue upto date disposal related cost sales value added tax sales taxes transactions balances subsidiary undertakings excluded revenue eliminated profit taken sales subsidiary undertakings sales joint ventures associated undertakings expenditure products sold customers outside group expenditure recognised respect goods services received supplied accordance contractual terms provision goodwill arising acquisition interestsin subsidiary made obligation exists future liability respect undertakings joint ventures associated undertakings past event amount obligation reliably representing excess purchase consideration estimated advertising promotion expenditure charged groups share separable net assets acquired capitalised profit loss account incurred shipment costs inter asa separate item case subsidiary undertakings company transfers charged cost sales distribution costs part cost investment case joint ventures sales customers included selling general associated undertakings goodwill denominated currency administrative expenditure restructuring costs recognised inwhich acquisition made financed case respect direct expenditures business reorganisation acquisitions prior goodwill written plans sufficiently detailed well advanced reserves subsequent disposal assets acquisitions appropriate communication affected related goodwill removed consolidated reserves undertaken balance sheet date charged consolidated profit lossaccount groups interests joint ventures accounted using research development thegross equity method groups interests associated research development expenditure charged profit undertakings accounted using equity method loss account period incurred tangible fixed assets used research development depreciated deferred taxation relief unrealised intragroup profit accordance groups policy accounted extent considered recoverable assets liabilities overseas subsidiary associated environmental expenditure undertakings joint ventures including related goodwill environmental expenditure related existing conditions resulting translated sterling rates exchange ruling balance past current operations current sheet date results cash flows overseas subsidiary future benefit discernible charged profit loss associated undertakings joint ventures translated account group determines liability sitebysite basis sterling using average rates exchange exchange adjustments records liability time probable arising opening net assets profits theyear reasonably estimated liability includes groups retained overseas subsidiary associated undertakings portion costs also portion potentially joint ventures translated sterling less exchange differences responsible parties costs probable arising related foreign currency borrowings taken directly able satisfy respective shares cleanup obligation reserves reported statement total recognised recoveries reimbursements virtually certain gains andlosses recorded assets translating sterlingassets liabilities results cash flows pensions postretirement benefits overseas subsidiary associated undertakings joint cost providing pensions employee postretirement ventures reported currencies hyperinflationary economies benefits charged consolidated profit loss account adjustments aremade reflect current price levels loss systematic rational basis based actuarial assumptions net monetary assetsis charged consolidated profit loss period benefit derived employees services account difference charge contributions paid included asset liability consolidated balance sheet glaxosmithkline notes financial statements accounting policiescontinued brands valued independently part fair value businesses acquired third parties brand legal disputes value substantial longterm brands provision made foranticipated settlement costs sold separately rest businesses acquired reasonable estimate made likely outcome legal brands areamortised estimated useful lives longer disputes group addition provision made years except end useful economic life legaland expensesarising fromclaims receivedorother brand foreseen disputesin respect product liability claims related toproducts sufficient history claims made settlementsan prior acquired minor brands similar intangibles incurred reported ibnr actuarial techniqueisused eliminated group balance sheet reserves year determine reasonable estimate groups exposureto acquisition unasserted claims productsand provision made basis provision ismade unasserted claims tangible fixed assets obligation exists dispute possible tangible fixed assets stated cost less provisions make reasonable estimate costs associated claims made depreciation impairment costs acquiring developing group third parties charged profit loss computer software internal use internet sites external account incurred use capitalised tangible fixed asset software site supports significant business system expenditure employee share plans leads creation durable asset incentives form shares provided employees depreciationis calculated write cost tangible fixed share option share award schemes respect certain award assets excluding freehold land equal annual instalments schemes andshare option grants company provides finance expected useful lives normal expected useful lives esoptrusts purchase company shares open market major categories tangible fixed assets reviewed annually meet companys obligation provide shares employees exercise option award anyexcess fair valueof shares date award overthe exercise price freehold buildings years optionsorawards charged profit loss account leasehold land shorter lease term periods service respect options awards buildings years granted respect share option grants share options plant machinery years exercised accounted share issues exercise price fixtures equipment years additional employer costs respect options awards erp systems software years charged profit loss account periods service computer software years assets liabilities esop trusts included group enterprise resource planning erpsystems software generally balance sheet costs running thetrusts charged profit involves significant customisation prior implementation loss account company shares held thetrusts deducted expected useful economic life seven years rather reserves held value whichrecognisesany maximum five years computer software ondisposal shortfall proceeds receivable employees exercise tangible fixed asset cost related accumulated ifthere deemed permanent impairment value depreciation removed financial statements reflected transfer profit loss account reserve net amount less proceeds taken consolidated profit loss account goodwill goodwill stated cost less provision amortisation leases amortisation calculated write cost equal annual leasing agreements transfer group substantially instalments expected useful life useful life benefits risks ownership asset treated normally expected exceed years finance leases asset purchased outright assets included intangible fixed assets capital element intangible fixed assets leasing commitments shown obligations finance intangible assets stated cost less provision amortisation leases assets held finance leases depreciated acquired licences patents knowhow marketing rights shorter ofthe lease terms useful lives assets amortised estimated useful lives equal instalments interest element lease rental charged profit longer years items capitalised restricted leases operating leases annual rentals related specific compounds products charged profit straightline basis lease term developed commercial applications estimated useful lives determining amortisation charge reviewed annually impairment fixed assets andtake account estimated time takes bring carrying values fixed assets reviewed impairment compounds products market marketable products indication assets might impaired anydevelopment costs incurred group provision impairment charged profit year areassociated acquired licence patent knowhow concerned firstyear impairment reviews conducted marketing rights written profit loss account acquired goodwill intangible assets certain intangibles whenincurred considered anindefinite life therefore amortised intangibles subject annual impairment tests impairment determined byreference higher net realisable value value use measured reference discounted future cash flowsnotes financial statementsglaxosmithkline accounting policiescontinued gains losses foreign exchange contracts designated hedges forecast foreign exchange transactions deferred investments joint ventures associates included measurement related foreign currency investments joint ventures associated undertakings transactions period occur gains losses balance carried consolidated balance sheet groups share sheet hedges accrued taken directly reserves except oftheir net assets date acquisition post forward premiumsdiscounts recognised interest acquisition retained profits losses together goodwill life contracts arising acquisition net amortisation interest differentials interest swap agreements recognised stocks profit loss account adjustment ofinterest expense stocksare included financial statements lower life agreement cost including manufacturing overheads appropriate net realisable value cost generally determined first debt instruments firstout basis debt instruments stated amount net proceeds adjustedto amortise issue cost debt evenly taxation termof debt group accounts taxation deferred accelerated reason timing differences originated new accounting policies future requirements reversed balance sheet date deferred tax assets december urgent issues task force issued abstract recognised extent considered recoverable amended abstract relating accounting future taxable profits deferred tax retained presentation esoptrustsand share options awards granted earnings overseas subsidiaries provided employees requirements became mandatory binding commitment distribute past earnings future periods reporting require shares held esop trusts deferred tax measured average tax rates expected shown deduction arriving shareholders funds apply periods timing differences charge profit loss account employee share options expected reverse deferred tax liabilities assets restricted intrinsic loss difference market discounted price exercise price date grant comparative data prior periods restated comparabilitytrading profit current asset investments profit tax reduced million current asset investments stated lower cost net net assets st december million realisable value practicable quantify effect different measurement basis adopted case securities acquired significant premium discount maturity value intended held redemption june council european union adopted cost adjusted amortise premium discount life regulation requiring listed companies member states tomaturity security floating rate bonds stated cost prepare consolidated financial statements accordance interest income taken profit loss account international financial reporting standards ifrs receivable basis glaxosmithklinehas completed itsconversion projectsubject changes standards pronouncements andunaudited equity investments included current assets regarded information restated onto anifrs basisis asavailable sale given pagesto derivative financial instruments exchange rates group hold issue derivative financial instruments trading purposes group uses average exchange rates prevailing period translate results cash flows overseas derivative financial instruments used manage exposure subsidiaries joint ventures associated undertakings market risks treasury operations principal derivative sterling period end rates translate net assets instruments currency swaps forward exchange contracts undertakings thecurrencies influence interest rate swaps derivative contracts treated translations relevant exchange rates inception economic hedge underlying financial instrument matching accounting treatment cash flows derivative contracts high correlation specific average rates financial instrument hedged inception us throughout hedge period derivative instruments longer euro designated hedges restated market value future yen changes value taken directly profit loss account period end rates us currency swaps forward exchange contracts used fix euro value related asset liability contract currency yen contract rate accrued profit loss account life contract glaxosmithkline notes financial statements merger glaxo wellcome smithkline beecham combination glaxo wellcome plc smithkline beecham plc treated merger th december ukgaap mergerrelief provisions companies act shares issued glaxosmithkline plc acquire glaxo wellcome smithkline beecham accountedfor par share premium arose shares acquired glaxosmithkline glaxo wellcome smithkline beecham similarly accounted nominal value shares issued consolidated financial statements glaxosmithkline results net assets glaxo wellcome smithkline beecham combined book amounts subject alignment adjustments segment information analysis turnover profit taxation total assetsandnet assetsby business geographical sector tangible fixed assets geographical sector turnover location customerareset business sectors consist pharmaceuticals prescription pharmaceuticals vaccines consumer healthcare oralcare otc medicines nutritional healthcare assets business sector adjusted ensure consistency thegeographical sectors reflect groups significant regional markets consistent groups regional market management reportingstructure business sector data includes allocation corporate costs sector sales business sectors groups activities organised global basis geographical sector figures therefore influenced location groups operating resources particular manufacturing research variations time intragroup trading funding arrangements group copromotes product third party records sale group records share revenue copromotion income within turnover nature copromotion activitiesissuch group records costs sales pharmaceutical turnover includes copromotion income million million nil restated restated turnover business sector pharmaceuticals consumer healthcare external turnover statutory profit tax business sector pharmaceuticals consumer healthcare operating profit share profits joint ventures associated undertakings profit disposal interest associate lossprofit disposal businesses product divestments net interest payable profit taxation profit taxation taxation minority interests preference share dividends statutory earnings total assets business sector pharmaceuticals consumer healthcare total assets net assets business sector pharmaceuticals consumer healthcare net assets notes financial statementsglaxosmithkline segment informationcontinued restated restated turnover location subsidiary undertaking usa europe international turnover including intersegment turnover usa europe international intersegment turnover usa europe international external turnover statutory profit tax location subsidiary undertaking usa europe international operating profit share profits joint ventures associated undertakings profit disposal interest associate profit disposal businesses product divestments net interest payable profit taxation profit taxation taxation minority interests preference share dividends statutory earnings total assets location subsidiary undertaking usa europe international total operating assets cash bank liquid investments total assets net assets location subsidiary undertaking usa europe international net operating assets net debt net assets glaxosmithkline notes financial statements segment informationcontinued plant land equipment computer assets buildings vehicles software construction total total tangible fixed assets location subsidiary undertaking usa europe international total turnover location customer usa europe international external turnover uk segment information given separately respect uk although included groups europe market region considered groups home segment purposes segmental reporting restated restated turnover location customer turnover including intersegment turnover intersegment turnover turnover location subsidiary operating profit total assets net operating assets merger items restructuring costs divested businesses manufacturing restructuring costs incurred glaxosmithkline implementation previously announced plans restructuring manufacturing activities merger integration costs relate integration glaxo wellcomeand smithkline beecham unified glaxosmithkline business costs include consultancy fees respect integration planning severance costs asset writeoffs costs related early vesting lapse performance conditions share options share incentive awards costs programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options integration costs incurred relating integration block drug businesses costs include professional fees severance costs asset writeoffs product divestment income arising related finalisation disposals famvir kytrilandother products required order obtain regulatory approval merger disposal businesses related finalisation disposals clinical laboratories healthcare services notes financial statementsglaxosmithkline merger items restructuring costs divested businesses continued disposal merger restructuring block drug subsidiaries total manufacturing restructuring merger integration costs block drug integration costs effect operating profit profit disposal businesses effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings disposal merger restructuring block drug subsidiaries total manufacturing restructuring merger integration costs block drug integration costs effect operating profit product divestments profit disposal businesses effect profit tax effect taxation operating items effect taxation nonoperating items effect taxation effect earnings operating incomeexpense royalties income operating expense income equity investments disposals royalties income principally core recurring income form royalties outlicensing intellectual property operating expense includes litigation costs provisions relating legal claims withdrawn products product withdrawals antitrust mattersand claims respect sales marketing reimbursement income equity investments disposals includes equity investment carrying value adjustments arising stock market changes product disposals equity investment sales glaxosmithkline notes financial statements operating profit restated restated following items charged operating profit employee costsnote advertising distribution costs depreciation tangible fixed assets owned assets leased assets amortisation goodwill amortisation intangible fixed assets exchange losses foreign currency depositsloans operating lease rentals plant land buildings audit fees fees auditors work auditors ukfirm auditors overseas firms analysis fees auditors work assurance auditrelated services tax services merger glaxo wellcome smithkline beecham services included within audit fees fee relating company audit glaxosmithkline plc included assurance services amounts related groups preparation adoption international financial reporting standards preparation section sarbanesoxley act tax services relates fees paid corporate tax compliance tax planning advice services include human resources advisory compliance treasury related services included within fees auditors work million paid auditors management consulting practice sold group applied discounting certain longterm assets liabilities using riskfree rates return joint ventures associated undertakings associated undertakings share profits quest diagnostics inc share losses associated undertakings amortisation goodwill share profitslossesof joint ventures share turnover joint ventures sales joint ventures associated undertakings notes financial statements glaxosmithkline net interest payable interest payable bank loans overdrafts loans respect finance leases realised losses unwinding discount provisions share interest payable associate investment income interest income realised gains unwinding discount assets taxation restated restated taxation charge based profits period uk corporation tax uk statutory rate less double taxation relief overseas taxation deferred taxation share taxation charge associates restated restated reconciliation current taxation rate group profits ukstatutory rate taxation overseas taxes average group tax rate effect special tax status manufacturing locations share option deductions merger restructuring costs rd credits permanent differences capital allowances excess depreciation intragroup profit reversing timing differences tax losses timing differences prior year items current tax rate ordinary activities capital allowances excess depreciation intragroup profit reversing timing differences tax losses timing differences share taxation charge associates prior year items uitf restatement tax rate ordinary activities group operates countries tax rate differs uktax rate average group tax rate determined aggregating local standard tax rates weighting proportion accounting profits profits arising manufacturing operations singapore puerto rico ireland taxed reduced rates effect reduction taxation charge increased earnings per share pin p p glaxosmithkline notes financial statements taxation continued integrated nature groups worldwide operations involving significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets gives rise complexity delayin negotiations revenue authorities profits individual group companies liable tax disagreements revenue authorities intragroup transactions particular price goods transferred group companies different tax jurisdictions produce conflicting claims revenue authorities profits taxed individual territories resolution issues continuing fact life glaxosmithkline group open issues revenue authorities usa uk japan canada far largest relates glaxo heritage products respect us internal revenue service irs uk inland revenue made competing contradictory claims glaxosmithkline attempted settle us dispute first direct discussion irs subsequently discussions us uk authorities terms double tax convention two countries discussions terminated july th january irs issued notice deficiency years claiming additional taxes billion nd april group filed petition us tax court disputing irs claim seeking refund billion taxeson th january irs issued notice deficiency years claiming additional taxes billionif irs claims years upheld group would additionally liable interest late payment estimated amount billionnet federal tax relief st december giving total billionfor years group expects tofile petition thetax claims april including claim refund taxes ask tax courtto consolidatethe irs claims years single trial provisional trial date claims setfor october similar tax issues remain open date glaxosmithkline expects receive substantial claims irs forthese yearsglaxosmithkline continues believe profits reported us subsidiaries period date ithas paid taxesin usa sufficient reflect activities us operations glaxosmithklineis continuing discussions inland revenue respect uk transfer pricing disputes glaxosmithkline uses best advice determining transfer pricing methodology seeking manage transfer pricing issues satisfactory conclusion basis ofexternal professional advice continues believe made adequate provision liabilities likely arise open assessments however continues wide difference views group irs inland revenue relevanttaxation authorities open issues exist ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings negotiations relevant tax authorities except shown annual report provision made taxation would arise distribution profits retained overseas subsidiary associated undertakings grounds remittance profit retained atst december required way incremental tax arise st december group income tax losses approximatelymillion million capital losses estimated excess ofbillion excess billion related deferred tax assets recognisedbecause insufficient evidence losses used current deferred deferred tax creditor tax debtor tax provision tax balances st january exchange adjustments charge profit loss account cash paid movements st december restated deferred taxation assetliability accelerated capital allowances stock valuation adjustment intragroup profit product business disposals pensions postretirement benefits tax losses legal disputes merger integration manufacturing restructuring net timing differences deferred taxation provided stock valuation adjustments intragroup profit timing differences shown arecurrent deferred taxation movements arise origination reversal timing differences net timing differences include accrued expenses provisionsnotes financial statements glaxosmithkline earnings per share restated restated p p p basic earnings per share adjustment merger items restructuring costs disposal subsidiaries merger integration transaction costs restructuring costs block drug integration costs disposal businesses adjusted earnings per share diluted earnings per share basic adjusted earnings per share calculated dividing profit attributable shareholders weighted average number ofshares issue period numbers used calculating basic diluted earnings per share reconciledbelow adjusted earnings per share calculated using business performance earningsduring years business performance primary performance measure used management presented excluding merger items integration restructuring costs disposals businesses management believed exclusion theseitems provided better comparison business performance periods presented completion programmes group reporting results statutory basis onlythis information provided addition statutory results prepared ukgaap given assist shareholders gain clearer understanding underlying performance business increase comparability periods presented net profit period attributable shareholders earnings basic diluted adjustments merger items restructuring costs disposal subsidiaries adjusted earnings weighted average number shares issue millions millions millions basic adjusted dilution share options diluted shares held esoptrustsare excluded trustees waived rights dividends shares held esop trusts dividends first interim second interim third interim fourth interim dividends per share p p p first interim second interim third interim fourth interim glaxosmithkline notes financial statements goodwill total cost st january exchange adjustments asset written cost st december amortisation st january exchange adjustments provision year asset written amortisation st december net book value st january net book value st december licences intangible assets patents etc brands total cost st january exchange adjustments additions disposals assets written cost st december amortisation st january exchange adjustments provision year disposals assets written amortisation st december impairment st january exchange adjustments impairment loss disposals impairment st december total amortisation impairment st december net book value st january net book value st december additions licences patentsin year relate thepurchasesof fraxiparineand arixtraproduct rightsfromsanofisynthelabo otc marketing rights orlistat rocheand various compound rightssee note brands largely comprise portfolio products acquired acquisition sterling winthrop inc panadol solpadeine hedex products acquired acquisition block drug company sensodyne polident andpoligrip considered indefinite life given strength durability brand level marketing support accordingly amortised thevaluation sterling brand reviewed annually using year cash flow forecast basis original independent assessment acquired posttax discount rate eight per cent valuation block drug brand also reviewed annually using five year cash flow forecast posttax discount rate eight per centnotes financial statementsglaxosmithkline plant land equipment computer assets tangible fixed assets buildings vehicles software construction total cost st january exchange adjustments additions disposals reclassifications cost st december depreciation st january exchange adjustments provision year disposals reclassifications depreciation st december impairment st january exchangeadjustments impairment loss disposals impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december groups land buildings comprises freehold propertiesmillion st january million properties leases years moremillion st january million properties leases less yearsmillion stjanuary million included plant equipment vehicles st december leased assets cost ofmillion st january million accumulated depreciation million st january million net book value million st january million impairment loss principally arises decisions rationalise facilities calculated based either net realisable value value use typically usinga discount rate eight per cent joint associated equity fixed asset investments ventures undertakings investments total st january exchange adjustments additions impairment transfers disposals retained profit year goodwill amortisation st december investments joint ventures comprisemillion share gross assets million andmillion share gross liabilities million principal associated undertaking quest diagnosticsinc us clinical laboratory business listed new york stock exchange investment book value st december ofmillion million market value ofmillion million st december group ownedpercent quest per cent book value includes goodwill amortised years amortisation charge wasmillion million goodwill st december amounts tomillion million goodwill ofmillion relates continuing group interest clinicallaboratories assets attributed quest remains eliminated group reserves equity investments comprise listed investments ofmillion million unlisted investments ofmillion million market value listed investments st december million million glaxosmithkline notes financial statements equity investments total st january exchange adjustments additions impairments transfers disposals st december equity investments include listed investments ofmillion million themarket value listed investments million million stocks raw materials consumables work progress finished goods debtors amounts due within one year trade debtors debtors prepaid pension contributions prepayments accrued income amounts due one year debtors prepayments accrued income deferred taxation note debtors include trading balances ofmillion million due joint ventures associated undertakings debtors due one year include insurance recovery receivables discounted using riskfree rate return creditors restated amounts due within one year trade creditors taxation note social security creditors accruals deferred income dividends payable amounts due one year creditors ccruals deferred income accruals include obligations wages salaries ofmillion millionnotes financial statementsglaxosmithkline provisions pensions legal liabilities charges postretirement manufacturing merger deferred benefits restructuring integration disputes taxation provisions total st january exchange adjustments charge year unwinding discount applied reclassifications movements st december group made special cash contributions totallingmillion million uk us pension schemes contribution relating us pension scheme included within amounts applied provision contributions relating uk pension scheme increased pension prepayment amount shown debtors innote group recognised costsin previous years respect plans manufacturingtheother restructuring initiated following merger glaxo wellcome smithkline beecham acquisition block drug plans largely completed costs recognised provision principally respect identified severances sites announced manufacturing activities cease expected incurred mainly costs asset writedowns recognised asimpairmentsof fixed assets group recognised costs inprevious yearsin respect plans integration glaxo wellcome smithkline beecham businesses implementation integration following merger substantially complete costs recognised provision respect identified severances expected incurred respect programme encourage staff convert glaxo wellcome smithkline beecham share options glaxosmithkline share options employees exercise options latter provision discounted million millionusing riskfree rates return glaxosmithkline involved number legal disputes including notification possible claims provisions legal disputesinclude amounts relating us antitrust product liability contract terminations selfinsurance environmental cleanup property rental companys directors taken legal advice established provisions taking account insurance agreements regard relevant facts circumstances matter andin accordance accounting requirements provisions discounted bymillion millionusing riskfree rates returnglaxosmithkline undertaken review product liability claims assessed number products history claims made settlements makes possible use ibnr incurred reported actuarial technique determine reasonable estimate groups exposure unasserted claims relation productsapart ibnr provision provisions made unasserted claims ultimate liability matters may vary amounts provided dependent upon outcome litigation proceedings investigations possible settlement negotiations nature groups business number matters including provided using ibnr actuarial technique may subject negotiation litigation severalyears largest individual amounts provided expected settled within three years discussion legal issues refer note legal proceedings contingent liabilities st december contingent liabilities comprising guarantees discounted bills items arising normal course business amounted tomillion million discussion tax issues refer note taxation legal issues refer note legal proceedings glaxosmithkline notes financial statements net debt liquid investments cash bank loans overdrafts due within one year per cent us us medium term note per cent sterling euro bond floating rate us european medium term notes per cent chf bond commercial paper bank loans overdrafts loans obligations finance leases loans due one year per cent us medium term note per cent sterling euro bond per cent us notes per cent us us medium term note per cent euro european medium term note per cent sterling european medium term note per cent euro european medium term note per cent us us medium term note per cent sterling european medium term note per cent us us medium term note loan stock bank loans loansand private financing obligations finance leases net debt balance sheet date groups liquid investments aggregate market value ofmillion millionliquid investments include redeemable preference shares fully collateralised highly rated bonds billion billion loans overdrafts due within one year commercial paper comprises us billion programme million millionwas issue st december million million backed committed facilities days duration million million million millionrenewable annually liquid investmentsas shown table weighted average interest rate commercial paper borrowings st december wasper cent per cent weighted average interest rate bank loans overdrafts due within one year st december wasper cent loans due one year threebonds issued theusmedium term note programme us million per cent coupon bond ausbillionper cent coupon bondand aus millionper cent coupon bond loans due one year repayable various periods follows one two years two three years three four years four five years five years loans repayable five years carry interest effective rates betweenper cent andper cent repayment dates range notes financial statementsglaxosmithkline net debt continued secured loans loans amounting tomillion million secured charges fixed current assets finance lease obligations rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total futurerental payments future finance charges total finance lease obligations financial instruments information given note commitments capital commitments contracted provided financial statements intangible fixed assets tangible fixed assets number commitments made licensing agreements principally theravance incexelixis inc tanabe seiyaku co ltdand human genome sciences inc group also commitments ofmillion million relating revenue payments made licences alliances principally exelixis inc commitments operating leases pay rentals next year operating leases land buildings expire one year less one five years five years operating leases plant equipment vehicles expire one year less one five years five years commitments operating leases pay rentals future years thereafter glaxosmithkline notes financial statements share share capital share premium account ordinary shares p p ccm oi uu nm number share capital authorised st december st december st december share capital issued fully paid st january share capital issued share option schemes share capital purchased cancelled st december share capital issued share option schemes share capital purchased cancelled st december share capital issued share option schemes share capital purchased cancelled st december st december st december st december number shares issuable outstanding optionsnote number unissued shares option st december issued share capital shares held esop trust shares held treasury shares free issue october glaxosmithkline commenced new billion share buyback programme followedthe completion billion buyback programme announced total billion spent new share buyback programme billion spent exact amount timing future purchases whether repurchased shares held treasury sharesor becancelled determined company dependent market conditions factors shares purchased period st january th february periodth february th february furthermillion shares purchasedat cost ofmillionall purchases publicly announced buyback programme table sets monthly purchases current share buyback programme average share price excluding number shares commisson stamp duty month january nil february march april may june july august september october nil november december total details substantial shareholdings refer substantial shareholdings page nonequity minority interests st january smithkline beecham holdings corporation sbh corp subsidiary incorporated delaware usa issue million flexible auction market preferred stock flex amps comprising shares issued six series sbh corp also issue million auction rate preference stock arps comprising shares issued five series arps flex amps together constituted preference shares represented nonequity minority interests redeemed march april notes financial statements glaxosmithkline profit reserves reserves loss account total restated restated restated st december previously reported prior year adjustment implementation uitf revised uitf st december restated exchange movements uktax exchange movements ordinary shares purchased cancelled investment esopshares profit attributable shareholders dividends unrealised profit disposal intellectual property st december exchange movements tax exchange movements unrealised profits ordinary shares purchased cancelled investment esopshares profit attributable shareholders dividends unrealised profit disposal intellectual property revaluation goodwill due exchange st december goodwill written back exchange movements tax exchange movements unrealised profits ordinary shares purchased cancelled ordinary shares purchased held treasury shares investment esopshares profit attributable shareholders dividends unrealised loss disposal intellectual property revaluation goodwill due exchange st december goodwill arising acquisitions st january written profit loss account reservesamounts million including goodwill million previously held goodwill reserve offset againstprofit loss account reservesin goodwill written back relates disposal part groups holding quest diagnosticsinc disposal groups holding glaxosmithkline pharmaceuticals chongqing limited goodwill denominated local currencies subject revaluation amounted million st december goodwill acquisitions st january capitalised accordance accounting policy set note exchange movements taken reserves include losses million losses million losses million foreign currency loans less deposits gains million gains million gains million retranslation net assets million million nil goodwill eliminated reservesthe tax exchange movements unrealised profits inof million million million relates taxable element foreign currency loans less deposits unrealised profits taken reserves exchange adjustments debited reserves cumulatively amount million million million reserves include merger reserve created merger glaxo wellcome smithkline beecham amounting million st december million million reserves also include capital redemption reserve created result share buyback programme amounting million st december million million following implementation uitf investments shares held esoptrusts amounting million st december million million shown deduction reserves total reserves amounted million st december million million million million million relates company million million million relates joint ventures associated undertakings profit glaxosmithkline plc year million million million dividends million million million gave retainedprofitof million loss million profit million cost shares purchased cancelled million million million shares purchased held treasury shares million nil nil unrealised profit capital reduction subsidiary nil nil million profit loss account reserve st december stood million million million million unrealised million million glaxosmithkline notes financial statements legal proceedings july glaxosmithkline filed action apotex us district court northern district illinois group involved various legal administrative infringement groups patent paroxetine hydrochloride proceedings principally product liability intellectual property tax hemihydrate apotex filed abbreviated new drug antitrust governmental investigations related private application anda us food drug administration litigation group makes provision proceedings fdaseeking approval introduce generic form paxil regular basis summarised notesand group may following trial february judge ruled make additional significant provisions legal proceedings glaxosmithklines patent valid infringed apotexs required event developments matters product groups appeal ruling noninfringement consistent generally accepted accounting principles litigation us court appeals federal circuit cafc particularly usa inherently unpredictable excessive hears appeals us district courts onpatentmatters ruled awards may justified evidencemay occur groups patent infringed invalid based upon group could future incur judgments enter public use clinical trials prior filing date settlements claims could result payments exceed usa group filed petition cafc rehearing current provisions amount would material appeal full court date report adverse effect groups financial condition results decision petition yet announced operations june glaxosmithkline filed action geneva intellectual property claims include challenges validity pharmaceuticals subsidiary novartis pharmaceuticals groups patents various products processesandassertions us district court eastern district pennsylvania noninfringement patents loss cases infringement groups patents paroxetine hydrochloride could result loss patent protection product issue following notice genevas anda filing case consequence loss could significant decrease consolidated similar infringement actions sales product could materially affect future results generic companies subsequently filed andas additional operations group infringement actions brought based patents issued legal expenses incurred relating defence groups subsequent original filing apotex northern intellectual property litigation costs provisions related district illinois group also filed action apotex product liability claims existing products charged selling relating new patents eastern district general administration costs litigation costs provisions pennsylvania december judge granted part relating legal claims withdrawn products antitrust denied part summary judgement motions filed apotex pricing matters charged operating incomeexpense result issues validity infringement three provisions made taking appropriate legal advice four new patents remain trial group petitioned reasonable estimate made likely outcome district court permit interim appeal cafcof summary dispute group established actuarially determined rulings one four new patents certain claims provision product liability claims incurred yet reported three invalid june group requested described note st december groups fdato remove three patents related paxilfrom register aggregate provision legal disputes including tax pharmaceutical patents maintained fda orange book matters described taxation note justover delisting affect validity patents billion ultimate liability legal claims may vary related patent litigation following fda approval anda amounts provided dependent upon outcome litigation apotex subsequently launched generic version paxil proceedings investigations possible settlement negotiations september significant matters described group continues pursue patent infringement claims litigation eastern district pennsylvania apotex intellectual property geneva alphapharm andrx teva pharmaceuticals zenith usa bulk suppliers basf sumika fine chemicals apotex alphapharm basf sumika filed counterclaims paxil actions alleging group violated antitrust unfair usa number distributors generic drugs filed competition laws february cafc heard apotexs applications fda market generic versions appeal decision us district court district paxilseroxatparoxetine hydrochloride prior expiration columbia denying apotexs request fda required groups patent paroxetine hydrochloride delist certain groups patents paxilfrom orange hemihydrate apotex launched generic version ofpaxilin book october cafc affirmed district court september distributors sought bring market decision dismissed casecertain claims anhydrate versions paroxetine hydrochloride counterclaims respect geneva alphapharm basf one case paroxetine mesylate response group filed actions sumika settled distributors infringement various groups patents basis generic anhydrate march glaxosmithkline filed action pentech versions infringe contain andor convert pharmaceuticals us district court northern district hemihydrate form andor infringe group patents illinois infringement groups patents paroxetine hydrochloride pentech filed anda capsule version paxil asserting compound presentation infringe groups patents patents invalidnotes financial statementsglaxosmithkline legal proceedings continued june group commenced action us district court district new jersey faulding april group reached settlement pentech pharmaceutical company alleging infringement two method par pharmaceuticals pentech granted rights use patents ondansetron faulding challenge pentechs anda paroxetine hydrochloride capsules compound patent case date report settlement allowed par distribute puerto rico stayed pending decisions teva reddy kali cases substitutable generic paroxetine hydrochloride immediate release august group commenced action us tablets supplied licensed group royalty payable district court district new jersey pliva alleging group par became entitled distribute product infringement groups patent reduced crystal size us market apotexs generic version paxilbecame ondansetron expires march taking account available september settlement par extension paediatric exclusivity pliva challenge pentech acknowledge glaxosmithkline patent covering compound patent emesis use patents case hemihydrate form paroxetine hydrochloride valid preliminary stages enforceable would infringed pentechs proposed capsule product bureau competition us federal trade january group commenced two additional actions commission reviewed settlement review voluntary us district court district new jersey conducted request group par pentech reduced crystal size patent kali apotex pentechs former supplier asahi glass co filed claims alleging contrast previous anda orally disintegrating tablets settlement violated antitrust laws claims kali challenge emesis use patents recent anda dismissed court similar claims brought apotex oral tablets challenge compound patent apotex sumika pending us district court eastern challenge either compound emesis use patents district pennsylvania connection anda zofran lamictal august group commenced action us district august group commenced action us district court district new jersey reddycheminor court district new jersey teva pharmaceuticals drreddys laboratories dr reddy certified invalidity three usa inc alleging infringement groups compound patent patents ondansetron active ingredient zofrantablets lamotrigine active ingredient lamictaloral tablets including compound patent expires july two patent affords protection january giving effect method use patents later expires december expected grant paediatric exclusivity fda instances taking account extension defendant hadfiled anda fda certification paediatric exclusivity july group filed action invalidity groups patent hatchwaxman stay drreddys laboratories district court infringement fda approval anda expired trial teva case groups patents related orally disintegrating tablet concluded january following trial parties reached presentation zofran october group filed action settlement agreement subject government review pursuant westward pharmaceuticals inc district court group granted teva exclusive royaltybearing infringement groups patents related injectable licence distribute usaa generic version lamotrigine presentation zofran dr reddy disintegrating tablet chewable tablets date later june case westward case consolidated earlier exclusive right manufacture sell tevas generic version dr reddy case prior trial reddycheminor westward lamotrigine tablets usa expected launch date withdrew challenges compound patent trial infringement groups method use process imitrex patents completed june date december group commenced action us report closing arguments held decision district court southern district new york announced dr reddys laboratories alleging infringement one two march group filed similar action teva primary compound patents sumatriptan active ingredient pharmaceuticals usa inc us district court district imitrex thepatent issue affords protection february delaware alleging infringement two method use patents giving effect grant paediatric exclusivity ondansetron teva certified invalidity noninfringement fda defendant filed anda fda two method use patents teva challenge certification invalidity compound patent compound patent trial judge ruled groups favour certify invalidity noninfringement second compound upholding validity method use patents teva appealed patent expires injune giving effect paediatric decision cafc oral argument expected exclusivity case early stages six generic thirdquarter september november companies filed andas imitrexbut cobalt january group filed actions teva pharmaceuticals certified invalidity compound court infringement groups patents related patentat issue dr reddys case group commenced injectable orally disintegrating tablet presentations zofran infringement action cobalt recently cases consolidated case appeal transferred us district court southern district new yorkin february group commenced action earlier ondansetron case involving orally disintegrating zofran usdistrict court district delaware tablets commenced group january spectrum pharmaceuticals alleging infringement thesame kali laboratories us district court district new compound patentatissue dr reddys case spectrum filed jersey kali group subsequently filed motions itscertification invalidity noninfringement patent summary judgement part anda filing approval sumatriptan injection case early stages glaxosmithkline notes financial statements legal proceedings continued advair september group applied us patent valtrex trademark office uspto reissue combination patent may group commenced action us district advair inhaled combination salmeterol fluticasone court district new jersey ranbaxy laboratories propionate expires september followed alleging infringement groups compound patent internal review concluded language valaciclovir active ingredient valtrex patent expires patent may accurately describe circumstances defendant filed anda fda invention may claim invention precisely certification invalidity groups compound patent could objective seeking reissuance strengthen noninfringement two patents expiring protection afforded patent expected listed orange book fda approval anda stayed administrative process uspto take one two years earlier october resolution patent application reissue pending patent remains infringement litigation discovery underway case forceand listed orange book avandia avandamet group holds patents relating advairwhich august group filed action us district court affected reissue application including compound district new jersey teva pharmaceuticals usa inc patent related active ingredient salmeterol affords infringement groups patent relating maleate salt protection august giving effect expected form rosiglitazone active ingredient avandia grant paediatric exclusivity fda various patents relating expires september group filed comparable diskusdevice expire period action court dr reddys laboratories alleging patents relating hfa formulation related technology infringement patent maleate salt form expire period dr reddys laboratories teva filed andas fda certifications invalidity groups maleate salt patent fda levitra approval andas stayed earlier november october pfizer inc filed action bayer ag resolution respective patent infringement actions glaxosmithkline us district court district delaware alleging manufacture sale levitra teva subsequently filed additional certification challenging vardenafil would infringe patent newly issued pfizer validity groups basic compound patent rosiglitazone asking bayer glaxosmithkline permanently enjoined january group commenced action september us patent trademark office initiated teva court infringement patent basic reexamination pfizer patent based questions compound patent currently expires although expiry patentability light prior art pfizer action including expected extended us patent additional suit filed court following launch trademark office granted patent term restoration levitrain usa predicated validity patent january group filed action us district court stayed pending outcome reexamination district ofnew jersey teva infringement december parties entered agreement settle two patentsteva filed anda fda patent infringement validity proceedings worldwide generic version avandametwith certifications invalidity basis including us action noninfringementof patents fda approval anda cervarix stayed earlier june resolution patent february merck co group announced cross infringementaction since avandametis protected licence settlement agreement certain patent rights related patents avandia avandiapatents issue found human papillomavirus hpv vaccinethe group receive invalid litigation teva dr reddys ruling upfront payment androyaltiesfrom merck based upon sales wouldbe dipositive avandametas well hpv vaccine upon development launch agreement wellbutrin xl resolves competing intellectual property claims related december biovail commenced actions us district merck glaxosmithkline hpv vaccines respectively court central district california anchen pharmaceuticals inthe us district court southern uk europe district florida abrika pharmaceuticals case seroxat alleging infringement biovail formulation patents wellbutrin following settlement august groups xl patents expire anchen abrika patent litigation synthon bv synthon free market filed anda fda certification invalidity paroxetine mesylate product many markets globally noninfringement biovail patents fda approval obtained marketing authorisations paroxetine mesylate andas stayed earlier may different salt form paroxetine used marketed resolution applicable patent infringement action form seroxatpaxilin certain markets patent litigation group party action licensee patents synthon ongoing synthon asserting counterclaims owner new drug application wellbutrin xlboth unfair competition group cases early stagesnotes financial statementsglaxosmithkline legal proceedings continued phenylpropanolamine following report yale haemorrhagic stroke project another generic version seroxatpaxilsactive ingredient found suggestion association first use paroxetine hydrochloride anhydrate generic products containing phenylpropanolamine ppa decongestant haemorrhagic anhydrate market european countries stroke group manufacturers voluntarily whilst products subject continuing withdrawnconsumer healthcare products ppa litigation actions settled expected active ingredient since ppa product withdrawal group settled future uk litigation named defendant numerous personal injury several years standing group apotex culminated class action lawsuits filed state federal courts alleging appeal court decision groups anhydrate process personal injury increased risk injury use products patent validbutnot infringed decision subject containing ppa unfair deceptive business practices appeal result litigation apotex enjoined plaintiffs seek remedies including compensatory punitive launching product one year damages refunds federal cases consolidated market damages enquiry relating theinjunction multidistrict litigation proceeding us district court take place due course district washington judge responsible proceedings denied class certification struck class product liability allegations federal personal injury consumer refund paxil class actions limited number cases group group received lawsuits claims filed behalf manufacturers defendants reaching trial patients alleging suffered symptoms state courts class certification denied california discontinuing treatment paxilparoxetine separately state court pennsylvania state court putative class action group received lawsuits claims patients dismissed leaving putative class actions pending commenced paxiltreatment committed attempted commit group litigation suicide andor acts violencethere also private consumer lawsuits alleging group concealed misrepresented baycol data paediatric clinical trials paxil august bayer ag withdrew baycolcerivastatin sodium worldwide light reports adverse events including deaths group received lawsuits filed state federal courts involving rhabdomyolosis glaxosmithkline participated usa canada behalf thousands plaintiffs marketing baycolin usa pursuant copromotion including purported class actions alleging paroxetine agreement bayer licenceholder active ingredient paxil addictive causes dependency manufacturer product withdrawal reactions plaintiffs seek remedies including compensatory punitive statutory damages cost following withdrawal bayer glaxosmithkline fund medical monitoring federal judge us named defendants thousands lawsuits filed state district court central district california denied class federal courts usa behalf individuals action certifications nationwide class california putative classes former baycolusers number suits statewide class cases filed federal court district allege plaintiffs suffered personal injuries including subsequently petition plaintiffs counsel federal court rhabdomyolosis use baycol others claim persons cases transferred district court consolidation took baycol although injured may risk future multidistrict litigation mdl first five cases scheduled injury may suffered economic damages purchasing start trial mdl court may using baycol plaintiffs seek remedies including compensatory determination whether lawsuits pending punitive statutory damages creation funds medical mdl state courts permitted proceed monitoring glaxosmithkline bayer corporation principal class actions us subsidiary bayer ag signed allocation agreement bayer corporation agreed pay per cent group received number claims lawsuits alleging settlements compensatory damages judgements treatment paxilhas caused homicidal suicidal party retaining responsibility attorneys fees behaviour exhibited users product none punitive damages federal cases consolidated purport class actions october fda multidistrict litigation proceeding us district court announced would require black box warning district minnesota numerous cases scheduled trial suicidality strengthened warnings selective serotonin state federal courts date statewide reuptake inhibitor ssri products including paxil class medical monitoring class action bayer glaxosmithkline avandia certified pennsylvania another class action group received lawsuits claims filed state glaxosmithkline named defendant federal courts usa behalf numerous patients alleging certified oklahomaa substantial number claims death rosiglitazone active ingredient avandia caused serious injury settled congestive heart failure liver damage none cases purports class action cases early stages although certain state court trials scheduled take place glaxosmithkline notes financial statements legal proceedings continued particular government inquired alleged promotion drugs offlabel uses well groupsponsored fenphen continuing medical education programmes speaker events fda became aware reports cardiac valvular special issue boards advisory boards speaker training programmes problems individuals fenfluramine dexfenfluramine clinical studies related grants fees travel entertainment alone combination phentermine prescribed part although original subpoena issued us attorneys regimen weight reduction requested voluntary office colorado scope inquiry nationwide withdrawal fenfluramine dexfenfluramine market group cooperating investigation early reports cardiac valvular problems subsequent stages group earlier responded october letter withdrawal products market spawned numerous fdas division drug marketing advertising product liability lawsuits filed manufacturers communication requesting information groups alleged distributors fenfluramine dexfenfluramine phentermine promotion wellbutrin sr offlabel use one number manufacturers phentermine group defendant thousands lawsuits various state federal average wholesale price district courts usa lawsuits seek relief including glaxosmithkline responded subpoenas office combination compensatory punitive damages inspector general us department health medical monitoring refunds purchases drugs human services us department justice states judicial panel multidistrict litigation issued order texas california connection allegations consolidating transferring federal actions district pharmaceutical companies including glaxosmithkline court eastern district pennsylvania court approved violated federal fraud abuse laws federal false global settlement proposed defendant wyeth sold claims act respect texas california comparable fenfluramine dexfenfluramine settlement subsequently state laws result way average wholesale price awp confirmed third circuit court appeals include determined reported certain drugs way phentermine defendants including group medicare medicaid programmes reimburse drugs individual plaintiffs may elect opt class settlement subsequently several states respective attorneys pursue claims individually tens thousands general several counties new york state filed civil lawsuits plaintiffs elected wyeth continues settle state federal court glaxosmithkline several individual state court cases trial group continues drug companies actions claimon behalf states dismissed lawsuits settled wyeth payers behalf instate patients consumers thimerosal damages restitution due awpbased price reporting glaxosmithkline along number pharmaceutical undefined set pharmaceutical products covered states companies named defendant numerous individual medicaid programmes addition private payer class action personal injury lawsuits state federal district courts lawsuits filed glaxosmithkline several usa alleging thimerosal preservative used federal district state courts federal cases manufacture vaccines causes neurodevelopmental disorders consolidated multidistrict litigation proceeding us injuries including autism three cases district court district massachusetts group purported class actions determination oneof five companies designated fast track discovery whether cases permitted proceed proceeding hearing privatepayer plaintiffs motion class action number purported class actions class certification took place february judge jurisdictions withdrawn dismissed plaintiffs seek yet ruled motion civil suits filed state remedies including compensatory punitive statutory court state attorneys general private payer class action damages cost fund medical monitoring case remanded state court early stages research although many lawsuits early stages nominal pricing number cases scheduled trial group advised us department justice lotronex investigating certain groups nominal pricing following voluntary withdrawal lotronexin usa arrangements determine whether arrangements qualify november number lawsuits filed nominal price exception best price reporting group state federal district courts including individual requirements medicaid drug rebate programme personal injury actions purported class actions asserting violate civil statutes laws group cooperating product liability consumer fraud claims plaintiffs seek remedies investigation conducted government including compensatory punitive statutory damages class attorneys involved awp investigation provided previously certified west virginia decertified documents information regarding nominal pricing action dismisseda large number claims brought arrangements number groups products following withdrawal settled paxilseroxat following announcement new york state attorney generals government investigations office states lawsuit subsequently settled august marketing promotion alleging failure disclose data use paxilin children february glaxosmithkline received subpoena adolescents similar cases purport us attorneys office colorado regarding groups sales class actions filed state federal courts promotional practices relating nine largest selling private plaintiffs cases early stages products period january presentnotes financial statementsglaxosmithkline legal proceedings continued relafen august us district court district uk investigation remains pending uk medicines massachusetts ruled groups patent nabumetone relafen healthcare products regulatory agency mhra determine invalid anticipatory art unenforceable grounds whether group complied pharmacovigilance inequitable conduct august cafc issued decision obligations reporting data clinical trials seroxatpaxil affirming district courts judgement invalidity declining children adolescents rule judgement inequitable conduct cidra puerto rico manufacturing site following district court decisionantitrustclaims alleging october fdainspectedthe groups manufacturing competitive injury overcharges filed teva eon facility cidra puerto rico cidra site engaged tableting pharmaceuticals generic manufacturers nabumetone packaging range glaxosmithkline products primarily purported classes direct indirect purchasers payers us market including paxil paxil cr coreg avandia individual retail chains avandametfollowing inspectionthe fda issued two forms observations possible deficiencies plaintiffs claims based allegations fraudulent manufacturing practices groupthe fda carried procurement patent wrongful listing patent inspection november subsequently issued fda orange book prosecution sham patent infringement two forms litigation cases originally filed us district courts district massachusetts eastern district fda observations relate certain aspects production pennsylvania transferred district massachusetts controls process validation laboratory investigationsthe group settled cases filed teva eon group group continues cooperate fda respondingto major retail pharmacy chains class direct purchasers observations contained forms court given preliminary approval tothesettlement assurance remedy fda may ultimately seek group reached class indirect purchasers hearing final approval settlement scheduled antitrust thmay additionally asettlementagreementhas paxil signedwith states regarding global claim alleged november us federal trade commission ftc staff overcharges connection state purchases drug advised group conducting nonpublic investigation determine whether group violating augmentin section federal trade commission act monopolizing us district court eastern district virginia attempting monopolize market paroxetine found various patents covering augmentininvalid holding hydrochloride preventing generic competition paxiland subsequently affirmed cafc following adverse requested group submit certain information connection trial court decision purportedantitrustclass actions filed investigation october ftc closed behalf classes direct indirect purchasers investigation basis finding action ultimately consolidated us district court eastern warranted district virginia plaintiffs alleged group knowingly obtained invalid patents engaged anticompetitive following public reference ftc investigation regarding paxil conduct prevent entry generic products violation purported class actions filed us district court monopolization section usantitrustlaws court eastern district pennsylvania behalf indirect purchasers approved groups settlement class action claims including consumers third party payers direct purchasers february group reached agreement principle plaintiffs claimed group monopolized market lek pharmaceuticals whollyowned subsidiaryof novartis paxilby bringing allegedly sham patent litigation allegedly resolve antitrust lawsuit filed lek district abusing regulatory procedures listing patents court soughtlost profits treble damages injunctive relief fda orange book court grantedfinalapproval attorneys fees settlement direct purchaser class preliminary approval settlement purported class indirect purchasers canadianimportation hearing date final approval indirect purchaser class group named seven purported class action settlement isthmarch group also reached final lawsuits along eight pharmaceutical companies settlement group chain drugstores state courts following groups actions toreduceillegal importation purported consumer fraud class action california remains prescription drugs canada lawsuits early stage separately state court class action allege companies entered unlawful conspiracy california federal class action florida prevent canadian pharmacies selling products purported indirect purchaser class action stayed us customers pending disposition federal court settlement separate group also named defendant along action city new york alleged overcharges also thirteen drug companies state court action california early stages plaintiffs independent pharmacies allege apotex alphapharm basf sumika filed antitrust defendants unlawfully conspired keep prices artificially high unfair competition counterclaims group based usa detriment plaintiffs relation allegations similar made purported class actions matter minnesota state attorney general filed identified proceeding paragraph discovery complaint alleging group violated state antitrust apotex matter early stages three actions commercial laws theseactions early stages stayed glaxosmithkline notes financial statements legal proceedings continued post balance sheet event wellbutrin sr th january glaxosmithkline announced december january february lawsuits agreed transfer european international several purported class actions filed copromotion rights levitrato bayer cash consideration us district court eastern district pennsylvania million reduction groups commitment group behalf direct indirect purchasers wellbutrin sr fund future research development product complaints allege violations us antitrust laws sham glaxosmithkline retains copromotion comarketing rights litigation fraud patent office group obtaining levitrain theusa markets enforcing patents covering wellbutrin sr complaints follow introduction generic competition wellbutrin sr related party transactions april district appellate court rulings generic glaxosmithkline held per cent interest quest manufacturer infringe groups patents cases diagnostics inc st december per cent early stages group quest diagnostics parties longterm contractual relationship quest diagnostics environmental matters primary provider clinical laboratory testing support glaxosmithkline notified potential responsibility groups clinical trials testing requirements worldwide relating past operations past waste disposal practices quest diagnostics provided services million certain sites primarily usa matters million group subject litigation including proceedings initiated us federal state governments waste disposal site group shionogi co ltd entered remediation costs tort actions brought private parties transactions usjoint venture company support research development activities conducted glaxosmithkline advised may responsible joint venture company glaxosmithkline provided party approximately sites appear services joint venture million million national priority list created comprehensive environmental st december balance due glaxosmithkline response compensation liability act superfund joint venture million million proceedings seek require operators hazardous dr shapiro nonexecutive director glaxosmithkline plc waste facilities transporters waste sites generators received fees hazardous waste disposed sites clean sites form adss subsidiary reimburse government cleanup costs company membership onthe groups scientific instances glaxosmithkline involved alleged generator advisory board included within annual remuneration hazardous waste although sites remuneration report pagesto glaxosmithkline involved current former operator facility although superfund provides defendants dr barzach former nonexecutive director glaxosmithkline jointly severally liable cleanup costs proceedings plc received fees subsidiary frequently resolved basis nature quantity company healthcare consultancy provided waste disposed site generator glaxosmithklines included within annual remuneration remuneration proportionate liability cleanup costs substantially report determined sites referred glaxosmithklines potential liability varies greatly site site cost investigation study remediation sites could time substantial glaxosmithkline routinely accrues amounts related share liability matters tax matters pending tax matters described notenotes financial statementsglaxosmithkline acquisitions disposals details acquisition disposal subsidiary associated undertakingsjoint ventures businesses given book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions fraxiparine fraxodi andarixtra fraxiparine fraxodi andarixtra inseptemberfor cash consideration million group acquired fraxiparine fraxodiand arixtraandrelated assets including manufacturing facility euclid srpartners lp year additional million invested euclid srpartners lpan associate company group per cent interest disposals quest diagnostics inc group disposed million shares investment quest diagnosticsincfor cash proceeds million reducing groups shareholding st december per cent recognising charge goodwill previously written offto reserves million profit million recognised glaxosmithkline vehicle finance ltd group disposed employee vehicle financingsubsidiaryresulting loss million glaxosmithkline pharmaceuticals chongqing ltd group disposed glaxosmithkline pharmaceuticals chongqing ltda group subsidiary located china million profit disposal million realised recognising charge forgoodwill previously writtenoff reserves million beeyar investments pty ltd july group disposed ofbeeyar investments pty ltdasubsidiary located south africa cash proceeds million realisingaprofitof million optilead srl year part groups holding associated undertaking optilead srl sold resulting loss million fraxiparine gsk gsk fraxodi quest vehicle pharmaceuticals beeyar arixtra euclidsr diagnostics finance chongqing investments total cash flows cash consideration paid net cash proceeds disposals book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions europharm europharm group completed buyout minority interests europharm holdings sa group subsidiary located romania million giving rise goodwill million capitalised iterfi sterilyo payment million made pursuant acquisition agreement based financial performance acquired company amount included deferred compensation glaxosmithklinenotes financial statements acquisitions disposals continued disposals sb clinical laboratories additional cash refund million received respect indemnified liabilities arising sb clinical laboratories disposal occurred refund follows successful outcome case uscourt appeal iterfi sb clinical sterilyo europharm laboratories total cash flows cash consideration paid net cash proceeds disposals book fair value net assets goodwill cost values adjustments acquired capitalised acquisition acquisitions iterfi sterilyo human kft iterfi sterilyo group acquired iterfisterilyo group initial cash consideration million payment paid million based financial performance acquired company net assets iterfisterilyo incorporated financial statements provisional fair values adjustments made values human kft group acquired vaccine related assets human kft manufacturing business located hungary cash consideration million disposals sb clinical laboratories cash refund million received respect indemnified liabilities arising sb clinical laboratories disposal occurred refund follows successful outcome case us court appeal sb clinical iterfi human laboratories sterilyo kft total cash flows cash consideration paid net cash proceeds disposals notes financial statementsglaxosmithkline financial instruments related disclosures group applies boardapproved limits amount credit exposure one counterparty employs strict minimum policies credit worthiness criteria choice counterparty discussion groups objectives policies management offinancial instruments associated risks fair value financial assets liabilities included treasury policies operating financial table pagepresents carrying amounts review prospects pages uk gaap fair values groups financial assets liabilities st december st december investments debtors creditors due within one year excluded group holds number equity investments frequently entities group entered research collaborations fair values financial assets liabilities included group seeks realise value investments atthe amount instrument could exchanged inpart research collaboration helps create therefore current transaction willing parties forced certain investments regarded available sale liquidationsale following methods assumptions accounted foras current asset investments purposes used estimate thefair values ofusgaap current asset investments classified equity investments market value based quoted market available sale prices case listed investments market value glaxosmithkline hedged part equity value reference quoted prices similar companies recent holdings largest equity investment quest diagnosticsinc financing information case material unlisted series variable sale forward contracts contracts investments equity collar structured five series one cash bank approximates carrying amount million quest sharesand mature liquid investments based quoted market prices similar companies recent financing information case group liquid investments representing funds surplus marketable securities approximates carrying amount immediate operating requirements accounted inthe case time deposits short maturity current asset investments purposes usgaap shortterm loans overdrafts approximates carrying investments classified available sale proceeds amount short maturity instruments sale investments classified available saleunder us gaap mediumterm loans market value based quoted market weremillionin year ended stdecember prices case eurobonds fixed rate proceeds include rollover liquid funds shortterm borrowings approximates carrying amount case deposit usgaap gross gains losses reflected offloating rate bank loans loans consolidated profit loss account respect investments forward exchange contracts based market prices classified available sale million andmillion exchange rates balance sheet date respectively currency swaps based market valuations balance sheetdate foreign exchange risk management equity collar fair value determined based option group entered forward foreign exchange contracts pricing model inorder swap liquid assets borrowings currencies interest rate instruments fair value determined using net required group purposes st december group present value discounted cash flows outstanding contracts sell purchase foreign currency debtors creditors approximates carrying amount total notional principal amount million provisions approximates carrying amount million majority contracts periods auction rate preference stockapproximates carrying months less amount case floating rate instruments end group number currency swaps flexible auction market preferred stockbased market inplace respect mediumterm debt instruments borrowings valuations balance sheet date denominated swapped foreign currencies match investments overseas group assets treated ahedge fair value investments shares relevant net assets exchange gains losses group st december investments recorded reserves shares million million fair value million millionbased quoted interest rate risk management market pricethe shares represent purchases esop trusts manage fixedfloating interest rate profile debt satisfy future exercises options awards employee group several interest rate swaps outstanding incentive schemesthey excluded financial instrument commercial banks st december disclosure concentrations credit risk credit exposures financialinstruments group believe exposed major concentrations credit risk financial instruments group exposed creditrelated losses event nonperformance counterparties financial instruments expect counterparties fail meet obligations glaxosmithklinenotes financial statements financial instruments related disclosures continued classification fair values financial assets liabilities following table sets classification financial assets liabilities provides reconciliation group net debt note shortterm debtors creditors excluded financial assets liabilities provisions included contractual obligation settle cash carrying fair carrying fair amount value amount value net debt liquid investments cash bank current asset financial instruments sterling notes bonds us dollar notes bonds private financing notes bonds swapped us dollars currency swaps interest rate swaps notes bonds swapped yen currency swaps euro notes bonds interest rate swap mediumterm borrowings shortterm loans overdrafts total borrowings total net debt fixed asset equity investments current asset equity investments debtors due year creditors due year provisions foreign exchange derivatives nonhedging derivatives auction rate preference stock flexible auction market preferred stock total nonequity minority interests total financial assets liabilities total financial assets total financial liabilities appropriatecurrency interest rate swaps presented alongside underlying principal instrument carrying amounts instruments adjusted effect currency interest rate swaps acting hedges difference carrying amount fair value equity fixed current assets liquid investments represents gross unrealised gains million million respectivelynotes financial statementsglaxosmithkline financial instruments related disclosures continued currency interest rate risk profile financial liabilities financial liabilities taking account currency interest rate swaps analysed total financial liabilities comprise total borrowings million million creditors due one year million million provisions million million nonequity minority interest preference shares ofnil millionbut exclude creditors due within one year foreign exchange derivatives million nil benchmark rate determining interest payments floating rate financial liabilities tables libor noninterest fixed rate floating rate bearing weighted weighted average average weighted st december interest years average rate rate years total currency fixed maturity us dollars sterling euro japanese yen currencies noninterest fixed rate floating rate bearing weighted weighted average average weighted st december interest years average rate rate years total currency fixed maturity us dollars sterling euro japanese yen currencies currency interest rate risk profile financial assets total financial assets comprise fixed asset equity investments million million current asset equity investments million million liquid investments million million cash bank million millionand debtors due one year million millionbut exclude foreign exchange derivatives nil millionthe benchmark rate determining interest receipts floating rate assets tablesbelow libor noninterest fixed rate floating rate bearing weighted weighted st december fixed average average years rate interest rate total currency rate fixed us dollars sterling euro japanese yen currencies noninterest fixed rate floating rate bearing weighted weighted st december fixed average average years rate interest rate total currency rate fixed us dollars sterling euro japanese yen currencies glaxosmithklinenotes financial statements financial instruments related disclosures continued currency exposure net monetary assetsliabilities groups currency exposures give rise net currency gains losses recognised profit loss account arise principally companies sterling functional currency monetary assets liabilities denominated overseas functional currency andborrowings designated hedge overseas net assetsare excluded table st december functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us dollars euro japanese yen st december functional currency group operation net monetary assetsliabilities sterling us euro yen total held nonfunctional currency sterling us dollars euro japanese yen finance total total debt leases maturity financial liabilities within one year demand one two years two five years five years gains losses net hedges unrecognised gains losses beginning year unrecognised gains losses arising previous years recognised year unrecognised gains losses arising year total unrecognised gains losses end year expected recognised within one year expectedto recognised one year total unrecognised gains losses end year unrecognised gains losses represent difference carrying amount fair value currency swaps interest rate swaps equity collar foreign exchange derivatives committed facilities group committed facilities back commercial paper programme million million million millionof daysdurationrenewable annually st december undrawn committed facilities totalled million million million millionnotes financial statementsglaxosmithkline employee costs restated restated wages salaries social security costs pension postretirement costs cost sharebased incentive plans severance costs arising integration restructuring activities pension postretirement costs arising integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance information directors remuneration given remuneration report pagesto average number persons employed group including directors year number number number manufacturing selling general administration research development average number group employees excludes temporary contract staff numbers group employees end financial year given financial record page pension postretirement costs uk pension schemes us pension schemes overseas pensions schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs pension postretirement costs arising integration restructuring pensions group undertakings operate pension arrangements cover groups material obligations provide pensions retired employees thesearrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length ofservice defined benefit schemes also include defined contribution sections aredescribed hybrid schemes table majority cases contributions defined benefit schemes determined accordance advice independent professionally qualified actuaries formal independent actuarial valuations groups main plans undertaken regularly normally least every three years theassets funded schemes generally held separately administered trusts insured assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment glaxosmithklinenotes financial statements employee costs continued pension costs defined benefit schemes accounting purposes assessed accordance independent actuarial advice generally using projected unit method spreading surpluses deficits average expected remaining service lives respective membershipsin certain countries pension benefits provided unfunded basis administered trustee companies whereassets held specific purpose matching liabilities unfunded schemes provision included within provisions pensions postretirement benefits liabilities generally assessed annually accordance advice independent actuaries market value assets groups funded defined benefit pension funds dates latest actuarial valuations date back billion actuarial value assets sufficient cover approximatelyper cent benefits accrued members allowing future salary andpension increases uk defined benefit pension schemes account approximatelyper cent groups plans asset valuation projected benefit terms us defined benefit pension schemes account approximatelyper cent groups plans asset valuation projected benefit terms group made special funding contributions uk us pension schemes totalling million group agreed trustees certain pension schemes make additional contributions dependent funding status schemesin following move ifrs pension costs group expected approximatelymillion higher uk uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled tojoin defined contribution scheme relevant assumptions used calculating pension costs ofall uk defined benefit schemes accounting purposes follows pa pa rate increase future earnings discount rate expected longterm rate return investments expected pension increases regular cost glaxo wellcome pension arrangements million reduced accounting cost million allowance made spreading surplus disclosed level percentage salary expected future working lifetime existing members someyears recent triennial actuarial valuations funding purposes carried asat st december date assets schemes represented per cent actuarial value benefits accrued members allowing future salary pension increases themarket value assets held schemes atst december million regular cost smithkline beecham schemes million increased accounting cost million allowance made spreading deficit expected future working lifetime current employees scheme years latest valuation carried st december date scheme assets represented per cent actuarial value accrued service liabilities based assumptions themarket value assets held scheme st december million usa usa former glaxo wellcome smithkline beecham defined benefit hybrid schemes merged relevant assumptions used calculating pension costs accounting purposes follows pa pa rate increase future earnings discount rate expected longterm rate return investments cash balance creditconversion rate regular cost main us schemesin million whichdecreased accounting cost million allowance made spreading thesurplusover expected future working lifetime current employees schemes latest valuation carried st january date actuarial value scheme assets representedper cent actuarial value theaccrued service liabilities themarket value assets held scheme st january million postretirement healthcare group operates number postretirement healthcare schemes principal one usa cost usscheme assessed using assumptions us pension scheme together assumption future medical inflation ofper centreducing one per cent per year five per cent total provision postretirement benefits st december amounted million millionnotes financial statementsglaxosmithkline employee costs continued frs disclosures group continues account pension arrangements accordance ssap accounting pension costs transitional provisions frs retirement benefits certain disclosures required basis valuation methodology adopted frs defined benefit schemes fair values pension scheme assets st december compared future pension liabilities calculated projected unit method applying following assumptions uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earnings discount rate expected pension increases na na na cash balance creditconversion rate na na na na inflation rate expected longterm rates return assets determined based actuarial advice fair values assets liabilities uk us defined benefit schemes together aggregated data defined benefit schemes group follows uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme liabilities value schemes surplus deferred tax liability value schemes deficit deferred tax asset group total uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme liabilities value schemes surplus deferred tax liability value schemes deficit deferred tax asset group total glaxosmithklinenotes financial statements employee costs continued uk usa rest world group average st december expected rate fair expected rate fair expected rate fair fair return value return value return value value equities property bonds assets fair value assets present value scheme liabilities value schemes surplus deferred tax liability value schemes deficit deferred tax asset group total uk defined benefit schemes also defined contribution sections account balances totalling million st december million million defined benefit sections uk schemes closed new members projected unit method valuing pension scheme liabilities current service cost increase percentage payroll members schemes approach retirement deficits frs reflectthe different basis valuing liabilities compared ssap liability frs us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation ofper centreducing one per cent per year five per cent basis liability usscheme assessed million million million reduced million million million taking account deferred tax defined benefit pension postretirement benefit schemes accounted frs following amounts would recorded profit loss account statement total recognised gains losses three years ended st december postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost curtailmentssettlements amounts creditedcharged net interest expected return pension scheme assets interest scheme liabilities amounts recorded statement total recognised gains losses actual return less expected return pension scheme assets experience gainslossesarising scheme liabilities changes assumptions relating present value scheme liabilities notes financial statementsglaxosmithkline employee costs continued postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost curtailmentssettlements amounts creditedcharged net interest expected return pension scheme assets interest scheme liabilities amounts recorded statement total recognised gains losses actual return less expected return pension scheme assets experience lossesgains arising scheme liabilities changes assumptions relating present value scheme liabilities postretirement pensions benefits uk usa rest world group group amounts charged operating profit current service cost past service cost curtailmentssettlements amounts creditedcharged net interest expected return pension scheme assets interest scheme liabilities amounts recorded statement total recognised gains losses actual return less expected return pension scheme assets experience gainslosses arising scheme liabilities changes assumptions relating present value scheme liabilities glaxosmithklinenotes financial statements employee costs continued postretirement pensions benefits movements deficits uk usa rest world group group deficits schemes st january exchange adjustments charged operating profit employer contributions finance incomeexpense actuarial losses recognised statement total recognised gains losses deficits schemes st december exchange adjustments charged operating profit employer contributions finance incomeexpense actuarial lossesgains recognised statement total recognised gains losses deficits schemes st december exchange adjustments charged operating profit employer contributions finance incomeexpense actuarial lossesgains recognised statement total recognised gains losses deficits schemes st december postretirement pensions benefits history experience gains losses uk usa rest world group group difference expected actual return scheme assets percentage scheme assets st december experience gainslossesof scheme liabilities percentage present value scheme liabilities st december total amount recognised statement total recognised gains losses percentage present value scheme liabilities st december notes financial statementsglaxosmithkline employee costs continued postretirement pensions benefits history experience gains losses uk usa rest world group group difference expected actual return scheme assets percentage scheme assets st december experience lossesgains scheme liabilities percentage present value scheme liabilities st december total amount recognised statement total recognised gains losses percentage present value scheme liabilities st december difference expected actual return scheme assets percentage scheme assets st december experience gainslosses scheme liabilities percentage present value scheme liabilities st december total amount recognised statement total recognised gains losses percentage present value scheme liabilities st december frs valuation basis applied financial statements instead ssap valuation basis effect profit loss account reserve taking account deferred tax would follows restated profit loss account reserve per balance sheet pension liability frs net pension assetunder ssap per balance sheet postretirement healthcare schemes frs net postretirement healthcare schemes provision per balance sheet profit loss account reserve including frs pension postretirement healthcare liability glaxosmithkline notes financial statements employee share schemes group operates share option schemes whereby options granted employees acquire shares adss glaxosmithkline plc grant price share award schemes whereby awards granted employees acquire shares adss glaxosmithkline plc cost subject tothe achievement performance targets group introduced new share award scheme restricted share plan whereby awards granted employees acquire shares adss glaxosmithkline plc cost three year period granting restricted share awards replaced granting options certain employeesas cost scheme readily equates potential gain made employee group operates share option schemes savingsrelated share option schemes grants share option schemes normally exercisable three ten years date grant grants savingsrelated share option schemes normally exercisable three years saving options share option schemes normally granted market price ruling date grant accordance uk practice majority options savingsrelated share option schemes granted price per cent market price ruling date grant accordance exemption granted uitf revised charge profit loss accountismade relation savingsrelated share option schemes options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december options granted options exercised options cancelled st december options granted options exercised options cancelled st december options granted options exercised options cancelled st december range exercise prices order encourage employees convert options excluding savingsrelated share options held glaxo wellcome smithkline beecham shares adss glaxosmithkline shares adss programme established give additional cash benefit ofper cent exercise price original option provided employeedidnot voluntarily leave group two years date merger anddidnot exercise option earlier six months expiry date original option two years date merger cash benefit also paid options expire unexercised market price exercise price date expiry options outstanding share option share option savingsrelated schemes shares schemes adss share option schemes st december weighted latest weighted latest weighted latest number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total options exercisable except options shares adss granted savingsrelated share options granted change effective exercise price outstanding options yearnofurther options granted st december andth februarynotes financial statementsglaxosmithkline employee share schemes continued options exercisable share option share option savingsrelated schemes shares schemes adss share option schemes weighted weighted weighted number exercise number exercise number exercise price price price st december st december st december glaxosmithkline share award schemes performanceshareplan group operates performance share plan whereby awards granted directors senior executives cost percentage award vests based upon performance group three year measurement period performance conditions consist two parts applies per cent award forawardsgranted first part condition compares glaxosmithklines total shareholder return tsr period tsr companies ukftse index period awards granted first part condition compares glaxosmithklines tsr period tsr pharmaceutical companies thecomparatorgroup period second part performance condition compares glaxosmithklines earnings per share growth increase ukretail prices index three year performance period awards granted directors members cet th december subject single performance condition compares glaxosmithklines tsr period tsr companies thecomparatorgroup period awards shares adss number shares adss issuable number number st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december awards granted awards exercised awards cancelled st december restrictedshareplan group operates restricted share plan whereby awards granted employees cost award vests three yearswith performance criteria attached shares adss number shares adss issuable number number st december awards granted st december glaxosmithkline notes financial statements employee share schemescontinued employee share ownership plan trusts group sponsors employee share ownershipplanesop truststo acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares onthe open market finance provided group way loans contributions expected cost ofthe obligations deliver shares schemes normally spread periods service respect awards options granted accelerated charge made respect outstanding cost providing shares awards options became exercisable solely result merger shares held share award schemes restated number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value results restated following implementation uitfreviseduitfrevisedrequires minimum expense difference fair value shares date award amount employee may required pay shares ie intrinsic value award trusts also acquire hold shares meet notional dividends reinvested deferred awards smithkline beechammidterm incentive plan trustees waived rights dividends shares held employee share ownership trusts option pricing purposes valuing options arrive stockbased compensation adjustment reconciliation us accounting principles innote blackscholes option pricing model used assumptions used model follows riskfree interest rate dividend yield volatility expected lives options granted share option schemes years years savingsrelated share option schemes years yearsnotes financial statementsglaxosmithkline reconciliation usaccounting principles additionally group reassesses useful lives existing recognised intangible assets intangible assets deemed analyses reconciliations presented note represent indefinite lives longer amortised instead tested financial information prepared basis us generally annually potential impairment separable intangible assets accepted accounting principles usgaap rather ukgaap finite lives continue amortised useful lives summary material differences uk us gaap group adopted sfas st january acquisition smithkline beecham implementation sfas resulted impairment combination glaxo wellcome plc smithkline beecham groups goodwill initial impairment million plc accounted merger pooling interests million net tax indefinitelived assets shown accordance ukgaap us gaap business cumulative effect accounting change combination qualify pooling interests accounting ukgaap costs incurred integrating glaxo wellcome determined accounting restructuring wellcome smithkline beecham block drug acquirer purchase business combination businesses following acquisitions accordingly net assets smithkline beecham fair valued respectively charged profit loss account post date acquisition result fair value exercise acquisition usgaap certain costs considered increases values smithkline beechams inventory tangible allocation purchase consideration thereby affecting fixed assets investments pension obligations recognised goodwill arising acquisition fair market values attributed intangible assets mainly ukgaapcertain intangible assets related specific product rights inclusive patents trade marks inprocess compounds products purchased third party research development together appropriate deferred developed commercial applications capitalised taxation effects difference cost acquisition usgaap payments made compounds products fair value assets liabilities smithkline still development yet received regulatory beecham recorded goodwill approval charged directly profit loss account timethat receive regulatory approval capitalised interest uk gaap group capitalise interest usgaap restructuring costs requires interest incurred part cost constructing fixed ukgaap restructuring costs incurred following acquisitions assets capitalised amortised life asset charged profit loss account post acquisition usgaap purposes certain costs recognised computer software liabilities upon acquisition opening balance sheet uk gaap group capitalises costs incurred acquiring developing computer software internal use restructuring costs recorded provision uk software supports significant business system gaap restructuring plan announced us expenditure leads creation durable asset us gaap provision may recognised criteria gaap group applies sop accounting costs met liability incurred accordingly adjustments computer software developed obtained internal use made eliminate ukgaapprovisions restructuring restricts categories costs capitalised costs notmeet usgaaprequirements goodwill intangible fixed assets marketable securities ukgaap goodwill arising acquisitions marketable securities consist primarily equity securities accounted purchase method eliminated certain liquid investments ukgaapthese securities shareholders funds additionally ukgaap requires stated lower cost net realisable value subsequent disposal closure business goodwill usgaap securities considered available sale previously taken directly shareholders funds charged sfas accounting certain investments debt equity income ukgaap goodwill arising acquisitions securities carried fair value unrealised gains capitalised amortised period exceeding losses net tax recorded separate component years intangible assets amortised estimated shareholders equity useful economic life except case certain acquired brands equity securities reviewed least annually end useful economic life brand temporary impairment factors considered foreseen investees current financial performance future us gaap goodwill arising acquisitions prior prospects thjune capitalised amortised period general market condition geographic exceeding years intangible assets including brands industry area investee operates amortised finite life july financial accounting duration extent market value standards board fasb issued statement financial accounting ifavailable cost standard sfasgoodwill intangible assets sfas requires goodwill longer amortised gross unrealised gains losses marketable securities estimated useful life group must instead identify value million million respectively st december reporting units purpose assessing least annually million million respectively st december potential impairment goodwill allocated reporting unit glaxosmithkline notes financial statements reconciliation us accounting principles continued changes accounted prior year adjustments ukgaap reconciliations profit attributable pensions postretirement benefits shareholders equity shareholders funds ukgaap key differences uk ssap usgaap usgaap restated accordingly reconcile relation defined benefit pension plans restated ukgaap figures ukgaapthe effect variations cost reconciling difference ukgaap usgaap remains accumulated successive valuations amortised respect charge recognised profit usgaap aggregate basis us gaap amortisation shares purchased esop trusts accounted within transition asset costs past service benefit shareholders equity gains losses issuance shares improvements separately tracked experience gainslosses employees recorded adjustments shareholders equity dealt aggregate basis amortised outside per cent corridor guarantor obligations uk gaap allows measurements plan assets liabilities group adopted fasbs financial interpretation based result latest actuarial valuation finguarantors accounting disclosure requirements usgaap requires measurement plan assets liabilities guarantees including indirect guarantees indebtedness made date financial statements others effect st january three months prior date requires group recogniseand measure fair value pension adjustment also includes impact changes prospective basis certain guarantees issued modified minimum pension liabilities included within accumulated st december ukgaapsuch guarantor obligations comprehensive income recognised additional criteria met liability incurred group decided align measurement datefor pension postretirement benefit plans derivative instruments st december certain groups plans measurement sfas accounting derivative instruments hedging date assets liabilities th september activitiesas amended sfas sfas impact reflected cumulative effect accounting interpreted derivatives implementation group adopted change million credit net tax income group effect st january sfas establishes accounting reporting standards derivative stockbased compensation instruments including certain derivative instruments embedded uk gaapshare options accounted equity contracts collectively referred derivatives exercised valued issuance price usgaap group hedging activities ukgaap derivative instruments applies sfas accounting stockbased compensationand used hedging recognised balance sheet related accounting interpretations accounting option plans matching principle used match gain loss require options fair valued grant date hedging contracts foreign currency transaction included profit loss vesting period options profits relate sfas requires entity recognise derivatives either assets liabilities group entitled receive tax deduction amount consolidated balance sheet measure instruments treated compensation us tax rules employee fair value changes fair value period recorded stock options exercised usemployees current earnings unless hedge accounting obtained group year ukgaapthis treated reduction tax designate derivatives qualifying hedge expense whereasunder usgaapa portion amount instruments sfassfas prescribes requirements credited equity designation documentation hedging relationships ongoing assessments effectiveness order qualify hedge employee share ownership plan trusts accounting prior uk gaap shares groups stock held esop trustswererecorded cost less provision representing group also evaluates contracts embedded derivatives difference cost option exercise price considers whether embedded derivatives accounted fixed asset investments projected losses bifurcated separated host contracts accordance exercise options covered shares recorded sfas requirements embedded derivatives exist profit loss account life theoptions clearly closely related host contract uitfabstract accounting esoptrustsand related accounted separately host contract derivatives amendments uitfabstract employee share schemeswere gains losses related fair value adjustments implemented groups ukgaap financial statements uitf derivative instruments classified consolidated statement changes presentation entitys shares held esop income cash flows accordance nature trust requiring recognised assets requiring derivative deducted arriving shareholders funds usgaap uitf revised requires minimum expense fair value book value derivative instruments respect difference fair value shares financial assets liabilities st december date award amount employee may disclosed classification fair value financial assets required pay shares ie intrinsic value award liabilities table notenotes financial statementsglaxosmithkline reconciliation us accounting principles continued sales incentives accordance ukgaap certain amounts paid group valuation derivative instruments customers recorded promotional expense included fair value derivative instruments sensitive movements operating income usgaap items recorded underlying market rates variables group monitors reduction revenue items result net fair value derivative instruments least quarterly basis impact income statement usgaap amount formal review every six months derivatives including would classified reduction revenue would interest rate swaps crosscurrency swaps valued using million million standard valuation models counterparty valuations third party valuations standard valuation models used group consider variable interest entities relevant discount rates market yield curve valuation january fasb issued interpretation fin date forward currency exchange rates counterparty risk consolidation variable interest entities december significant rates variables obtained market sources issued fin r revision interpretation valuations based remaining term maturity revised interpretation certain entities known variable interest instrument foreign exchange contracts valued using forward entities vies must consolidated primary beneficiary rates observed quoted prices relevant markets entity primary beneficiary generally defined possible group assumes parties longterm contracts majority risks rewards arising vie economically viable reserves right exercise early additionally vies significant majority termination rights economically beneficial rights variable interest held certain disclosures required exist contract group completed review potential vies andas dividends consequencehas consolidated theravance incfrom may uk gaap dividends proposed provided year see note c pageno vies group respect recommended board primary beneficiary identified ofdirectors approval shareholders usgaap suchdividends provided declared board recent financial accounting standards board fasb ofdirectors pronouncements may fasb issued fasb staff position fsp consolidated summary statement cash flows fasaccounting disclosure requirements related usgaap cash flow statement reports changes cash medicare prescription drug improvement modernization cash equivalents includes shortterm highly liquid act superseding fsp fsp addresses investments original maturities three months less accounting implications act entity sponsors onlythree categories cash flows reported operating postretirement health care plan providing prescription drug activities including tax interest investing activities benefits act introduces usa prescription drug including capital expenditure acquisitions disposals together benefit medicareas well federal subsidy sponsors cashflows available sale current asset investments certain postretirement health care plans companies andfinancing activities including dividends paid summary elected deferral fsp fsp effective statement ofcash flows presented page reporting periods commencing th june estimated amountof federal subsidy treated prior cash cash equivalents service gain credited profit loss account uk gaapthe cash balance includes cash bank average service lives employeesunder usgaap cash balances usgaapcash cash equivalents change resulted decrease million accumulated include cash bank certain liquid investments original benefit obligation reduction million net periodic maturities three months less postretirement benefit cost year ended st december comprehensive income statement requirement sfas reporting comprehensive income provide comprehensive income statement met ukgaap statement total recognised gains losses pagesand reclassifications certain prior year balances reclassified comparative purposes certain amounts previously presented aggregate reconciliation profit usgaap ukgaap presented separately current year presentation provide information related adjustments glaxosmithkline notes financial statements reconciliation us accounting principles continued following summary material adjustments profit shareholders funds would required us gaap applied instead uk gaap restated restated profit notes profit attributable shareholders ukgaap goodwill amortisation reversal including goodwill associated undertakings amortisation impairment intangible assets b acquisition disposal ofproduct rights b capitalised interest tangible fixed assets disposal interest associate disposal goodwill subsidiaries product divestments equity investments recognition cost sales fair value stepup inventory pensions postretirement benefits f stockbased compensation derivative instruments hedging fair value put option granted minority shareholders c guarantor obligations restructuring tax benefits exercise us stock options deferred taxation variable interest entities c net income us gaap cumulative effect changes accounting principles cumulative effect changes accounting principles net income cumulative effect changes accounting principles certain items year ended st december reclassified comparative purposes earnings per share usgaap p p p basic net income per share cumulative effect changes accounting principles usgaap cumulative effect changes accounting principles per share usgaap basic net income per share cumulative effect changes accounting principles usgaap diluted net income per share cumulative effect changes accounting principles usgaap cumulative effect changes accounting principles per share usgaap diluted net income per share cumulative effect changes accounting principles usgaap earnings per ads usgaap basic net income per ads cumulative effect changes accounting principles usgaap cumulative effect changes accounting principles per ads usgaap basic net income per ads cumulative effect changes accounting principles usgaap diluted net income per ads cumulative effect changes accounting principles usgaap cumulative effect changes accounting principles per ads usgaap diluted net income per ads cumulative effect changes accounting principles usgaap notes financial statementsglaxosmithkline reconciliation us accounting principles continued restated equity shareholders funds notes equity shareholders funds uk gaap usgaapadjustments goodwill product rights b pension intangible asset b tangible fixed assets capitalised interest marketable securities investments fair value stepup inventory pensions postretirement benefits f restructuring costs derivative instruments hedging fair value put option granted minority shareholders c guarantor obligations dividends deferred taxation e variable interest entities c shareholders equity us gaap consolidated statement cash flows usgaap net cash provided operating activities net cash used investing activities net cash used financing activities net increasein cash cash equivalents exchange rate movements cash cash equivalents beginning year cash cash equivalents end year notes profit equity shareholders funds reconciliations goodwill following tables set uk usgaap adjustments required uk gaap statement profit loss balance sheet respect goodwillincluding goodwill respect associated undertakings income statement amortisation ukgaap amortisation usgaap uk usgaap adjustment amortisation including goodwill respect associated undertakings balance sheet goodwill ukgaap goodwill usgaap uk usgaap adjustments million millionusgaap goodwill balance st december million million respect goodwill arising acquisition smithkline beecham glaxo wellcome glaxosmithkline notes financial statements reconciliation us accounting principles continued following tables present changes goodwill allocated groups reportable segments consumer pharmaceuticals healthcare total st december additions exchange adjustments st december asset written exchange adjustments st december b intangible assets following tables set ukto usgaap adjustments required ukgaap statement profit loss balance sheet respect intangible assets income statement amortisation charge ukgaap amortisation charge usgaap ukto usgaap adjustment amortisation impairment charge ukgaap impairment charge usgaap ukto usgaap adjustment forimpairments cumulative effect change accounting principle uk usgaap adjustment forimpairments period following initial implementation sfas carrying value brands determined indefinite lives reviewed impairment million million net tax recognised recorded cumulative effect change accounting principle addition adjustmentsfor amortisation impairmentsfurther uk usgaap adjustmentsarose year million million million respect acquisition licences patents etc capitalised ukgaap charged directly toresearch development expenseunder usgaap million nil respect disposals product rights higher carrying value usgaap ukgaap balance sheet intangible assets ukgaap intangible assets usgaap ukto usgaap adjustments less pensions intangible asset net ukto usgaap product rights adjustments intangible assets usgaap analysed follows acquired products licences patents etc brands pensions intangible assets usgaap following tables present details groups intangible assets differentiating subject amortisation whichare subject amortisation intangible assets subject amortisation intangible assets subject amortisation intangible assets usgaap notes financial statementsglaxosmithkline reconciliation us accounting principles continued following intangible assets subject amortisation product product rights rights cost accumulated amortisation impairment net carrying values certain product rights reviewed impairment million recorded impairments million recorded million related paxilwhich impaired following launch usa generic paxilproduct fair values determined using discounted cash flow model discussed notelegal proceedings number distributors generic drugs filed applications market generic versions ofa number groups products prior expiration groups patents generic versions products launched future periods earlier dates group currently expects impairments carrying value products may arise estimated future amortisation expense next five years intangible assets subject amortisation st december follows year total intangible assets subject amortisation include pension asset million st december million st december certain product rights intangible assets relating product rights analysed follows cost impairment net impairment charge nilwas recognised million c theravance may group formed strategic alliance theravanceincto develop commercialise novel medicines across variety important therapeutic areas terms alliance theravance received million significant part related groups purchase theravance shares group call option increase ownership per cent significant premium price paid transaction theravances shareholders put option lower exercise price cause glaxosmithkline acquire half outstanding stock given maximum number shares subject put optionthe groups obligation capped million group exclusive option license potential new medicines theravances programmes august upon exercising option theravance programme group responsible relevant development manufacturing commercialisation activities depending success programmes theravance receive clinical regulatory commercial milestone payments royalties subsequent sales medicines based assessment performed group primary beneficiary theravance defined fin r result theravance consolidated groups us gaap financial statements may net assets acquired measured fair value principaladjustment carrying value net assets theravances balance sheet prior acquisition recognition inprocess research development iprd valuation million iprdwas writtenoff immediately acquisition accordance usgaap purchase accounting effect consolidating theravance todecrease shareholders equityandnet income million additionally group accounted theravance put option discussed accordance sfas accounting certain financial instruments characteristics liabilities equity requires group record fair value put option liability fair value ofthe theravance put optionat st december million initial consolidation theravance value put option millionin accordance sfas accounting derivative instruments hedging activities call option recognised financial statements readily convertible cash glaxosmithkline notes financial statements reconciliation us accounting principles continued taxation restated restated total tax expense uk gaap current tax expense deferred tax creditexpense total tax expense us gaap current tax expense deferred taxcredit total tax expense cumulative effect changes accounting principles total tax expense ukto usgaap adjustments current tax expense deferred taxcredit total tax expense cumulative effect changes accounting principles total tax expense e deferred taxation usgaap classification glaxosmithklines deferred taxation liabilities assets us gaap follows restated liabilities stock valuation adjustment current deferred taxation liabilities accelerated capital allowances product rights timing differences total deferred taxation liabilities assets intragroup profit timing differences current deferred taxation assets asset disposal pensions postretirement benefits tax losses manufacturing restructuring legal disputes timing differences total deferred taxation assets net deferred taxation us gaap net deferred taxation ukgaap uk usgaap adjustment notes financial statementsglaxosmithkline reconciliation us accounting principles continued f pensions postretirement costs usgaap uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes postemployment costs analysed funded defined benefithybrid schemes unfunded defined benefit schemes defined contribution schemes unfunded postretirement healthcare schemes postemployment costs disclosures include additional information required sfas r pension costs uk us major overseas defined benefit pension plans restated following tables accordance us gaap pension costs million million million respect minor retirement plans recalculated accordance requirements sfas excluded net periodic pension costfor major retirement plans service cost interest cost expected return plan assets amortisation prior service cost amortisation transition obligation amortisation net actuarial loss net periodic pension costunder us gaap termination benefits curtailment costs adjustment change accounting principle group decided align measurement date pension plans certain groups pension plans measurement date pension assets liabilities th september group elected change measurement date plans th september st december major assumptions used computingpension costs pa pa pa rates future pay increases discount rate expected longterm rates return plan assets aggregate average international plan assumptions vary significantly us assumptions estimated future benefit payments glaxosmithkline notes financial statements reconciliation us accounting principles continued change benefit obligation benefit obligation beginning year amendments service cost interest cost plan participants contributions actuarial loss benefits paid termination benefits curtailment costs exchange benefit obligation end year benefit obligation end year pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation st december million st december million change plan assets fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions benefits paid exchange fair value plan assets end year fair value plan assets end year pension plans accumulated benefit obligations excess plan assets plan assets consist primarily investments uk overseas equities fixed interest securities securities linked uk retail prices index property st december uk equities includedmillion glaxosmithkline shares million shares market value million million normal employer contributions expected approximately million funded status funded status unrecognised net actuarial loss unrecognised prior service cost unrecognised transition obligation net amount recognised amounts recognised statement financial position prepaid benefit cost accrued pension liability intangible asset accumulated comprehensive income net amount recognised notes financial statementsglaxosmithkline reconciliation us accounting principles continued postretirement healthcare usgaap postretirement healthcare costs uk us major overseas postretirement healthcare schemes restated following tables accordance usgaap costs nil million nil recalculated excluded net healthcare cost service cost interest cost amortisation prior service cost amortisation net actuarial loss net healthcare cost major assumptions used calculating net healthcare cost pa pa pa rate future healthcare inflation discount rate rate future healthcare inflation reflects fact benefits certain groups participants capped change benefit obligation benefit obligation beginning year amendments service cost interest cost plan participants contributions actuarial loss benefits paid exchange benefit obligation end year change plan assets fair value plan assets beginning year employer plan participants contributions benefits paid fair value plan assets end year funded status funded status unrecognised net actuarial loss unrecognised prior service cost accrued postretirement healthcare cost decrease increase impact one per cent variation rate future healthcare inflation effect total service interest cost effect provision postretirement benefits glaxosmithkline notes financial statements principal group companies following represent principal subsidiary associated undertakings glaxosmithkline group stdecember details given principal country operation location headquarters business segment business activities equity share capital undertakings wholly owned group except percentage interest shown otherwise companies incorporated principal country operation except stated europe location subsidiary undertaking segment activity england brentford glaxosmithkline holdings onelimited phch h brentford glaxosmithkline services unlimited phch brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc ph f brentford smithkline beecham plc phch e h p r brentford wellcome limited phch h greenford glaxo group limited ph h greenford glaxo operations uk limited ph p brentford glaxo wellcome international bvfootnote phch h brentford glaxo wellcome investments bvfootnote phch h stockley park glaxo wellcome uk limited ph h p brentford glaxosmithkline export limited ph e brentford glaxosmithkline research development limited ph dr brentford glaxosmithkline uklimited ph p brentford smithkline beecham investments limited phch f brentford smithkline beecham swg limited ch e brentford smithkline beecham research limited ph brentford staffordmiller limited ch p greenford wellcome foundation limited ph p brentford setfirst limited phch fh formerly glaxosmithkline luxembourg sa footnote ii austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biologicals sa ph em pr rixensart glaxosmithkline biologicals manufacturing sa ph h guernsey st peter port smithkline beechamlimited phch denmark ballerup glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharmaas ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h pr buehl glaxosmithkline healthcare gmbh ch h greece athens glaxosmithkline aebe phch h hungary budapest glaxosmithkline kft phch e italy verona glaxosmithkline spa ph h mr milan glaxosmithkline consumer healthcare sp ch h luxembourg mamer glaxosmithkline international luxembourg sa phch f hnotes financial statementsglaxosmithkline principal group companies continued europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline bv ph zeist glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p warsaw glaxosmithkline consumer healthcarespzoo ch portugal lisbon glaxosmithklineprodutos farmaceuticos lda ph republic dublin glaxosmithkline consumer healthcare ireland limited footnote iii ch ireland carrigaline smithkline beecham cork limitedfootnote iii ph p carrigaline smithkline beecham manufacturinglimitedfootnote iii ph p spain tres cantos glaxosmithkline sa ph aranda de duero glaxosmithkline sa ph p alcaladehenares smithkline beecham sa ph p sweden mlndal glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch h muenchenbuchsee glaxosmithkline ag ph zug adechsa gmbh ph e usa usa philadelphia smithkline beecham corporation phch e hm p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h p wilmington glaxosmithkline financial inc ph f wilmington glaxosmithkline holdings americas inc phch h americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc phch p r asia pacific australia boronia glaxo wellcome australia pty ltd phch e p r china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd ph p r india mumbai glaxosmithkline pharmaceuticals limited ph p nabha glaxosmithkline consumer healthcare limitedfootnote iv ch p malaysia petaling jaya selangor glaxosmithkline pharmaceutical sdn bhd ph darul ehsan new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch pe philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd ph p singapore glaxosmithkline pte ltd ph south korea seoul glaxosmithkline korea ph p taiwan taipei glaxo wellcome taiwan limited ph p glaxosmithkline notes financial statements principal group companies continued japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline kk phch p r latin america argentina buenos aires glaxosmithkline argentina sa phch p brazil rio de janeiro glaxosmithkline brasil ltda phch p colombia bogota glaxosmithkline colombia sa phch mexico mexico city glaxosmithkline mexico sade cv phch e ps puerto rico guaynabo glaxosmithkline puerto rico inc ph san juan sb pharmco puerto rico inc ph p venezuela caracas glaxosmithkline venezuela ca phch middle east africa egypt cairo glaxosmithklinesae ph p south africa bryanston glaxosmithkline south africa pty ltd phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret ph p usa location associated undertaking business usa teterboro quest diagnosticsincorporatedfootnote v clinical testing footnotes incorporated netherlands ii originally incorporated luxembourg registered guernsey iii exempt provisions section companies amendmentact ireland iv consolidated subsidiary undertaking accordance section companies act grounds ofdominant influence v equity accounted grounds significant influence directly held wholly owned subsidiary glaxosmithkline plc business segment phpharmaceuticals chconsumer healthcare business activity ddevelopment eexporting ffinance hholding company iinsurance mmarketing pproduction rresearch sservice full details group subsidiary associated undertakings attached companys annual return filed registrar ofcompaniesglaxosmithkline investor information section includes financial record presentinghistorical information prepared ukgaap addition historical information restated accordance international financial reporting standards presented section alsodiscusses shareholder return return shareholders form dividends share price movements provides information shareholders financial record information prepared ukgaap quarterly trend five yearrecord financial information international financial reporting standardsifrs background ifrs accounting policies ifrsadjustments ifrs pharmaceutical turnover total group ifrsconsolidated income statement ifrsconsolidated balance sheet ifrsconsolidated statement recognised income expense ifrsconsolidated cash flow statement shareholder return shareholder information share capital taxation information shareholders glaxosmithkline financial record quarterly trend unaudited analysis provided quarter group results sterling financial year analysis comprises statutory results business performance results pharmaceutical sales therapeutic area profit loss account statutory months q cer cer turnoverpharmaceuticals consumer healthcare total turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings business disposals profit disposal interests associates profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p profit loss account business performance turnover pharmaceuticals consumer healthcare total turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit pharmaceuticals consumer healthcare total trading profit operating incomeexpense operating profit share profitslosses joint ventures associated undertakings business disposals profit ondisposalof interest associates profit interest net interest payable profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends adjusted earnings profit attributable shareholders adjusted earnings per share p pfinancial recordglaxosmithkline months q months q q cer cer cer cer cer p p p p p p p p p p glaxosmithkline financial record pharmaceutical turnover total group q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover includes copromotion incomefinancial recordglaxosmithkline pharmaceutical turnover usa q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccines hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover includes copromotion income glaxosmithkline financial record pharmaceutical turnover europe q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerasee lexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover includes copromotion incomefinancial recordglaxosmithkline pharmaceutical turnover international q q q q cer cer cer cer respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir ageneraselexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandia avandamet vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover includes copromotion income glaxosmithkline financial record five year record record financial performance provided analysed accordance current reporting practice turnover business segment pharmaceuticals consumer healthcare pharmaceutical turnover therapeutic area central nervous system respiratory antibacterials antivirals metabolic vaccines oncology emesis cardiovascular urogenital others continuing business divested products pharmaceutical turnover geographic area usa europe international asia pacific japan latin america middle east africa canada international pharmaceutical turnover inand includes copromotion income consumer healthcare sales otc medicines oral care nutritional healthcare continuing business divested products financial recordglaxosmithkline restated restated restated restated statutory results turnover operating profit profit taxation earnings profit attributable shareholders dividends retained profit basic earnings per share p diluted earnings per share weighted average number shares issues basic diluted return capital employed per cent return capital employed calculated statutory profit taxation percentage average capital employed year merger restructuring disposal subsidiaries manufacturing restructuring merger costs product divestments items lossprofit taxation lossprofit attributable shareholders business performance results turnover rd expenditure per cent sales trading profit per cent sales net interest payable profit taxation adjusted earnings profit attributable shareholders years business performance primary performance measure used management presented excluding merger items integration restructuring costs disposals business management believesthat exclusion items providesa better comparison way business managed givesan indication performance group terms elements revenue expenditure local management able influence information provided addition statutory results prepared ukgaap given assist shareholders gain clearer understanding underlying performance business increase comparability periods presented statutory results include itemsfor withthe completion programmes group reporting results statutory basis amounts accordance us gaap turnover net incomeloss basic net incomeloss per share pence p p p p diluted net incomeloss per share pence p p p p information presents us gaap net incomeloss net incomeloss per share results years ended st december adjusted reverse amortisation expense goodwill indefinitelived intangible assets sfas also applied years adjusted net incomeloss adjusted basic net incomeloss per share pence p p adjusted diluted net incomeloss per share pence p p glaxosmithkline financial record balance sheet restated restated restated restated net assets fixed assets assets liabilities net operating assets net debt net assets capital employed share capital share premium reserves equity shareholders funds minority interests capital expenditure tangible fixed assets amounts accordance us gaap total assets net assets shareholders equity number employees usa europe international asia pacific japan latin america middle east africa canada international manufacturing selling administration research development number employees number permanent employed staff end financial period excludes employees employed managed glaxosmithkline contract basis exchange rates guide holders adrs following tables set periods indicated information exchange rate us dollars sterling reported federal reserve bank new york noon buying rate average average rate year calculated average noon buying rates last day month year feb jan dec nov oct sept high low noon buying rate onthfebruary usglaxosmithkline financial information international financial reporting standards ifrs background financial instruments financial instruments comparative periods presented annual report ie ifrs project recorded existing uk gaap basis rather june council european union adopted accordance ias financial instruments regulation requiring listed companies member states disclosure presentationand ias financial instruments prepare consolidated financial statements accordance recognition measurementsee international financial reporting standards ifrs first glaxosmithkline annual report prepared ifrs ifrsfinancial informationhas prepared basis year ending st december first taking exemptions financial results announcement prepared accordance ifrs first quarter financial instruments glaxosmithkline intends adopt ias full howeverone groups project convert financial reporting uk exemptions available ifrs relaxes requirement gaap ifrs completed subject changes comparative informationpresented annual report standard pronouncements training programmehas comply ias ias glaxosmithkline intends rolled finance staff worldwide adjusted take advantage exemptionand soin historical data provide comparative information financial instruments willbe accounted presented ifrs prepared uk gaap basis unaudited consolidated results glaxosmithkline plc st january therewasan adjustment opening converted currentuk gaapbasis onto ifrs basis balance sheet reflect movements uk gaap presented pagesto carrying values ias ias values many willbethe earliest year full ifrs financial statements financial instruments fair value willbe presented annual report transition date ifrs glaxosmithkline st january normally financial instruments concerned accounting changes nature would require full retrospective held fair value ifrs movements recorded application ifrs transitional rules certain equity adjustments onlyhave applied effect equity investments transition date ofst january liquid investments derivatives classified cash flow hedging instruments basis preparation data ifrs financial informationhas prepared basis held fair value ifrs movements recorded ofall ifrs standing interpretations committee sic income statement international financial reporting interpretations committee ifric equity collar linked groups investment quest interpretations issued iasb effective reporting diagnosticsinc put call options linked groups strategic glaxosmithkline chosen adopt iasbs amendments alliance theravanceinc ias employee benefits early permits actuarial gains derivatives classified hedging instruments losses differences expected actual returns including embedded derivatives effect changes actuarial assumptions recognised derivatives classified fair value hedges together statement ofrecognisedincome andexpense hedged element relevant asset liability financial information presentedunder ifrsis unaudited presentation differences nonequity minority interests repaid ifrsexemptions ifrsfirsttime adoption international financial reporting ias valuationrules applied standardspermits companies adopting ifrs first would charge profit taxthe largest time take exemptions full requirements ifrs elements arise quest collar million transition periodglaxosmithkline intends take million theravance put call options following key exemptions million nil valuationsare inherently unpredictable changes fair values financial instruments could business combinations business combinations prior havea material impact future resultsand financial transition date st january restated positionof glaxosmithkline onto ifrs basis employee benefits cumulative actuarial gains losses recognised equity transition date sharebased payments ifrs sharebased paymentapplies equity instruments share optionsgranted since th november glaxosmithkline elected adopt full retrospective application standard glaxosmithklinefinancialinformation ifrs ifrs accounting policies foreign currency transactions foreign currency transactions group companies booked following ifrs accounting policies expected applied inlocal currency exchange rate ruling date glaxosmithkline plc consolidatedffinancial statements transaction foreign currency assets liabilities retranslated local currency rates exchange ruling balance sheet date exchange differences areincluded inthe income statement consolidation consolidated financial statements include revenue assets liabilities results cash flows revenue recognised income statement goods company subsidiaries includingesoptrusts services supplied made available external customers groups share net assets results joint orders received title risk loss passes ventures associates customer turnover represents net invoice value deduction discounts allowances givenand accruals financial statements ofundertakings consolidated madeup estimated future rebates returns methodology st december assumptions used estimate rebates returns monitored entities group ability exercise control adjusted regularly light contractual historical accounted subsidiarieswhere group ability information past experience turnover also includes co exercise joint control accounted joint ventures promotion income group records share group ability exercise significant influence revenue related cost sales value added tax accounted associates sales taxes excluded revenue interests acquired entities consolidated effective expenditure date acquisition interests sold consolidated upto expenditure recognised respect goods services received date disposal supplied accordance contractual terms provision transactions balances subsidiaries eliminated made obligation exists future liability respect profit taken sales subsidiaries sales joint past event amount obligation ventures associates products sold customers reliably estimated advertising promotion expenditure outside groupdeferred tax relief unrealised intragroup charged income statement incurred shipment costs profit accounted extent considered intercompany transfers charged cost sales distribution recoverable costs sales customers included selling general administrative expenditure restructuring costs recognised goodwill arising acquisition interestsin subsidiaries joint respect direct expenditures business reorganisation ventures associates representing excess purchase plans sufficiently detailed well advanced consideration groups share fair values appropriate communication affected identifiable assets liabilities contingent liabilities acquired undertaken balance sheet date capitalised asa separate item case subsidiaries part cost investment case joint ventures research development associates goodwill denominated currency research development expenditure charged income operation acquired case acquisitions prior statement period incurred development goodwill written directly equity subsequent expenditure iscapitalised criteria recognising asset disposal assets acquisitions related goodwill aremetusually point regulatory filing major market remains equity charged consolidated income property plant equipmentused research development statement isdepreciated accordance groups policy results assets liabilities associates joint ventures incorporated consolidated financial statements using environmental expenditure equity method accounting environmental expenditure related existing conditions resulting past current operations current assets liabilities overseas subsidiaries associates joint future benefit discernible charged income statement ventures including related goodwill translated sterling grouprecognisesits liability sitebysite basiswhen itcan rates exchange ruling balance sheet date results reliablyestimated liability includes groupsportion cash flows overseas subsidiaries associates joint ventures total costs also portion potentially responsible translated sterling using average rates exchange parties costs probable able exchange adjustments arising opening net assets satisfy respective shares cleanup obligationrecoveries profits theyear retained overseas subsidiaries associates reimbursements recorded assets virtually certain joint ventures translated sterling less exchange differences arising related foreign currency borrowings hedge groups net investment operations taken separate component equity translating sterling theassets liabilities results cash flows overseas subsidiaries associates joint ventures reported currencies hyperinflationary economies adjustments aremade reflect current price levels loss net monetary assetsis charged consolidated income statementfinancial information ifrsglaxosmithkline ifrs accounting policies continued property plant equipment property plant equipment ppe stated cost pensions postemploymentbenefits purchase construction less provisions depreciation costs providing pensions defined benefit schemes impairment financing costs capitalised calculated using projected unit credit method spread period benefit expected derived depreciation calculated write cost ppe excluding employees servicesin accordance advice qualified freehold land using straightline basis expected useful actuaries pension obligations measured present value life normal expected useful lives major categories estimated future cash flows discounted rates reflecting ppe reviewed annually yields high quality corporate bonds pension scheme assets measured fair value balance sheet date actuarial gains freehold buildings years losses differences expected actualreturns leasehold land lease term years andthe effect changes actuarial assumptions recognised buildings statement ofrecognisedincome andexpensein plant machinery years year arise fixtures equipment years groups contributions defined contribution plans ondisposal ppe cost related accumulated charged income statement incurred depreciation impairments removed financial statements net amount less proceeds taken costs postemployment liabilities calculated income statement similar way defined benefit pension schemes spread period benefit expected derived leases employees servicesin accordance advice qualified leasing agreements transfer group substantially actuaries benefits risks ownership asset treated finance leases asset purchased outright legal disputes assets included inppe computer software capital provision made foranticipated settlement costswhere elements leasing commitments shown obligations reasonable estimate made likely outcome legal finance leases assets held finance leases disputes group addition provision made depreciated basis consistent similar owned assets legalorother expensesarising fromclaims receivedorother lease term shorter interest element lease rental disputesin respect product liability claims related products included income statement leases operating sufficient history claims made settlements leases annual rentals included income statement incurred reported ibnr actuarial technique used straightline basis lease term determine reasonable estimate groups exposure unasserted claims products provision made goodwill basis provision made unasserted claims goodwill stated cost lessimpairments goodwill deemed obligation exists dispute possible indefinite useful life tested impairment annually make reasonable estimate costs associated claims made group third parties charged income fair value interest acquired entitys assets statementas incurred liabilities contingent liabilities exceeds consideration paid excess recognised immediately gain income employee share plans statement incentives form shares provided employees share option share award schemes theseoptions awards fair valued grant datesand cost charged income statement relevant vesting periods thegroupprovides finance esoptrusts purchase company shares open market meet theobligation provide shares employees exercise optionsor awardscosts running esop trusts charged income statement shares held esoptrusts deducted reserves held value ofthe proceeds receivable employees exercise deemed apermanent impairment value reflected bya transfer toretained earnings glaxosmithklinefinancial information ifrs ifrs accounting policies continued inventories inventories included financial statements lower intangible fixed assets cost including raw materials direct labour direct costs intangible assets stated cost lessprovisionsfor amortisation related production overheadsandnet realisable value impairments costis generally determined first first basis licences patents knowhow marketing rights separately acquired acquired part business combination taxation amortised estimated useful lives time deferred tax provided full using liability method available use estimated useful lives determining temporary differences arising tax bases assets amortisation charge reviewed annually andtake liabilities carrying amountsin financial account estimated time takes bring compounds statements deferred tax assets recognisedto extent products market anydevelopment costsincurred group probable future taxable profits available andassociated withacquired licences patents knowhow temporary differences utilised marketing rights written income statement deferred tax provided temporary differences arising whenincurred unless criteria recognition internally investments subsidiaries associates joint ventures except generated intangible asset met timing reversal temporary difference brands valued independently part fair value controlled probable temporary difference businesses acquired third parties brand reverse foreseeable future value substantial longterm brands deferred tax provided using rates tax enacted sold separately rest businesses acquired substantively enacted balance sheet date deferred tax brands areamortised theirestimated useful lives except liabilities assets discounted considered useful economic lifeis indefinite prior acquired minor brands similar intangibles derivative fifnancial instruments hedging activities eliminated group balance sheet reserves year derivative financial instruments used manage exposure acquisition market risks treasury operations principal derivative instruments used glaxosmithklineareforeign currency swaps costs acquiring developing computer software interest rateswaps forward foreign exchange contracts internal use internet sites external use capitalised group hold issue derivative financial instruments intangible fixed assets software site supports trading speculative purposes significant business system expenditure leads creation durable asset erp systems software amortised derivative financial instruments initially recognised seven years computer software three balance sheet cost thenremeasured subsequent five years reporting dates tofair valuehedging derivatives classified inception fair value hedges cash flow hedges net impairment ofnoncurrentassets investment hedges carrying values allnoncurrentassets reviewed changes fair value derivativesdesignatedas fair value impairment indication assets might hedges recorded income statementwiththe changes impaired additionally goodwill intangible assets fair value hedged asset liability indefinite useful livesand intangible assets yet available forusearetestedfor impairment annually changes fair value derivativesdesignatedas cash flow provision impairment charged income statement hedges recognised equity amounts deferred equity year concerned transferred income statement line withthe hedged forecasttransaction investments joint ventures associates hedges net investmentsin foreign entities accounted investments joint ventures associates carried ina similar wayto cash flow hedges consolidated balance sheet groups share oftheir net assets date acquisition postacquisition retained profits changes fair value derivative instruments losses together goodwill arising acquisition qualify hedge accounting recognised immediately income statement availableforsale investments availableforsale investments initially recorded cost debt instruments remeasured subsequent reporting dates fair value unhedgeddebt instruments stated amount net unrealised gains losses availableforsale investments proceedsadjustedto amortise issue costsof debtover recognised directly equity disposal impairment itsterm investments gains losses equity recycled income statement equity investments recorded noncurrent assets unless expected sold within one yearfinancial information ifrsglaxosmithkline ifrs adjustments adjustment sharebased payments expected reduce normal level million asummary principal differences uk gaap considerably higher charge arises two ifrs apply glaxosmithklineisset main factors relatively share options granted financial effect shown pagesto gwsb merger finalised customer allowances full catchup grant early year followed adjustment isa reclassification turnover normal annual grant november addition expenses profit cash flow effect ifrs detailed grants made average share price excess rules relation certain marketing promotional share options become exercisable expenditure deducted turnover rather therefore fall charge charge recorded expense howeverthese rules exist us reflect current share prices normal grant levels gaap eitf accounting consideration given vendor customer requires marketing advertising coregcapitalisation amortisation promotion payments made customers deducted north american rights coregwere acquired time turnover significant impact inthe consumer gwsb merger partial consideration required disposal healthcare business payments large retailers instore kytril roche uk gaap accounted advertising preferential shelfspace product listings etc exchange assets value attributed coreg commonplace balance sheet ifrs however requires acquired rights coregto added intangible assets fair value glaxosmithkline believes reflects best practice revenue date acquisition million amortised recognitionandhence absence detailed guidance remaining useful life eight years adjustment reduces ifrs decided adopt revenue recognition policy profit tax million million ifrs line eitf therefore going forward would eps pence pence difference turnover reported ifrs turnover reported us gaap adjustment impact intangible assets amortisation profit tax eps uk gaap glaxosmithkline amortises intangible assets estimated expected useful lives acquisition sharebased payments maximum years ifrs permits amortisation present uk gaap approach sharebased payments commence asset becomes available use annual record intrinsic loss grant suffered company impairment testing required point glaxosmithkline means share options granted market price determined point amortisation productrelated charge income statement shares options assets commences ifrs normally regulatory approval granted cost employee eg longterm majority glaxosmithklines intangible assets relates incentive plans income statement charged amount acquisition rights compounds development equal market price date award spread reached point amortisation commences led performance period usually three years reduction amortisation charge periods presented ifrs sharebased payment ukgaap equivalent frs likely reverse future compounds reach sharebased payment came force regulatory approval amortisation charged shorter requirethe fair value equity instruments issued tobe period profit tax increases million charged income statement forshare awards granted million eps pence pence senior executives although calculation different resultant charge materially different uk gaap goodwill amortisation major difference arises respect share optionsof uk gaap requires goodwill amortised estimated million adjustmentin million arises expected useful life glaxosmithkline determined grant share options market price approximately normally longer years ifrs however employees glaxosmithkline chosen recognise goodwillis considered indefinite life unvested options awards retrospectively amortisedbut subject annual impairment testing adjustment therefore reverses goodwill amortisation charged glaxosmithkline receives tax credit appropriate relates uk gaap including recorded profit share share options awards exercised based gains associates line relating acquisition groups interest theholders makeand dependant tax rules country quest diagnosticsinc business combinations deduction claimed deferred tax asset exemption ifrs goodwill previously written direct represents estimate future tax relief gain reserves uk gaap recycled income statement based potential gains available option award disposal partdisposal subsidiary associate holders balance sheet date movement deferred would uk gaap adjustment increases tax asset one balance sheet nextmayresultin either profit tax million million eps tax credit tax charge recorded income statement pence pence adjustment reduces profit tax million million earnings million millionand eps pence pence glaxosmithklinefinancial information ifrs ifrs adjustments continued deferred tax intercompany profit uk gaapdeferred tax provision intercompany pensions postemployment benefits profit held inventory calculated supplying companys glaxosmithkline accounts uk gaap pensions effective tax rate ifrs however takes balance sheet approach postemployment benefits opebs accordance ssap recognition deferred tax results tax rate spreads costs providing benefits company holding inventory balance sheet date estimated average service lives employees additional applied provision proportions groups frs disclosures give pension fund surpluses deficits inventory held specific locations change significantly one liabilities opebs based valuation methodologies balance sheet date next could significant change required standard value deferred tax asset reflected ias employee benefitstakes similar valuation approach tax charge year frs accordance transitional provisions ofifrs surpluses deficits recognised balance adjustments sheet transition date st january addition number minor adjustments following anamendmentto ias issued iasb december reclassifications including permitted recognise movements surpluses computer software recorded intangible asset deficits immediately balance sheets outside income unless forms integral part operating system statement similar way frs means tangible fixed asset cases balance sheet reflects full surplus deficit positions deferred tax brands acquired company funds difference fair value brands groups policy charge operating businesses acquisition thetaxvalue taxable temporary difference service cost element pension charge gets arises reported withincost salesselling general administrative cash equivalents reclassification liquid investments expenditure orresearch development appropriate maturities less three months acquisition charge element related funding deficit included within cash cash equivalentsand reported selling general administrative expenditure provisions reclassificationwhere elements provisions ias service cost element total charge expected paid within one year balance sheetdate considerably higher ssap funding deficit exception pensions opebs presented element lower leads additional reclassification within current liabilities adjustment income statement expense headings cash flow statement usa recently enacted medicare prescription drug move ukgaap ifrs change cash improvement modernization act expected lead flows group ifrs cash flow format similar uk payments received glaxosmithkline us gaap presents various cash flows different categories government respect employee healthcare plans different order ukgaap cash flow statement present clear consensus receipts ifrs accounting adjustments net within cash generated accounted ias glaxosmithkline recognised operations except intangible assets reclassification receipts asactuarial adjustmentsand impact inclusion liquid investments maturity less recognised balance sheetthis treatment would change three months acquisition together related exchange guidance issued requires different accounting treatment adjustmentswithin cash cash equivalents ifrs overall impact adjustments pensions opebs decrease profit tax million increase million decrease eps pence nil share profits associates ukgaap share profits associates reported within profit tax group however ifrs requires share profits tobe net profit attributable group ie interest tax minority interests associate leads reclassification adjustment removing share associates interest tax minority interests lines income statement netting together share profitsof associates line adjustment reduces profit beforetax million million affect epsfinancial information ifrsglaxosmithkline ifrs pharmaceutical turnover total group months months q q q q respiratory seretideadvair flixotideflovent serevent seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil ir paxil cr wellbutrin wellbutrin ir sr wellbutrin xl imigranimitrex lamictal requip antivirals hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpes valtrex zovirax zeffix antibacterials augmentin augmentin ir augmentin es augmentin xr zinnatceftin metabolic avandiaavandamet vaccines hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac total pharmaceutical turnover includes copromotion income glaxosmithklinefinancial information ifrs ifrsconsolidatedincome statement statutory months months uk gaap adjustments ifrs growth ukgaap adjustments ifrs cer turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit operatingincomeexpense operating profit share profitslosses joint ventures associates disposal interests associates disposal businesses profit interest financecosts net profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p p p p p ifrsconsolidatedincome statement business performance months months uk gaap adjustments ifrs growth ukgaap adjustments ifrs cer turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit operatingincomeexpense operating profit share profitslosses joint ventures associates disposal interests associates disposal businesses profit interest financecosts net profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends adjusted earnings profit attributableto shareholders adjusted earnings per share p p p p p pfinancial information ifrsglaxosmithkline ifrsconsolidatedincome statement statutory q months q ukgaap adjustments ifrs ukgaap adjustments ifrs ukgaap adjustments ifrs turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit operating incomeexpense operating profit share profitslosses joint ventures associates disposal interests associates disposal business profit interest financecosts net profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p p p p p p p p ifrsconsolidatedincome statement statutory months q q ukgaap adjustments ifrs ukgaap adjustments ifrs ukgaap adjustments ifrs turnover cost sales selling general administrative expenditure research development expenditure operating costs trading profit operating incomeexpense operating profit share profitslosses joint ventures associates disposal interests associates profit interest financecosts net profit ordinary activities taxation taxation profit ordinary activities taxation equity minority interests preference share dividends earnings profit attributable shareholders basic earnings per share p p p p p p p p p glaxosmithklinefinancial information ifrs ifrs consolidated balance sheet st december st december ukgaap adjustments ifrs ukgaap adjustments ifrs property plant equipment goodwill intangible assets investments associates joint ventures investments deferred tax assets noncurrent assets noncurrent assets current assets inventories trade receivables liquid investments cash cash equivalents assets held sale current assets total assets shortterm borrowings trade payables current tax payable shortterm provisions current liabilities longterm borrowings deferred tax provision pensions postemployment benefits provisions noncurrent liabilities noncurrent liabilities total liabilities net assets equity share capital share premium account shares held esoptrusts reserves retained earnings equity shareholders funds nonequity minority interests equity minority interests capital employed ifrs consolidated statement recognised income expense st december st december ukgaap adjustments ifrs ukgaap adjustments ifrs exchange movements tax exchange movements unrealised gains loss shares employee share schemes goodwill written back revaluation goodwill due exchange unrealisedloss disposal intellectual property actuarial gainslosses defined benefit plans net gainslosses recognised directly equity profit attributable shareholders totalrecognised income expense year financial information ifrsglaxosmithkline ifrsconsolidated cash flow statement months months q q q q cash flows operating activities cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase tangible fixed assets proceeds sale tangible fixed assets purchase intangible assets purchase equity investments proceeds sale equity investments purchase businesses net cash acquired disposal businessesand interest associates investment joint ventures associates interest received dividends joint ventures associates net cash outflow investing activities cash flow financing activities increasedecreasein liquid investments proceeds shares employee share options issue share capital share capital purchased cancellation purchase treasury shares redemption preference shares issued subsidiary increasein longterm loans repayment longterm loans net repayment shortterm loans net repayment obligations finance leases interest paid dividends paid gsk shareholders dividends paid minority interests dividends paid preference shares financing cash flows net cash outflow financing activities exchange adjustments increasedecreasein cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period cash cash equivalents end period comprise cash cash equivalents overdrafts glaxosmithkline shareholder return share price dividends per share guide shareholders table sets dividends per share paid last five years st january year gsk p gw p sb p high year low year st december decreaseincrease table sets middle market closing prices derived london stock exchange daily official list dividends paid glaxo wellcome smithkline beecham companys share pricedecreasedbyfiveper cent shareholders expressed dividends per glaxosmithkline price st januarytoat share st december compares anincreasein ftse index ofeightper cent year dividends per ads guide holders adrs tablebelow setsout market capitalisation dividendsper ads paid us dollars last five years market capitalisation glaxosmithkline st december translated us dollars applicable exchange rates wasbillion date glaxosmithkline fourthlargest company market capitalisation ftse year gsk gw sb index smithkline beecham plc floating rate unsecured loan stock loan stock listed exchange holders may require smithkline beecham plc redeem loan stock dividends paid glaxo wellcome smithkline beecham par ie every loan stock held first business adr holders expressed dividends per glaxosmithkline day march june september december holders wishing adsone glaxosmithkline ads represents two glaxosmithkline redeem part loan stock complete shares notice back loan stock certificate return registrar arrive least days relevant dividend calendar redemption date fourth quarter taxation exdividend date th february general information concerning uk us tax effects record date th february share ownership set 'taxation information payable thapril shareholders'on first quarter dividends exdividend date th may record date th may glaxosmithkline pays dividends quarterly board declared payable th july dividends follows second quarter dividends per share pence pence exdividend date rd august first interimpaid st july record date th august second interimpaid th september payable th october third interimpaid th january fourth interimpayable th april third quarter total exdividend date nd november record date th november payable th january glaxosmithkline shareholder information ordinary shares share price information share price information available company 's website company 's shares listed london stock exchange wwwgskcom information uk also available ceefax teletext andfrom ftcityline calling registrar calls charged p minute plus vat times company 's share register administered lloyds tsb registrars also provide following services annual general meeting glaxosmithkline investment plan plan enables shareholders reinvest quarterly dividends queen elizabeth ii conference centreth may andor make monthly investments company 's ordinary broad sanctuary westminster shares using special dealing arrangement london swp ee glaxosmithkline individual savings account annual general meeting company 's principal forum glaxosmithkline individual savings account isa communication private shareholders addition formal taxefficient way invest company 's ordinary shares resolutions put meeting presentation chief executive officer performance business glaxosmithkline corporate sponsored nominee future development opportunity questions corporate sponsored nominee provides facility board chairmen board 's committees shareholders hold shares without need share take questions matters relating committees certificates shareholders ' details held main share register remain confidential investors holding shares company nominee service arrange nominee service appointed shareview service corporate representative proxy respect shareholding shareview portfolio service provides shareholders order attend vote meeting information investment company shareholders may register service wwwshareviewcouk adr holders wishing attend meeting must obtain proxy bank new york enable attend shareview dealing service meeting vote business transacted adr holders shareview dealing service telephone internal share may instruct bank new york tothe way dealing facility available ordinary shareholders logging shares represented adrs voted completing wwwshareviewcoukdealing calling returning voting card provided bythe bankin accordance instructions given american depositary shares company 's shares listed new york stock exchange financial reporting form american depositary shares adss financial reporting calendar evidenced american depositary receipts adrs one represents two ordinary shares announcement st quarter results th april announcement nd quarter results th july adr programme administrator announcement rd quarter results th october adr programme administered bank new york preliminary announcement annual results th february provides global buydirect service direct ads purchasesale dividend reinvestment plan adr holders publication annual reportreview march share dealing facility results announcements hoare govett limited operates postal share dealing service results announcements issued london stock companys ordinary shares enables investors buy sell exchange andareavailable theirnews serviceat shares competitive commission charges transactions time shortly afterwardstheyare issued mediamade executed settled pershing securities limited details available website andsent ussecurities service together purchase sale forms may exchange commission new york stock exchange obtained telephoning financial reports smith barney part citigroup also offers share dealing service company publishes annual report investor companys ordinary shares adss details needing full detail report annual review service obtained contacting see contact details available date publication website inside back cover annual review sent shareholders date provision details intended publication shareholders may also elect receive report invitation inducement engage investment activity writing companys registrars alternatively shareholders advice share dealing obtained stockbroker may elect receive notification email publication independent financial adviser financial reports registering wwwshareviewcouk copies previous financial reports available website printed copies obtained registrar uk customer response center usa glaxosmithkline share capital nature trading market glaxo wellcome ordinary shares company listed london fiscal period stock exchange th december shares also st january th december pence per share listed new york stock exchange inthe form american high low depositary shares adss date following table sets periods indicated high low middle market closing quotations pence shares fiscal period london stock exchange derived daily official st januaryto th december list high low last reported sales prices us dollars usdollars per ads adss new york stock exchange derived high low new york stock exchange composite tape information relating share ads prices glaxo wellcome smithkline beecham prior date smithkline beecham themerger also given fiscal period glaxosmithkline pence per share st januaryto th december pence per share fiscal periods th december high low high low quarter ended st march february january december fiscal period st january th december november usdollars per ads october high low september quarter ended st december quarter ended th september quarter ended th june quarter ended st march quarterended st december quarter ended th september quarter ended th june quarter ended st march yearended st december yearended st december th st december us dollars per ads fiscal periods th december high low quarter ended st march february january december november october september quarter ended st december quarter ended th september quarter ended th june quarter ended st march quarter ended st december quarter ended th september quarter ended th june quarter ended st march yearended st december yearended st december th st december th february share capitalglaxosmithkline analysis shareholdings number total total number analysis shareholdings st december accounts accounts shares shares holding shares totals held nominee companies investment trust companies insurance companies individuals corporate bodies bny nominees limited held treasury shares glaxosmithkline totals bank new yorks holding held bny nominees limited represents companys adr programme whereby ads represents two ordinary shares p nominal value atth february number holders record shares usa waswith holdings ofshares thenumberof registered holders adrs waswith holdings ofadrs certain shares adrs held brokers nominees result number holders record registered holders usa representative number beneficial holders orofthe residence beneficial holders control company far known company directly indirectly owned controlled one corporations government thecompany know arrangements operation might result change control company substantial shareholdings th february company received notification following interestsof three per cent inthe shares issue excluding treasury shares bnynominees limited holdsshares representing per cent shares held behalf holders adrs evidence adss legal general investment management limited holds shares representing per cent barclays plc holds shares representingper cent far known company person owner three per cent shares issue excluding treasury shares company directors officers interests directors officers companyas defined thecompanies act share options company given theremuneration reportpages exchange controls limitations affecting securityholders currently uk laws decrees regulations restricting import export capital affecting remittance dividends orother payments holders companys shares nonresidents uk limitations relating nonresidents uk english law companys memorandum articles association right tobe holder tovote respect companys shares documents display memorandum articles association thecompany otherdocuments referred annual report available inspection registered office company publications year glaxosmithkline producing corporate responsibility report covering performance areas including community investment business ethics integrity access medicines rd environmental health safety report published onthe website end march glaxosmithkline taxation information shareholders information shareholders stamp duty uk stamp duty stamp duty reserve tax sdrt subject summary main tax consequences holders shares certain exemptions payable purchase shares adrs citizens residents uk usa rate per cent purchase price minimum set complete analysis possible tax charge stamp duty liability arises consequences purchase ownership securities intended general guide holders advised consult us shareholders advisers respect tax consequences purchase ownership shares adrs following summary certain uk taxation usa consequences state local tax laws usa federal income tax considerations may relevant implications new ukus income tax convention usholder shares adrs summary applies shareholder holds shares adrs capital assets statement based upon uk us tax laws practices citizen resident usa domestic corporation date report otherwise subject united states federal income taxation new ukus income tax convention came force net income basis respect shares adrs st march provisions new treaty apply uk resident uk uktax purposes hold shares tax purposes st april ukcorporation tax th april purposes trade profession vocation carried uk income tax capital gains tax st may uk branch agency withholding taxes ustax purposes provisions new treaty apply st may withholding taxes taxation dividends st january ustaxes however holders shares gross amount dividends received including amounts adrs ability elect continue use respect associated tax credit uk withholding tax treated provisions previous treaty months following foreign source dividend income us tax purposes new treatys entry force election must made eligible dividend received deduction allowed us advance first event new treaty would apply corporations dividends adrs payable us dollars dividends shares payable sterling dividends paid us holders adrs generally treated owners pounds sterling included income us dollar underlying shares purposes current usauk amount calculated reference exchange rate day double taxation conventions relating income gains dividends received holdersubject certain income tax convention estate gift taxes estate gift exceptions individual eligible us holder subject us tax convention purposes us internal revenue taxation maximum rate per cent respect qualified code amended code dividends received shareholders advised following analysis deals dividends paid th april consult tax advisers confirm eligibility advance corporation tax act abolished taxation capital gains uk shareholders generally us holders subject uk capital gains tax subject us tax capital gains realised sale taxation dividends disposal shares adrs th april rate tax credits reduced one ninth result compensating reductions rate tax estate gift taxes dividend income increase tax borne uk estate gift tax convention us shareholder resident individual shareholders tax credits however generally subject uk inheritance tax longer repayable shareholders tax liability less associated tax credit stamp duty uk stamp duty sdrt subject certain exemptions taxation capital gains payable issue transfer shares adr custodian uk shareholders may liable uk tax gains depository rate per cent price issued disposal shares adrs may also entitled amount consideration provided transferred indexation relief taper relief sales indexation relief sale value transferred consideration calculated market value shares st march cost subsequent purchases date sdrt would payable transfer adr uk purchase indexation relief individual shareholders stamp duty payable transfer adr ceased th april taper relief available individual provided instrument transfer executed remains shareholders hold deemed hold shares least times outside uk stamp duty transfer three years sold adr would payable rate per cent consideration transfer sale underlying shares inheritance tax would result liability uk stamp duty case may individual shareholders may liable inheritance tax sdrt rate per cent minimum charge transfer shares adrs tax may charged amount stamp duty liability arises value shareholder 's estate reduced result transfer way gift disposal less full market value gift disposal subject uk inheritance tax us estate gift tax estate gift tax convention would generally provide tax paid usa credited tax payable ukglaxosmithkline cross reference form f table provided cross reference information included annual report requirements form f item item identity directors senior management advisors na financial information consolidated statements financial information offer statistics expected timetable na financial statements see item key information legal proceedings selected financial data b significant changes risk factors note post balance sheet event information company offer listing history development company inside front cover share price history b business overview c markets products additional information competition b memorandum articles association footnote regulation c material contracts na marketing distribution exchange controls manufacture supply e taxation research development h documents display intellectual property environment health safety quantitative qualitative disclosures market risk access medicines treasury policies investment communities note financial instruments related disclosures c organisational structure description securities equity securities na property plantsand equipment defaults dividend arrearages delinquencies na environmental responsibility note segment information material modifications rights security holders note tangible fixed assets use proceeds na operating financial review prospects controls procedures operating results reserved audit committee financial expert b code ethics b liquidity capital resources c principal accountant fees services c research development patents licenses etc exemptions listing standard audit committees na trend information e purchases equity securities issuer affiliated e balance sheet arrangements na purchasers f tabular disclosure ofcontractualobligations financial statements na directors senior management employees financial statements directors senior management independent auditors report footnote ii b compensation consolidated statement profit loss remunerationreport consolidated statement total recognised gains c board practices losses corporate governance consolidated statement cash flow employees consolidated balance sheet glaxosmithkline people reconciliation movements consolidated equity note employee costs shareholders funds financial record company balance sheet e share ownership notesto financial statements glaxosmithkline people exhibits footnote ii note employee share schemes share options incentive plans footnote directors interests information responsive item incorporated reference memorandum articles association glaxosmithkline major shareholders related party transactions pages groups annual report form f major shareholders year ended st december b related party transactions ii see companys form f filing securities exchange note related party transactions commission glaxosmithkline glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax us equivalent tax depreciation advance corporation tax act advance payment uk tax made dividends paid direct us equivalent american depositary receipt adr receipt evidencing title ads glaxosmithkline adr represents two ordinary shares american depositary shares adss ordinary shares registered new york stock exchange calledup share capital ordinary shares issued fully paid cer growth growth constant exchange rates combined code guidelines required listing rules financial services authority address principal aspects corporate governance company glaxosmithkline plc creditors accounts payable currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates debtors accounts receivable defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share earnings per share basic income per share employee share ownership plan trusts trusts established group satisfy share based employee incentive plans equity shareholders funds aggregation shares reserves owned shareholders us equivalent shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity gearing ratio net debt percentage shareholders funds net debt minority interests group glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements bymaking offsetting commitments intangible fixed assets assets without physical substance brands licences patents knowhow marketing rights purchased outside parties interest cover number times profit interest exceeds net interest payable interest payable interest expense interest receivable interest income nonequity minority interest preference shares issued subsidiary outside parties preference shares shares issued varying dividend rates treated outside interests profit income profit loss account reserve retained earnings profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue shares outstanding statement total recognised gains losses statement comprehensive income stocks inventories subsidiary undertaking affiliate glaxosmithkline holds majority shareholding andor exercises control tangible fixed assets property plant equipment turnover revenuecontact details internet information investors company available glaxosmithklines corporate website wwwgskcom head office registered office glaxosmithkline plc great west road brentford middlesex tw gs tel united kingdom united states america investor relations investor relations great west road one franklin plaza brentford po box middlesex tw gs philadelphia pa tel tel toll free fax tel outside usa fax registrar lloyds tsb registrars adr programme administrator causeway bank new york worthing shareholder relations west sussex bn da po box wwwshareviewcouk church street station new york ny general enquiries annual report orderline wwwadrbnycom corporate nominee service tel toll free tel inside uk tel outside usa tel outside uk customer response center shareholder investment plans tel toll free dividend reinvestment enquiries tel inside uk corporate share dealing facility tel outside uk ordinary holders smith barney tel outside uk employees attn gskservices state street monthly savings plan enquiries th floor tel inside uk boston tel outside uk tel toll free isa enquiries tel outside usa tel inside uk fax tel outside uk thetaylorgroupsmithbarneycom glaxo wellcome smithkline beecham corporate peps share centre limited oxford house oxford road aylesbury bucks hp sz tel corporate share dealing facility smith barney attn gskservices citigroup centre level canada square canary wharf london e lb tel fax thebalaesgroupcitigroupcom printed midas press uk paper used production document made pulp harvestedfrom sustainable forests also using sawmill residues forest thinnings elemental chlorinefreewwwgskcom